Page last updated: 2024-09-04

abiraterone and Prostatic Neoplasms, Castration-Resistant

abiraterone has been researched along with Prostatic Neoplasms, Castration-Resistant in 514 studies

Research

Studies (514)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	333 (64.79)	24.3611
2020's	181 (35.21)	2.80

Authors

Authors	Studies
Cao, C; Chen, Y; Li, X; Yan, G; Yu, J; Zhang, L; Zhou, F; Zhou, P	1
Endo, S; Fujii, S; Fujimoto, N; Gouda, H; Hu, D; Iguchi, K; Ikari, A; Irie, K; Kawai, M; Matsukawa, T; Matsunaga, T; Nakayama, T; Oguri, H; Okada, T; Segawa, J; Toyooka, N; Xia, S	1
Endo, S; Fujimoto, N; Fujita, M; Ikari, A; Ikeda, H; Ishikawa, T; Kamatari, YO; Kudo, Y; Matsunaga, T; Okada, T; Ota, A; Tanaka, Y; Toyooka, N	1
Lu, Z; Luo, X; Meng, X; Wang, A; Wang, Y; Yang, Y	1
Kulkarni, AA; Lutsey, PL; Prizment, A; Rao, A; Rubin, N; Ryan, CJ; Shah, S; Tholkes, A	1
Alverbratt, C; Fallara, G; Garmo, H; Hjelm Eriksson, M; Lissbrant, IF; Stattin, P; Vikman, H	1
Ai, J; Bai, S; Lei, H; Liao, D; Peng, G; Qiu, S; Wei, Q; Xiong, X; Xu, H; Yang, L; Yi, X	1
Benedi-González, J; Bilbao Gomez-Martino, C; Díaz Almirón, M; Escario-Gómez, M; Espinosa Arranz, E; García Trevijano Cabetas, M; González-Del Valle, L; Herrero Ambrosio, A; Romero-Garrido, JA; Sobrino Jiménez, C	1
Andrikopoulou, A; Briasoulis, A; Dimopoulos, MA; Fiste, O; Gavriatopoulou, M; Gumeni, S; Kaparelou, M; Kastritis, E; Koutsoukos, K; Kunadis, E; Liontos, M; Markellos, C; Skafida, E; Terpos, E; Trougakos, IP; Zagouri, F	1
Azad, AA; Bonnitcha, P; Briscoe, K; Butler, LM; Crumbaker, M; Davis, ID; Du, P; Fettke, H; Fitzpatrick, M; Horvath, LG; Huynh, K; Jia, S; Joshua, AM; Kwan, EM; Lin, HM; Mahon, KL; Mak, B; Marx, G; Meikle, PJ; Meikle, TG; Mellett, NA; Scheinberg, T; Stockler, MR; Stricker, PD; Sullivan, DR; Tran, B; Yeung, N; Yu, J; Zhang, A	1
Freedland, SJ; George, DJ; Huang, A; Janjan, N; Mardekian, J; Ramaswamy, K; Russell, D; Schultz, NM	1
Ito, T; Koie, T; Miyake, H; Naiki, T; Nakane, K; Shiroki, R; Sugiyama, Y; Takahara, K; Yasui, T	1
Blanchet, P; Brureau, L; Gourtaud, G; Roux, V; Sadreux, Y; Senechal, C; Vestris, PG	1
Geynisman, DM; Heiss, BL; Martinez, E; Stadler, WM; Szmulewitz, RZ; Wong, ASC; Yong, WP	1
Long, Q; Mamtani, R; Marar, M; Narayan, V; Parikh, RB; Vapiwala, N	1
Beamud-Cortés, M; Collado-Borrell, R; Escudero-Vilaplana, V; García-Sánchez, S; Herranz, A; Narrillos-Moraza, Á; Pérez-Ramírez, S; Sanjurjo, M; Vicente-Valor, J; Villanueva-Bueno, C	1
Agarwal, N; Azad, A; Benzaghou, F; Carles, J; Chowdhury, S; Kerloeguen, Y; Kimura, A; McGregor, B; Merseburger, AS; Mohamed, N; Oudard, S; Pal, S; Panneerselvam, A; Saad, F; Soares, A; Wang, F	1
Arlt, W; de Ridder, CMA; Graeser, R; Hofland, J; Jenster, GW; Moll, JM; Taylor, AE; Teubel, WJ; van Weerden, WM	1
Collado-Borrell, R; Escudero-Vilaplana, V; Herranz, A; López-López, C; Revuelta-Herrero, JL; Ruiz-Briones, P; Sanjurjo, M; Somoza-Fernández, B; Vicente-Valor, J; Villanueva-Bueno, C	1
Cattarino, S; Gentilucci, A; Mariotti, G; Salsiccia, S; Sciarra, A	1
Chiba, S; Egawa, S; Habuchi, T; Hata, K; Hatakeyama, S; Horikawa, Y; Ishida, T; Kashima, S; Kimura, T; Koizumi, A; Kumazawa, T; Maita, S; Narita, S; Nomura, K; Ohyama, C; Okane, K; Sato, H; Shimoda, J; Suzuki, T; Takayama, K; Yamamoto, R; Yanagisawa, T	1
Bryce, AH; Gao, H; Gu, Y; Kalari, KR; Kim, W; Qin, B; Qin, S; Scholz, JA; Sinnwell, JP; Tan, W; Wang, L; Wei, L; Weinshilboum, RM; Xie, F; Yin, P; Yu, J; Zhang, H; Zhuang, Y	1
Caram, MEV; Hollenbeck, BK; Kaufman, SR; Lai, LY; Oerline, MK; Shahinian, VB; Tsao, PA	1
Cintra, MTG; Costa, AL; de Almeida, DCB; de Carvalho, FB; de Oliveira Faria, BL	1
Calais, G; Cancel, M; Florence, AM; Fromont, G; Laurent, E; Linassier, C; Narciso, B; Pobel, C	1
Bian, C; Chen, X; Gao, Y; He, D; Hou, Z; Huang, S; Li, Z; Liu, Y; Mei, Z; Qin, Y; Tan, Q; Wang, C; Wang, X; Wu, D; Xu, C; Yang, T; Zhang, X; Zhu, X; Zhuang, Q	1
Fujimoto, N; Fukuda, A; Harada, K; Hiroshige, T; Igawa, T; Minato, A; Mizushima, Y; Nagata, Y; Obara, W; Tomisaki, I	1
Anderson, M; Cao, Y; Chang, M; Rojas, V; Trieu, J; Varada, N; Vogelzang, NJ	1
Anand, A; Bian, C; Chen, S; Chi, Y; Huang, S; Li, Z; Liu, Y; Qin, Y; Richter, J; Tian, J; Wang, C; Wang, W; Wu, D; Xu, C; Yang, T; Zhang, L; Zhu, X	1
Aggarwal, RR; Borno, HT; Bucknor, M; Kwon, DH; Paciorek, A; Small, EJ; Zhang, L	1
Allegra, A; Aquilano, M; Cerbai, C; Ciccone, LP; Desideri, I; Detti, B; Di Cataldo, V; Francolini, G; Garlatti, P; Guerrieri, B; Livi, L; Loi, M; Lucidi, S; Mangoni, M; Meattini, I; Salvestrini, V; Stocchi, G; Visani, L	1
Beránek, J; Danielak, D; Krejčí, T	1
Kelly, WK; Lu-Yao, G; Shah, YB; Shaver, AL	1
Alekseev, B; Burgents, J; Chiuri, VE; Clarke, NW; Degboe, A; Fléchon, A; Gresty, C; Jassem, J; Jones, R; Kang, J; Kocak, I; Redfern, C; Saad, F; Sala, N; Thiery-Vuillemin, A; Wiechno, P	1
Chang, YH; Chu, YC; Chuang, CK; Hsieh, ML; Huang, LK; Kan, HC; Lee, CL; Lin, PH; Liu, CY; Pang, ST; Shao, IH; Wu, CT; Yu, KJ	1
Bennett, CL; Carson, KR; Drake, BF; Eisen, SA; Knoche, EM; Luo, S; Reimers, MA; Sanfilippo, KM; Schoen, MW; Whitmer, AL; Yan, Y	1
Bhargava, V; Bryce, AH; Carlson, RE; Dehm, SM; Gormley, M; Hillman, DW; Jimenez, RE; Kalari, KR; Kohli, M; Li, Y; Qin, S; Sicotte, H; Sinnwell, JP; Tan, W; Vedell, PT; Wang, L; Weinshilboum, RM	1
Armstrong, A; Jiang, XS; Labriola, MK; Seale, KN	1
Ellis, CS; Kolesar, JM; McCorkle, JR; Myint, ZW; Otto, DE; Wang, P; Wu, J	1
Chang, CF; Chang, KC; Chang, PH; Chang, YH; Chen, HK; Chen, HY; Chuang, CK; Hsieh, CH; Huang, WK; Kuan, FC; Kuo, YC; Lai, EC; Lin, PH; Lin, YC; Pang, ST; Sheng, TW; Su, PJ; Su, YL; Tsan, DL; Wang, YL; Yu, KJ; Yu, SM	1
Borsellino, N; Fazio, I; Galanti, D; La Vecchia, M; Lo Casto, A	1
Eto, M; Habuchi, T; Huang, M; Kagaya, H; Kashima, S; Miura, M; Nara, T; Narita, S; Numakura, K; Saito, M; Shiota, M; Takahashi, Y; Yamamoto, R	1
Balk, SP; Chen, S; Croucher, PJP; Dalrymple, S; Einstein, DJ; Erlander, MG; Isaacs, JT; Jonas, O; Luo, J; Makusha, L; Nouri, M; Patterson, JC; Rashed, S; Ridinger, M; Varkaris, A; Varmeh, S; Whitman, MA; Xie, F; Yaffe, MB	1
Egawa, S; Eto, M; Haginaka, J; Horiyama, S; Inoue, R; Kanji, H; Kobayashi, K; Matsuyama, H; Shiota, M; Tashiro, K	1
Habuchi, T; Hamaya, T; Hashimoto, Y; Hata, K; Hatakeyama, S; Kimura, T; Narita, S; Ohyama, C; Okamoto, T; Ozaki, K; Tanaka, T; Togashi, K; Yamamoto, H; Yanagisawa, T; Yoneyama, T	1
Cao, H; Chen, L; Feng, Y; Gao, R; Song, Z; Wang, D	1
Cetin, B; Gumusay, O; Wabl, CA	1
Enei, Y; Fukuokaya, W; Habuchi, T; Hara, S; Hata, K; Hatakeyama, S; Kimura, T; Matsukawa, A; Miki, J; Miyajima, K; Mori, K; Nakazono, M; Narita, S; Ohyama, C; Otsuka, T; Sano, T; Shariat, SF; Yanagisawa, T; Yata, Y	1
Bracarda, S; Chen, G; Chi, KN; de Bono, J; Garcia, J; Harris, A; Hinton, H; Massard, C; Matsubara, N; Olmos, D; Sandhu, S; Sane, R; Schenkel, F; Sternberg, CN; Sweeney, C	1
Deng, WM; Gao, X; He, YD; Li, LY; Luo, ZH; Meng, ZA; Tang, XM; Tao, W; Wang, BY; Xia, TL; Zhang, LX	1
Chen, T; Ding, J; Gu, T; Li, J; Zhu, Q	1
Abida, W; Bambury, RM; Bryce, AH; Chowdhury, S; Daugaard, G; Despain, D; Emmenegger, U; Fizazi, K; Gingerich, JR; Heidenreich, A; Heyes, CA; Krieger, L; Lindberg, H; Loehr, A; McDermott, R; Morris, D; Nolè, F; Ostler, P; Pintus, E; Piulats, JM; Reaume, MN; Redfern, C; Ryan, CJ; Sáez, MI; Sautois, B; Sridhar, SS; Staffurth, J; Watkins, SP	1
Deris, A; Sohrabi-Haghighat, M	1
Beuzeboc, P; Sabouret, A	1
Antonarakis, ES; Armstrong, AJ; Danila, DC; George, DJ; Gore, Y; Gupta, S; Halabi, S; Nanus, DM; Roy, A; Szmulewitz, RZ; Tubbs, A; Wenstrup, R; Yang, Q	1
Cai, D; Chen, J; Chen, N; Chen, Y; Dai, J; Hu, X; Liang, J; Liu, H; Liu, Z; Ni, Y; Nie, L; Pan, X; Shen, P; Sun, G; Wang, M; Wang, Z; Xu, N; Yin, W; Yin, X; Zeng, H; Zeng, Y; Zhang, X; Zhang, Y; Zhao, F; Zhao, J; Zheng, L; Zhu, S; Zhu, X	1
Cunha André, M; Gameiro Marques, R; Leal Carvalho, M; Mendonça Macedo, A; Silva Figueira, N	1
Abida, W; Antonarakis, ES	1
Annala, M; Benoist, GE; Boerrigter, E; Donnellan, G; Hamberg, P; Herberts, C; Kwan, EM; Mehra, N; Ng, SWS; Schalken, JA; Somford, DM; Sumiyoshi, T; Tolmeijer, SH; van Erp, NP; van Oort, IM; Wyatt, AW	1
Antonarakis, ES; Armstrong, AJ; Beltran, H; Beumer, JH; Bobek, O; Bryce, AH; Goldkorn, A; Hahn, O; Halabi, S; Heller, G; Hillman, DW; Langevin, B; Lewis, LD; McGary, EC; Mehan, PT; Morris, MJ; Roth, BJ; Ryan, C; Schwartz, L; Small, EJ; Taplin, ME; Watt, C; Xiao, H	1
Danyi, A; de Jong, AC; de Ridder, J; de Wit, R; Feng, F; Lolkema, MP; Sjöström, M; van Riet, J	1
Barata, PC; Caputo, SA; Casado, CV; Gupta, K; Habibian, N; Hawkins, ME; Huang, M; Jaeger, EB; Jang, A; Lanka, SM; Layton, JL; Ledet, EM; Lewis, BE; Lieberman, AD; Miller, PJ; Pocha, O; Sartor, O; Schwartz, J; Sweeney, PL	1
Gong, N; Huang, S; Wang, X; Xiang, Z; Xu, C; Yi, C; You, X; Yu, J	1
Balusson, F; Gravis, G; Kerbrat, S; Mathieu, R; Oger, E; Scailteux, LM; Vincendeau, S	1
Abdel-Gawad, O; Atawia, IM; Gupta, S; Kushwaha, PP; Lin, S; Shankar, E; Verma, S	1
Deol, ES; Fiala, MA; Luo, S; Mian, H; Sanfilippo, KM; Schoen, MW; Wildes, T	1
Sartor, O	2
Buck, SAJ; de Bruijn, P; de Wit, R; Ghobadi-Moghaddam-Helmantel, IM; Koolen, SLW; Lam, MH; Mathijssen, RHJ	1
Bloor, LE; Bohnert, ASB; Burns, J; Caram, MEV; Entenman, S; Kumbier, K; Skolarus, TA; Sparks, JB; Tsao, PA	1
Antonarakis, ES; Arafa, AT; Blader, LR; Engle, J; Jha, G; Ramakrishna, K; Ryan, CJ; Zorko, NA	1
Cho, JS; Choi, SM; Choi, WS; Choi, YD; Chung, BH; Hong, SH; Jeon, SS; Jeong, SH; Kang, TW; Kim, BH; Kim, SY; Kwak, C; Kwon, D; Kwon, TG; Lee, HJ; Lee, NR; Park, SW; Shin, SJ; Yeon, SE; Yun, SJ	1
Al-Rejaie, SS; Baker, A; Elgorban, AM; Mohany, M; Sajid Khan, M; Syed, A	1
Bergman, AM; Buck, SAJ; Coenen, MJH; de Jonge, E; de Wit, R; Huitema, ADR; Koolen, SLW; Mathijssen, RHJ; Meertens, M; Oomen-de Hoop, E; van Ooijen, FMF; van Schaik, RHN	1
O'Reilly, D	1
Boegemann, M; Kessel, K; Rahbar, K; Schäfers, M; Schlack, K; Seifert, R; Weckesser, M	1
Arasaratnam, M; Bhatnagar, A; Crumbaker, M; Gurney, H; McKay, MJ; Molloy, MP; Thaysen-Andersen, M	1
Bisbjerg, R; Fode, M; Kistorp, CM; Kvorning Ternov, K; Lindberg, H; Palapattu, G; Sønksen, J; Østergren, PB	1
Bamias, A; Carles, J; Castellano, D; de Bono, J; de Wit, R; Eymard, JC; Feyerabend, S; Fizazi, K; Geffriaud-Ricouard, C; Helissey, C; Iacovelli, R; Kramer, G; Melichar, B; Ozatilgan, A; Sternberg, CN; Sverrisdóttir, Á; Theodore, C; Tombal, B; Wülfing, C	1
Artigas, C; Flamen, P; Gil, T; Martinez Chanza, N; Peltier, A; Plouznikoff, N; Sideris, S	1
Aghaee-Bakhtiari, SH; Jalili, A; Mahjoubin Tehran, M; Rezaei, S; Sahebkar, A	1
Anceschi, U; Brassetti, A; Calabrò, F; Cindolo, L; De Nunzio, C; Ferriero, M; Flammia, RS; Gallucci, M; Ghahhari, J; Giacinti, S; Guaglianone, S; Leonardo, C; Mastroianni, R; Schips, L; Simone, G; Tema, G; Tubaro, A; Tuderti, G	1
Allioli, N; Crouzet, S; Decaussin-Petrucci, M; Freyer, G; Gillet, PG; Maillet, D; Peron, J; Plesa, A; Rimokh, R; Ruffion, A; Tartas, S; Vlaeminck-Guillem, V	1
Ai, J; Dong, X; Han, X; Peng, R; Wei, Q; Xu, H; Yang, L; Zhao, X; Zheng, X	1
Hadaschik, B; Hess, J; Hess-Busch, Y	1
Karaağaç, M; Karakurt Eryılmaz, M	1
Corona, SP; D'Angelo, A; Roviello, G; Sobhani, N	1
Balestra, A; Droz-Perroteau, C; Fizazi, K; Fourrier-Reglat, A; Guiard, E; Joly, F; Jove, J; Lacueille, C; Lamarque, S; Moore, N; Oudard, S; Rouyer, M; Tubach, F	1
Condon, B; Liskaser, G; Murphy, DG; Thangasamy, IA	1
Aschelter, AM; De Sanctis, V; Macrini, S; Marchetti, P; Marinelli, L; Osti, MF; Reverberi, C; Tronnolone, L; Valeriani, M	1
Ploussard, G	1
Appleman, LJ; Chatta, K; DiPippo, VA; Fleming, MT; Gore, I; Hussain, A; Israel, RJ; McClay, EF; Mega, AE; Modiano, M; Olson, WC; Petrylak, DP; Sartor, AO; Shore, ND; Singh, P; Smith, DC; Somer, B; Stambler, N; Tagawa, ST; Vogelzang, NJ; Wadlow, R	1
Azuma, H; Fujiwara, Y; Hirano, H; Ibuki, N; Ichihashi, A; Inamoto, T; Komura, K; Matsunaga, T; Minami, K; Nishimoto, Y; Nomi, H; Saito, K; Takahara, K; Takai, T; Tanaka, T; Tanda, N; Taniguchi, K; Tsujino, T; Tsutsumi, T; Uchimoto, T; Uehara, H; Yoshikawa, Y	1
Barata, PC; Chapman, L; Christensen, BR; Cotogno, P; Layton, JL; Ledet, EM; Lewis, BE; Manogue, C; Moses, M; Ranasinghe, L; Sartor, O; Steinwald, P	1
Gotoh, M; Hattori, K; Hattori, R; Ishikawa, T; Kato, M; Kawanishi, H; Naito, Y; Sano, T; Tochigi, K; Tsuzuki, T; Yamamoto, A; Yuba, T	1
Badrising, SK; Beeker, A; Bergman, AM; Celik, F; Coenen, JLLM; Haanen, JB; Hamberg, P; Lam, MGEH; Loosveld, OJL; Louhanepessy, RD; Oostdijk, A; van der Noort, V; Vegt, E; Wagenaar, N; Zuetenhorst, H; Zwart, W	1
Higa, J; Larsen, C; Savino, S; Scholz, M; Vogelzang, N; Wilenius, K	1
Assenholt, J; Hansen, TF; Madsen, JS; Osther, PJS; Zedan, AH	1
Ahmed, ME; Andrews, JR; Bryce, AH; Karnes, RJ; Kwon, E	1
Banna, GL; Basso, U; Benanti, C; Bimbatti, D; De Giorgi, U; Di Quattro, R; Libra, M; Lipari, H; Malatino, L; Pitrè, A; Rundo, F; Schepisi, G; Urzia, V	1
Casadei, C; Cursano, MC; De Giorgi, U; Iuliani, M; Paganelli, G; Santini, D; Stellato, M; Tonini, G	1
Feng, Y; Guan, Y; Liao, G; Pang, J; Tong, T; Xiong, H	1
Arenas-Bonilla, AJ; Flores-Martín, JF; Galisteo-Moya, R; Gutiérrez-Tejero, F; Moreno-Jiménez, J; Nieblas-Toscano, D; Ramos-Alaminos, CI; Salas-Moreno, MC; Velarde-Muñoz, C	1
George, DJ; Higano, CS; Jiao, X; Kalinovský, J; Miller, K; Saad, F; Sartor, O; Sternberg, CN; Tangirala, K; Tombal, B	1
Baser, O; George, DJ; Huang, A; Lechpammer, S; Mardekian, J; Ramaswamy, K; Sandin, R; Schultz, NM; Wang, L	1
Deng, T; Ge, R; Lin, X; Long, X; Olumi, AF; Taplin, ME; Wang, H; Wang, Z; Wu, CL; Wu, S; Zhang, Z	1
Briganti, A; Egawa, S; Karakiewicz, PI; Kimura, S; Kimura, T; Miura, N; Mori, K; Mostafaei, H; Pradere, B; Quhal, F; Sari Motlagh, R; Shariat, SF	1
Hu, S; Liu, C; Song, S; Su, H; Wang, B; Xu, X; Ye, D; Zhang, Y; Zhu, Y	1
Carretero-González, A; Castellano, D; de Velasco, G; Lora, D; Lorente, D; Manneh, R	1
De Bono, J; Gibbs, P; IJzerman, M; Kwan, EM; Pereira-Salgado, A; Tran, B	1
Chen, C; Fang, H; Ge, H; He, H; He, L; Wan, Y; Wang, L; Wang, Y; Wu, Y	1
Csizmarik, A; Fazekas, T; Grünwald, V; Hadaschik, B; Hüttl, A; Jurányi, Z; Kocsis, Z; Kramer, G; Maj-Hes, A; Nyirády, P; Püllen, L; Sevcenco, S; Shariat, SF; Szarvas, T	1
Alvarez-Madrazo, S; Baillie, K; Bennie, M; Cameron, D; Clarke, J; Crearie, C; Jones, RJ; Kavanagh, K; Keel, A; Kurdi, A; Laskey, J; Morrison, D; Mueller, T; Pan, J; Wu, O	1
Adelman, CA; Agarwal, N; Burgents, J; Chi, KN; de Bono, J; Fizazi, K; Goessl, C; Hussain, M; Kang, J; Kohlmann, A; Mateo, J; Mehra, N; Olmos, D; Saad, F; Sandhu, S; Sartor, O; Shore, N; Thiery-Vuillemin, A; Twardowski, P; Wu, W	1
Csizmarik, A; Keresztes, D; Küronya, Z; Nagy, N; Nyirády, P; Riesz, P; Szarvas, T; Váradi, M	1
Antonarakis, ES; Bertan, C; Carreira, S; Chen, Y; De Bono, JS; Dolling, D; Fountain, J; Isaacs, WB; Lu, C; Luo, J; Sharp, A; Terbuch, A; Wang, H; Yu, J	1
George, DJ; Higano, CS; Jiao, X; Kalinovsky, J; Miller, K; Saad, F; Sartor, O; Shore, N; Sternberg, CN; Tangirala, K; Tombal, B	1
Abou Chakra, M; Dellis, A; Moussa, M; Papatsoris, A; Sryropoulou, D	1
Egawa, S; Fukuokaya, W; Kimura, S; Kimura, T; Koike, Y; Miki, K; Sasaki, H; Tashiro, K; Tsuzuki, S; Urabe, F	1
Hu, X; Liu, L; Wang, S; Wang, W; Wang, X; Yang, H; Yu, X; Zhang, X	1
Annala, M; Aragón, IM; Castro, E; Cendón, Y; Chi, KN; Finch, DL; Gleave, ME; Khalaf, DJ; Lorente, D; Lozano, R; Oja, C; Olmos, D; Pacheco, MI; Romero-Laorden, N; Taavitsainen, S; Vergidis, J; Wyatt, AW; Zulfiqar, M	1
Sharifi, N	1
Antonarakis, ES; Carducci, MA; Denmeade, SR; Eisenberger, MA; Fu, W; Luo, J; Markowski, MC; Marshall, CH; Ngomba, N; Paller, CJ; Rifkind, I; Schweizer, MT; Sinibaldi, V; Sullivan, R; Teply, BA; Wang, H	1
Allman, K; Barata, P; Fallah, J; Garcia, JA; Gilligan, TD; Gupta, R; Li, H; Martin, A; Ornstein, MC; Rini, BI; Sheng, IY	1
Attard, G; Casadei, C; Conteduca, V; De Giorgi, U; Demichelis, F; Gonzalez-Billalabeitia, E; Gurioli, G; Jayaram, A; Lolli, C; Matteucci, F; Paganelli, G; Romanel, A; Scarpi, E; Schepisi, G; Tandefelt, DG; Wetterskog, D; Wingate, A	1
Aparicio, A; Araujo, JC; Boukovala, M; Corn, PG; Efstathiou, E; Hoang, A; Kim, J; Logothetis, CJ; Pagliaro, L; Spetsieris, N; Subudhi, SK; Tannir, NM; Troncoso, P; Tsikkinis, A; Tu, SM; Wang, J; Wang, X; Weldon, JA; Wen, S; Zurita, AJ	1
Abida, W; Aggarwal, RR; Alumkal, JJ; Attwell, S; Bauman, L; Campeau, E; Feng, FY; Heath, EI; Lakhotia, S; Nanus, DM; Norek, K; Pantuck, AJ; Schweizer, MT; Small, EJ; Snyder, M	1
Agarwal, N; Barata, PC; Cotogno, P; Hahn, AW; Layton, J; Ledet, E; Lewis, B; Lilly, MB; Manogue, C; Moses, M; Niu, A; Nussenzveig, R; Sartor, O	1
Cayol, F; Frecha, C; Martínez-Gregorio, H; Montealegre-Páez, L; Oliver, J; Pacheco-Orozco, RA; Perdomo, S; Vaca-Paniagua, F	1
Ahmed, ME; Alamiri, J; Alom, M; Andrews, JR; Haloi, R; Higa, J; Jeffrey Karnes, R; Joshi, V; Kwon, E; Motterle, G; Shah, PH	1
Bourlon, C; Bourlon, MT; Carretero-Gonzalez, A; Carril-Ajuria, L; Castellano, D; de Velasco, G; Martin-Soberon, M; Remolina-Bonilla, YA	1
Afonso, A; Carneiro, F; Coelho, S; Lopes, AR; Maurício, MJ; Medeiros, R; Patrão, AS; Pinto, AR; Rosinha, A; Silva, J	1
Artemov, D; Bařinka, C; Gabrielson, K; Guo, X; Hapuarachchige, S; Huang, CT; Lupold, SE; Pomper, MG; Raman, V	1
Alongi, F; Arcangeli, S; Borghesi, S; Fersino, S; Jereczek-Fossa, BA; Magrini, SM; Mortellaro, G	1
Chang, HM; Chen, HL; Chen, TC; Cheng, HM; Hao, SY; Huang, WH; Juan, YS; Lee, HY; Teoh, JY; Tsai, HY	1
Gotoh, M; Hattori, K; Hattori, R; Ishikawa, T; Kato, M; Kawanishi, H; Kimura, T; Matsukawa, Y; Naito, Y; Nishikimi, T; Sano, T; Tsuzuki, T; Yamamoto, A; Yuba, T; Yuguchi, Y	1
Bensfia, S; Carles, J; Castellano, D; de Bono, J; de Wit, R; Eymard, JC; Facchini, G; Feyerabend, S; Fizazi, K; Geffriaud-Ricouard, C; Helissey, C; Iacovelli, R; Kramer, G; Liontos, M; Melichar, B; Oudard, S; Ozatilgan, A; Poole, EM; Sternberg, CN; Sverrisdóttir, Á; Theodore, C; Tombal, B; Wülfing, C	1
Armstrong, CM; D'Abronzo, LS; Evans, CP; Gao, AC; Li, PK; Liu, C; Liu, L; Lombard, AP; Lou, W; Ning, S; Yang, JC; Zhao, J; Zhao, R	1
Abe, T; Eto, M; Inokuchi, J; Kashiwagi, E; Machidori, A; Monji, K; Naito, S; Shiota, M; Takahashi, R; Takeuchi, A; Yokomizo, A	1
Balusson, F; Campillo-Gimenez, B; Despas, F; Happe, A; Kerbrat, S; Mathieu, R; Nowak, E; Oger, E; Scailteux, LM; Vincendeau, S	2
Amaravadi, R; Black, TA; Buckingham, TH; Calara-Nielsen, K; Carpenter, EL; Cherkas, Y; Foulk, B; Gross, S; Haas, NB; He, M; Jones, JO; LaRiviere, MJ; Long, Q; Majmundar, KJ; Min, EJ; Pal, SK; Patel, J; Savitch, SL; Smirnov, D; Vaughn, DJ; Wellen, KE; Yee, SS	1
Csizmarik, A; Fazekas, T; Grünwald, V; Hadaschik, B; Hüttl, A; Kramer, G; Maj-Hes, A; Nyirády, P; Sevcenco, S; Shariat, SF; Szarvas, T; Tschirdewahn, S; Váradi, M	1
Iwamoto, H; Izumi, K; Kadomoto, S; Kadono, Y; Kano, H; Makino, T; Mizokami, A; Naito, R; Shigehara, K; Shimada, T; Yaegashi, H	1
Eto, M; Inokuchi, J; Kashiwagi, E; Kobayashi, S; Machidori, A; Matsumoto, T; Monji, K; Shiota, M; Takahashi, R; Takeuchi, A	1
Hu, X; Hui, Y; Liu, L; Wang, S; Wang, W; Wang, X; Yu, X; Zhang, X	1
Clements, S; Descamps, T; Fischer, S; Gillessen, S; Green, A; McWilliam, A; Oing, C	1
Fontana, F; Limonta, P; Marzagalli, M; Montagnani Marelli, M; Moretti, RM; Raimondi, M	1
Fallara, G; Garmo, H; Lissbrant, IF; Montorsi, F; Stattin, P; Styrke, J	1
Cao, W; He, L; Huang, S; Li, Y; Liu, B; Liu, Y; Long, W; Mai, L; Wu, J; Zhang, Z; Zhou, F	1
Li, Q; Xie, D; Zhang, PF	1
Aslan, M; Brooks, JD; Corey, E; Ghoochani, A; Hsu, EC; Nguyen, HM; Paulmurugan, R; Rice, MA; Stoyanova, T	1
Casadei, C; Conteduca, V; Crucitta, S; Cucchiara, F; Danesi, R; De Giorgi, U; Del Re, M; Gurioli, G; Lolli, C; Restante, G; Schepisi, G	1
Abouassaly, R; Bryk, DJ; Ericson, K; Fascelli, M; Haywood, SC; Khanna, A; Murthy, PB; O'Connor, LP; Yerram, NK	1
Eto, M; Inokuchi, J; Kashiwagi, E; Kobayashi, S; Koura, M; Matsumoto, T; Monji, K; Shiga, KI; Shiota, M; Takeuchi, A; Ueda, S; Yokomizo, A	1
Arranz, JA; Castro, E; Climent, MA; Gallardo, E; González Del Alba, A; Gonzalez-Billalabeitia, E; Lorente, D; Maroto, JP; Méndez-Vidal, MJ; Vazquez, S	1
Ebinç, S; Isikdogan, A; Kaplan, MA; Karaağaç, M; Kaya, AO; Koca, S; Kut, E; Menekşe, S; Oruç, Z; Özyurt, N; Sakin, A; Sever, ÖN; Tatlı, AM; Turhal, NS; Yasin, İ; Zeynelgil, E	1
Akamatsu, S; Eto, M; Fujiwara, M; Habuchi, T; Narita, S; Ogawa, O; Shiota, M; Sumiyoshi, T; Uchiumi, T	1
Amling, CL; Aronson, WJ; Cooperberg, MR; De Hoedt, AM; Freedland, SJ; Howard, LE; Kane, CJ; Klaassen, Z; Polascik, TJ; Terris, MK; Vidal, AC; Zhao, H	1
Agarwal, N; Dall'Era, M; Evans, CP; Gao, AC; Lara, PN; Liu, C; Pan, CX; Parikh, M; Robles, D; Wu, CY	1
Castellano, D; de Bono, J; de Wit, R; Fizazi, K; Foster, MC; Geffriaud-Ricouard, C; Ozatilgan, A; Sternberg, CN; Suzuki, H; Tombal, B; Wülfing, C	1
Aben, KKH; Bergman, AM; Coenen, JLLM; de Wit, R; Gerritsen, WR; Kuppen, MCP; Mehra, N; Somford, DM; Uyl-de Groot, CA; van den Bergh, ACM; van den Eertwegh, AJM; van Moorselaar, RJA; van Oort, IM; Westgeest, HM	1
Bradic, B; Chi, KN; De Meulder, M; Espina, BM; Francis, P; Graff, JN; Hayreh, V; Hazra, A; Lattouf, JB; Mamidi, RNVS; Posadas, EM; Rezazadeh Kalebasty, A; Saad, F; Shore, ND; Yu, A; Zhu, E	1
Izard, JP; Robinson, AG; Vera-Badillo, FE	1
Bungaro, M; Buttigliero, C; DI Maio, M; DI Stefano, RF; Pisano, C; Samuelly, A; Scagliotti, GV; Tarenghi, F; Tucci, M; Turco, F; Vignani, F	1
Bothos, J; Cathomas, R; Cho, S; de Bono, JS; Fleming, MT; He, P; Hinrichs, MJ; Liang, M; Martinez, P; Miralles, MS; Petrylak, DP; Rosenbaum, AI; Vashisht, K; Wang, JS; Williams, M; Zhang, Q	1
Anand, M; Antonarakis, ES; Armstrong, AJ; Barnett, ES; Berry, WR; Brown, LC; Carbone, EA; Danila, DC; George, DJ; Giannakakou, P; Gill, A; Gregory, SG; Gupta, S; Halabi, S; Healy, P; Jendrisak, A; Luo, J; Nanus, DM; Scher, HI; Schonhoft, JD; Szmulewitz, RZ; Wenstrup, R; Yang, Q; Zhao, JL	1
Bratt, O; Fode, M; Kistorp, C; Klausen, TW; Lindberg, H; Nolsøe, AB; Palapattu, G; Sønksen, J; Ternov, KK; Østergren, PB	1
Annala, M; Azad, AA; Bacon, JVW; Beja, K; Chi, KN; Ferrario, C; Fu, S; Gingerich, JR; Hotte, SJ; Iqbal, N; Kallio, HML; Khalaf, DJ; Lo, G; North, SA; Nykter, M; Ong, M; Pezaro, CJ; Ruether, JD; Schönlau, E; Sipola, J; Sridhar, SS; Taavitsainen, S; Tran, B; Vandekerkhove, G; Wadhwa, D; Wong, A; Wood, LA; Wyatt, AW	1
Antonarakis, ES; Armstrong, AJ; Barnett, E; Carbone, E; Danila, DC; Dos Anjos, CH; George, D; Gill, A; Gonen, M; Halabi, S; Lu, J; Luo, J; Scher, HI; Schonhoft, JD; Szmulewitz, R; Tagawa, S; Wenstrup, R; Yang, Q; Zhao, JL	1
Aksoy, S; Akyol, F; Guler, OC; Hurmuz, P; Kose, F; Muallaoglu, S; Onal, C; Oymak, E; Ozyigit, G; Tilki, B	1
Buck, SAJ; de Wit, R; Robbrecht, DGJ	1
Bögemann, M; Rexer, H; Stenzl, A	1
Annala, M; Beja, K; Chi, KN; Eigl, BJ; Finch, DL; Fu, S; Gleave, ME; Herberts, C; Khalaf, DJ; Kollmansberger, CK; Nykter, M; Oja, CD; Sipola, J; Taavitsainen, S; Vandekerkhove, G; Vergidis, J; Warner, EW; Wong, A; Wyatt, AW; Zulfiqar, M	1
Chi, KN; Eigl, BJ; Finch, D; Khalaf, DJ; Kollmannsberger, CK; Nappi, L; Noonan, K; Soleimani, M; Struss, W; Sunderland, K; Vergidis, J; Zou, K; Zulfiqar, M	1
Alibhai, SMH; Breunis, H; Emmenegger, U; Feng, G; Fleshner, N; Gregg, R; Hansen, A; Joshua, A; Timilshina, N; Tomlinson, G; Warde, P	1
Alekseev, B; Alves, GV; Atduev, V; Borre, M; Bournakis, E; Bracarda, S; Buchschacher, GL; Chen, G; Chi, KN; Corrales, L; de Bono, JS; Gafanov, R; Gallo, J; Garcia, J; Hanover, J; Harle-Yge, ML; Massard, C; Matsubara, N; Olmos, D; Parnis, F; Puente, J; Sandhu, S; Sternberg, CN; Stroyakovskiy, D; Sweeney, C; Wongchenko, MJ	1
Bamias, A; Carles, J; Castellano, D; de Bono, J; de Wit, R; Eymard, JC; Feyerabend, S; Fizazi, K; Geffriaud-Ricouard, C; Helissey, C; Iacovelli, R; Kramer, G; Melichar, B; Ozatilgan, A; Poole, EM; Sternberg, CN; Sverrisdóttir, Á; Theodore, C; Tombal, B; Wülfing, C	1
Chen, J; Dai, J; Liang, J; Liu, Z; Ni, Y; Shen, P; Sun, G; Wang, Z; Zeng, H; Zhang, H; Zhang, X; Zhang, Y; Zhao, J; Zhu, S; Zhu, X	1
Chow, K; Clarke, D; Cmero, M; Corcoran, NM; Costello, AJ; Dundee, P; Grima, C; Grummet, J; Hovens, CM; Howard, N; Kerger, M; Kurganovs, NJ; Macintyre, G; Mangiola, S; McCoy, P; Ngyuen, A; Norden, S; Parente, P; Peters, JS; Ruljancich, P; Ryan, A; Stuchbery, R	1
Ai, J; Bai, S; Lei, H; Liao, D; Peng, G; Qiu, S; Xiong, X; Xu, H; Yang, L; Yi, X	1
Anton, A; Azad, A; Gibbs, P; Goh, J; Gunjur, A; Kwan, EM; Parente, P; Parnis, F; Pezaro, C; Semira, MC; Shapiro, J; Spain, L; Torres, J; Tran, B; Weickhardt, A; Wong, S	1
Castro, E; de Velasco, G; di Capua, C; Ferrer, C; Llacer, C; Lorente, D; Lozano, R; Olmos, D; Rodrigo, M; Romero-Laorden, N; Sánchez-Hernández, A; Sánchez-Iglesias, Á	1
Duh, MS; Ghate, SR; Ionescu-Ittu, R; Kim, J; Laliberté, F; Lejeune, D; Mahendran, M; Shore, ND; Yang, L; Yu, L	1
Chen, L; Cheng, L; Li, X; Li, Y; Liu, B; Lu, D; Lv, F; Song, Y; Wang, D; Xing, Y; Yu, Y; Zhang, P	1
Balk, SP; Cheng, HH; Chew, F; Kantoff, PW; Kolokythas, O; Marck, BT; Matsumoto, AM; Montgomery, RB; Mostaghel, EA; Nelson, PS; Schweizer, MT; Sharifi, N; Taplin, ME; Yu, EY	1
Chen, J; Chen, N; Chen, X; Dai, J; He, B; Liang, J; Liu, Z; Ni, Y; Nie, L; Shen, P; Sun, G; Tao, R; Wang, Z; Zeng, H; Zhang, H; Zhang, M; Zhang, X; Zhao, J; Zhu, S; Zhu, X	1
Benoist, GE; Boerrigter, E; Donders, R; Mehra, N; Overbeek, JK; Ter Heine, R; van Erp, NP; van Oort, IM	1
Bamias, A; Carles, J; Castellano, D; de Bono, J; de Wit, R; Eymard, JC; Feyerabend, S; Fizazi, K; Foster, MC; Geffriaud-Ricouard, C; Helissey, C; Iacovelli, R; Kramer, G; Melichar, B; Ozatilgan, A; Sternberg, CN; Sverrisdóttir, Á; Theodore, C; Tombal, B; Wülfing, C	1
Armstrong, A; Balk, M; Brown, B; Bui, C; Chambers, J; Deangelis, J; Fitch, K; Flanders, S; Sawhney, TG	1
Dineen, M; Guancial, E; Hansen, E; Sahasrabudhe, D; Sievert, L	1
Alexandre, J; Azoulay-Rutman, E; Blanchet, B; Bonnet, C; Boudou-Rouquette, P; Carton, E; Chah Wakilian, A; Goldwasser, F; Golmard, JL; Huillard, O; Noé, G; Orvoen, G; Thomas-Schoemann, A; Vidal, M; Villeminey, C	1
Antonarakis, ES; Carducci, MA; Chen, Y; Denmeade, SR; Eisenberger, MA; Lu, C; Luber, B; Luo, J; Maughan, BL; Paller, CJ; Pienta, KJ; Silberstein, JL; Taylor, MN; Wang, H; Zhu, Y	1
Berdah, JF; Culine, S; Massard, C; Pasquier, D; Penel, N; Turpin, A	1
Balk, SP; Bubley, GJ	1
Fujisawa, M; Miyake, H; Nishikawa, M	1
Aieta, M; Bianchi, E; Caffo, O; Campadelli, E; Carrozza, F; Chiuri, VE; Conteduca, V; De Giorgi, U; Facchini, G; Lolli, C; Maines, F; Massari, F; Salvi, S; Scarpi, E; Schepisi, G; Veccia, A	1
Akamatsu, S; Antonarakis, ES; Inoue, T; Kamba, T; Kobayashi, T; Maughan, BL; Ogawa, O; Terada, N; Yamasaki, T	1
Amadori, D; Attard, G; Casadio, V; Castellano, D; Climent, MA; Conteduca, V; De Giorgi, U; Dearnaley, D; Demichelis, F; Duran, I; Fernandez-Calvo, O; Fernandez-Perez, MP; Font, A; Gallardo, E; Gasi Tandefelt, D; González Del Alba, A; Gonzalez-Billalabeitia, E; Grande, E; Gurioli, G; Jayaram, A; Lolli, C; Mellado, B; Méndez-Vidal, MJ; Puente, J; Rodriguez, A; Romanel, A; Sáez, MI; Salvi, S; Santander, C; Sharabiani, MTA; Vazquez-Estevez, S; Wetterskog, D; Wingate, A	1
Carlson, RE; Clark, T; Costello, BA; Dehm, SM; Eckloff, BW; Henzler, C; Hillman, DW; Ho, Y; Hon, T; Huang, H; Jen, J; Jimenez, R; Kohli, M; Lang, JM; Li, Y; Pitot, HC; Quevedo, JF; Sicotte, H; Silverstein, KAT; Sperger, JM; Tan, W; Thai, H; Tseng, E; Van Etten, JL; Vedell, PT; Wang, L; Wieben, ED; Yang, R	1
Yuasa, T	1
Mitsuzuka, K	1
Egawa, S; Kimura, S; Kimura, T; Miki, J; Miki, K; Mori, K; Onuma, H; Sasaki, H; Yamamoto, T	1
Gallagher, M; Reinhart, M; Sartor, O; Summers, N; Vanderpuye-Orgle, J	1
Borza, T; Caram, MEV; Griggs, JJ; Hollenbeck, BK; Miller, DC; Min, HS; Mukherjee, B; Skolarus, TA	1
Saad, F; Traboulsi, SL	1
Aggarwal, RR; Alumkal, JJ; Alyamani, M; Anantharaman, A; Beer, TM; Dittamore, R; Fong, L; Friedlander, TW; Graff, JN; Huang, Y; Kim, W; Lin, AM; Paris, PL; Paz, R; Premasekharan, G; Russell, C; Ryan, CJ; Sharifi, N; Small, EJ; Zejnullahu, K; Zhang, L	1
Borghesi, S; Bruni, A; Carfagno, T; D'Angelillo, RM; Detti, B; Fondelli, S; Francolini, G; Ingrosso, G; Livi, L; Olmetto, E; Santini, R; Santoni, R; Triggiani, L; Trodella, LE	1
Bernemann, C; Lennerz, JK; Schrader, AJ; Steinestel, J	1
Antonarakis, ES; Luber, B; Luo, J; Wang, H	1
Becker, C; Roos, FC; Thelen, P; Tsaur, I	1
Cai, W; Chi, C; Dong, B; Fan, L; Hu, J; Pan, J; Shangguan, X; Shao, X; Wang, R; Wang, X; Wang, Y; Xie, S; Xin, Z; Xu, F; Xue, W; Zhou, L; Zhu, Y	1
Bianchini, D; de Bono, J; Gilman, A; Hall, E; IJzerman, M; Kolinsky, M; Lorente, D; Mateo, J; Mehra, N; Miranda, M; Omlin, A; Payne, H; Perez, R; Pezaro, C; Porta, N; Ravi, P; Rescigno, P; Terstappen, L; Tunariu, N	1
Cheng, WY; Dhawan, R; Duh, MS; Gauthier-Loiselle, M; Miao, R; Oh, WK; Sung, J; Vekeman, F	1
Black, PC; Struss, WJ	1
Bietenbeck, A; Gschwend, JE; Heck, MM; Nawroth, R; Retz, M; Ruland, J; Schmid, S; Secci, R; Seitz, AK; Tauber, R; Thalgott, M; Thoene, S; Winter, C	1
Bando, Y; Fujisawa, M; Furukawa, J; Harada, KI; Hinata, N; Nakano, Y; Terakawa, T	1
Blasi, L; Cicero, G; De Luca, R; Dieli, F; Pavone, C; Pepe, A; Simonato, A	1
Enokida, H; Inoue, S; Ishibashi, K; Izumi, K; Kamiyama, M; Kawai, N; Mizokami, A; Namiki, M; Shima, T; Takahara, S; Tanaka, N; Yoshio, Y	1
Grimm, MO; von Rundstedt, FC; Winter, BM	1
Fukasawa, S; Kamiya, N; Kawahara, T; Kawakami, S; Matsubara, N; Otsuka, M; Satoh, T; Suzuki, H; Tabata, KI; Uemura, H; Yamada, Y; Yano, A	1
Borgmann, H; Ost, P; Ploussard, G; Surcel, CI; Tsaur, I	1
Lundholm, M; Nilsson, RJA; Schröder, M; Thellenberg-Karlsson, C; Tjon-Kon-Fat, LA; Widmark, A; Wikström, P; Wurdinger, T	1
Bianchi, E; Caroli, P; Celli, M; Conteduca, V; De Giorgi, U; Fantini, L; Galassi, R; Matteucci, F; Moretti, A; Paganelli, G; Rossi, L; Scarpi, E	1
Aggarwal, R	1
Burgio, SL; Caroli, P; Casadio, V; Conteduca, V; De Giorgi, U; Gurioli, G; Lolli, C; Matteucci, F; Menna, C; Paganelli, G; Salvi, S; Scarpi, E; Schepisi, G; Testoni, S	1
Brown, JS; Cunningham, JJ; Gatenby, RA; Zhang, J	1
Bansal, S; Emmenegger, U; Kulkarni, GS; Nam, RK; Saskin, R; Satkunasivam, R; Wallis, CJD	1
Attard, G; Linch, M	1
Attard, G; Balk, SP; Bevan, C; Burnstein, K; Cato, L; Cherkasov, A; De Bono, JS; Dehm, SM; Dong, Y; Gao, AC; Gleave, M; Heemers, H; Kanayama, M; Kittler, R; Lang, JM; Lee, RJ; Logothetis, CJ; Luo, J; Matusik, R; Plymate, S; Raj, GV; Sawyers, CL; Selth, LA; Soule, H; Tilley, W; Weigel, NL; Zoubeidi, A	1
Albany, C; Antonarakis, ES; Cao, X; Caram, MV; Chinnaiyan, AM; Cooney, KA; Corn, PG; Daignault-Newton, S; Feng, FY; Hussain, M; Knudsen, KE; Kunju, LP; Lonigro, RJ; Mehra, R; Montgomery, B; Robinson, D; Shevrin, DH; Siddiqui, J; Smith, DC; Stadler, WM; Stein, MN; Tomlins, SA; Twardowski, PW; Whang, YE; Wu, YM	1
Cai, W; Chi, C; Dong, B; Fan, L; Pan, J; Qian, H; Shangguan, X; Shao, X; Wang, R; Wang, Y; Xu, F; Xue, W; Zhang, Y; Zhou, L; Zhu, Y	1
Heidenreich, A; Nilsson, S; Parker, C; Shore, N	1
Antonarakis, ES; Boucher, K; Guedes, LB; Klimek, S; Liu, Z; Lotan, TL; Maughan, BL; Rajoria, G; Zoino, R	1
Hao, S; He, Y; Huang, H; Kohli, M; Li, B; Lu, J; Tindall, DJ; Wang, L; Ye, Z; Zhu, R	1
Azuma, T	1
Buelens, S; Claeys, T; Dhondt, B; Kumps, C; Lumen, N; Ost, P; Poelaert, F; Thas, O; Vandesompele, J; Vynck, M; Yigit, N	1
Folkvaljon, Y; Franck Lissbrant, I; Hjälm-Eriksson, M; Lambe, M; Robinson, D; Stattin, P; Törnblom, M; Ventimiglia, E	1
Baser, O; Huang, A; Miao, R; Sonpavde, G; Wang, L	1
Burgio, SL; Caffo, O; Chiuri, VE; Conteduca, V; De Giorgi, U; Fratino, L; Galli, L; Kinspergher, S; Lolli, C; Maines, F; Maugeri, A; Menna, C; Salvi, S; Santini, D; Santoni, M; Scarpi, E; Schepisi, G	1
Ampe, J; Beije, N; Bols, A; Brouwer, A; Brouwers, B; de Kruijff, I; De Laere, B; De Maeseneer, D; Demey, W; Dirix, L; Everaert, E; Fransis, K; Ghysel, C; Hoekx, L; Lybaert, W; Oeyen, S; Ost, P; Rutten, A; Schrijvers, D; Sleijfer, S; Strijbos, M; van Dam, PJ; van Dam, V; Van den Eynden, G; Van Kerckhove, P; Van Laere, S; Van Oyen, P; Vandebroek, J	1
Drakaki, A; Faiena, I; Pantuck, AJ; Salmasi, A	1
Chan, FL; Hu, H; Ng, CF; Wang, Y; Wang, Z; Wu, D; Xiao, L; Xu, K; Xu, Z; You, W; Yu, S	1
Antonarakis, ES; Chen, Y; Isaacs, WB; Lai, Z; Liang, C; Lu, C; Luber, B; Luo, J; Piana, D; Silberstein, JL; Wang, H	1
Thoma, C	2
Aggarwal, R; Chang, E; Fong, L; Friedlander, TW; Kim, W; Lin, AM; Louttit, M; Ryan, CJ; Siegel, AP; Wei, XX; Zhang, L	1
Elkon, JM; Lin, J; Millado, KF; Millett, RL	1
Butler, LM; Centenera, MM; Ebrahimie, E; Selth, LA; Tilley, WD	1
Ahire, K; Bhatnagar, A; Crumbaker, M; Gurney, H; Karuso, P; McKay, MJ; Molloy, MP	1
Gourdin, T	2
Bauernhofer, T; Belic, J; Cherkas, Y; Geigl, JB; Gormley, M; Graf, R; Gross, M; Heitzer, E; Li, W; Patel, J; Perakis, S; Smirnov, D; Speicher, MR; Ulz, P; Waldispuehl-Geigl, J	1
Kolesar, JM; Liu, GX	1
Carthon, B; Chiong, E; Figg, WD; Fishkin, P; Harvey, RD; Ibraheem, A; Karrison, T; Kozloff, MF; Martinez, E; Nabhan, C; Peer, CJ; Ratain, MJ; Stadler, WM; Szmulewitz, RZ; Yong, WP	1
Attard, G; Jayaram, A; Wetterskog, D	1
Alexander, DD; Deuson, R; Fryzek, JP; Reichert, H; Summers, N; Townes, L; Vanderpuye-Orgle, J	1
Bianchini, D; Crespo, M; de Bono, JS; Dolling, D; Figueiredo, I; Flohr, P; Lorente, D; Mateo, J; Miranda, S; Olmos, D; Scher, HI; Seed, G; Terstappen, LWMM	1
Buzza, M; Casey, O; Catto, J; Chan, JM; Courneya, KS; Finn, SP; Galvão, DA; Gledhill, S; Greenwood, R; Guinan, EM; Hart, NH; Hughes, DC; Kenfield, SA; Mucci, L; Newton, RU; Plymate, SR; Praet, SFE; Ryan, CJ; Saad, F; Van Blarigan, EL; Zhang, L	1
He, P; Shen, W; Wang, Y; Zhang, H; Zhou, Z	1
Anai, S; Fujimoto, K; Inoue, T; Miyake, M; Nakai, Y; Tanaka, N	1
Antonarakis, ES	3
Alekseev, B; Burgents, J; Chiuri, VE; Clarke, N; Fléchon, A; Goessl, C; Hodgson, D; Jassem, J; Jones, R; Kocak, I; Kozarski, R; Learoyd, M; Redfern, C; Saad, F; Sala, N; Wiechno, P	1
Ali, R; Chambers, C; Ghosh, S; North, S; Sawyer, M; Shivji, A	1
Franklin, GE; Rathbun, JT	1
Fizazi, K; Hamilou, Z; Saad, F	1
Crabb, SJ	1
Andresen-Daniil, C; Attard, G; Borre, M; Gurney, H; Kalleda, R; Loriot, Y; Pham, T; Taplin, ME	1
Arranz Arija, JA; Bracarda, S; Chan, WY; de Bono, JS; De Giorgi, U; Font, A; Gendreau, S; Jinga, V; Ma, H; Maslyar, DJ; Massard, C; Patel, PH; Radavoi, GD; Riisnaes, R; Rodrigues, DN; Shih, KC; Xu, N	1
Azad, A; Banks, P; Bolton, D; Castro, E; Clark, AK; Clouston, D; Dehm, SM; Frydenberg, M; Furic, L; Goad, J; Goode, DL; Grummet, J; Hannan, RD; Hanson, AR; Harewood, L; Hedwards, S; Henzler, C; Huglo, A; Keerthikumar, S; Kourambas, J; Lawrence, MG; Lawrentschuk, N; Li, Y; Lister, N; Lopez-Campos, F; Mitchell, C; Moon, D; Murphy, DG; Niranjan, B; Norden, S; Obinata, D; Papargiris, M; Pearson, RB; Pedersen, J; Pezaro, CJ; Pook, D; Porter, LH; Rebello, RJ; Risbridger, GP; Ryan, A; Sandhu, S; Selth, LA; Sengupta, S; Snow, R; Taylor, RA; Thorne, H; Tilley, WD; Toivanen, R; Van Gramberg, J; Wang, H; Wong, SQ; Yang, R	1
Saad, F	2
Barret, E; Bennamoun, M; Bonnetain, F; Cathala, N; Cathelineau, X; Charton, E; Fenioux, C; Henriques, J; Joulia, ML; Louvet, C; Molitor, JL; Mombet, A; Prapotnich, D; Ropert, S; Rozet, F; Sanchez-Salas, R	1
Baldauf, S; Bartsch, G; Borgmann, H; Brandt, MP; Dotzauer, R; Frees, S; Haferkamp, A; Jäger, W; Neisius, A; Schneider, M; Thomas, C; Tsaur, I	1
Attard, G; Castro, E; Cendón, Y; Correa, R; Cruz, JJ; Garcés, T; Grau, G; Gutierrez-Pecharoman, A; Herrera, B; Jayaram, A; López, PP; López-Campos, F; Lorente, D; Lozano, R; Montesa, A; Nombela, MP; Olmos, D; Pacheco, MI; Rivera, L; Romero-Laorden, N; Rosero, A; Saez, MI; Van de Poll, F; Villatoro, R	1
Alva, AS; Cao, X; Chinnaiyan, AM; Delekta, A; Jing, X; Juckette, KM; Kim, Y; Luo, E; MacLeod, AR; Parolia, A; Qiao, Y; Shukla, S; Su, F; Tan, M; Tien, JC; Vo, J; Wang, L; Wang, X; Xiao, L; Xu, A; Zhang, Y; Zheng, H	1
Akise, Y; Endo, J; Itabashi, Y; Kageyama, T; Mitamura, H; Murata, M; Nagatomo, Y; Nakajima, Y; Tsugu, T	1
Tannock, IF	1
Ratain, MJ; Stadler, WM; Szmulewitz, RZ	1
Karrison, T; Ratain, MJ; Stadler, WM; Szmulewitz, RZ	1
Eisenberger, MA; Velho, PI	1
Alexandre, J; Blanchet, B; Goldwasser, F; Tiako Meyo, M	1
Beuselinck, B; Moes, DJAR; Osanto, S; Spriet, I; Stroobants, S; van Erp, NP; Van Nieuwenhuyse, T; Woei-A-Jin, FJSH	1
Kolesar, JM; Liu, G	1
Di Nunno, V; Massari, F; Santoni, M	1
Cheng, WY; Drea, E; Duh, MS; Gauthier-Loiselle, M; Miao, R; Oh, WK; Szatrowski, TP; Vekeman, F	1
Armstrong, AJ; George, DJ; Zhang, T	1
Basso, U; Caffo, O; Campadelli, E; Conteduca, V; De Giorgi, U; Facchini, G; Fratino, L; Gasparro, D; Kinspergher, S; Maines, F; Massari, F; Messina, C; Mosillo, C; Procopio, G; Rossetti, S; Sabbatini, R; Sava, T; Scagliarini, S; Sirotova, S; Veccia, A; Verzoni, E	1
Ampe, J; Beije, N; Bols, A; Brouwer, A; Brouwers, B; de Kruijff, IE; De Laere, B; De Maeseneer, D; Del Favero, J; Demey, W; Dirix, LY; Everaert, EG; Fransis, K; Ghysel, C; Goossens, D; Grönberg, H; Heyrman, L; Hoekx, L; Lindberg, J; Lybaert, W; Mayrhofer, M; Oeyen, S; Ost, P; Rajan, P; Rantalainen, M; Rutten, A; Schrijvers, D; Sleijfer, S; Strijbos, M; Ullén, A; van Dam, PJ; van Dam, V; Van den Eynden, GG; Van Laere, SJ; Van Oyen, P; Whitington, T; Yachnin, J	1
Balk, SP; Calagua, C; Chen, S; Condulis, J; Einstein, DJ; Liu, X; Ma, F; Russo, JW; Taplin, ME; Voznesensky, O; Ye, H	1
Barata, PC; Edwin, NC; Emamekhoo, H; Garcia, JA; Grivas, P; Woo, KM	1
Arai, S; Balk, SP; Bhasin, M; Bhasin, SS; Calagua, C; Corey, E; Gao, C; Montgomery, B; Mostaghel, EA; Nelson, PS; Russo, JW; Taplin, ME; Voznesensky, OS; Ye, H	1
Brown, JS; Cunningham, JJ; Gatenby, RA; Staňková, K	1
Bolognini, C; Gassian, N; Klajer, E; Loriot, Y; Meynard, G; Thiery-Vuillemin, A	1
He, Y; Mu, H; Nan, C; Wang, S; Wang, Y; Yang, S	1
Chen, J; Gao, AC; Liao, B; Liu, J; Liu, Z; Shen, P; Shu, K; Sun, G; Yang, Y; Zeng, H; Zhang, X; Zhao, J; Zhao, P	1
Amores Bermúdez, J; Caballero Cobos, R; Campanario Pérez, R; Gamaza Martínez, R; Herrera Torres, M; Juárez Soto, A; Saiz Marenco, R	1
Scher, HI; Teo, MY	1
Taneja, SS	3
Eto, M; Imada, K; Inokuchi, J; Kashiwagi, E; Murakami, T; Shiota, M; Takeuchi, A; Tatsugami, K	1
Armstrong, CM; Chen, HW; Dall'Era, M; Evans, CP; Gao, AC; Liu, C; Liu, L; Lombard, AP; Lou, W; Noel, ODV; Tepper, CG; Yang, JC; Zhao, R	1
Bryce, AH; Dorff, TB; Groshen, S; Ji, L; Quinn, DI; Wong, W; Yap, KK	1
Chi, KN; Eigl, BJ; Finch, DL; Gleave, ME; Ivanov, N; Khalaf, DJ; Kollmannsberger, CK; Oja, C; Sunderland, K; Vergidis, J; Zulfiqar, M	1
Bristow, RG; Gillessen, S; Oing, C; Rebello, RJ	1
Carles, J; Gillessen, S; Heidenreich, A; Heinrich, D; Keizman, D; Miller, K; Nilsson, S; O'Sullivan, JM; Reeves, J; Saad, F; Seger, M; Wirth, M	1
Morgans, AK; Ryan, CJ	1
Berruti, A; Dalla Volta, A; Formenti, AM	1
Chen, X; Chen, Y; Gong, U; Jiang, A; Li, G; Niu, Y; Shang, Z; Sun, G; Wei, F	1
Attard, G; Casadio, V; Castro, E; Conteduca, V; De Giorgi, U; Farolfi, A; Gonzalez-Billalabeitia, E; González-Del-Alba, A; Gurioli, G; Hernando, S; Jayaram, A; Lolli, C; Marin-Aguilera, M; Maugeri, A; Medina, A; Mellado, B; Morales-Barrera, R; Olmos, D; Puente, J; Rodriguez-Vida, A; Romero-Laorden, N; Salvi, S; Scarpi, E; Schepisi, G; Vidal, MJM; Villa-Guzmán, JC; Wetterskog, D; Wingate, A	1
Shao, N; Ye, DW; Zhu, Y	1
Chen, Z; Li, X; Lin, Z; Ma, X; Wu, X; Zou, L	1
Akamatsu, S; Fujimoto, A; Goto, T; Inoue, T; Kamba, T; Kobayashi, T; Li, X; Makino, Y; Miyazaki, Y; Mizuno, K; Ogawa, O; Okasho, K; Sumiyoshi, T; Terada, N; Utsunomiya, N; Yamasaki, T	1
Anand, M; Antonarakis, ES; Armstrong, AJ; Berry, WR; Chen, Y; Danila, DC; Dittamore, R; Galletti, G; George, DJ; Giannakakou, P; Gregory, SG; Gupta, S; Halabi, S; Healy, P; Kemeny, G; Lu, C; Luo, J; Nanus, DM; Rasmussen, J; Rothwell, CJ; Scher, HI; Silberstein, JL; Somarelli, JA; Szmulewitz, RZ; Tagawa, ST; Thornburg, B; Wilder, RS	1
Carraro, P; Dittadi, R; Polesello, V; Zivi, A	1
Alsinnawi, M; Balk, S; Bianchi-Frias, D; Burns, J; Cho, E; Montgomery, RB; Mostaghel, EA; Nelson, PS; Porter, C; Slee, AE; Sowalsky, A; Taplin, ME; True, L; Ye, H; Zhang, A; Zhang, X	1
Barata, PC; Sartor, AO	1
Anderson, AR; Brown, JS; Dinh, MN; Gatenby, RA; West, JB; Zhang, J	1
Aprikian, AG; Bladou, F; Cury, F; Dragomir, A; Hu, J; Kassouf, W; Lahcene, H; Perreault, S; Vanhuyse, M	1
Barbosa, FG; Buchpiguel, CA; Costa, LB; Dzik, C; Marin, JFG; Nunes, RF; Queiroz, MA	1
Cursano, MC; De Giorgi, U; Iuliani, M; Paganelli, G; Santini, D	1
Hindié, E; Morgat, C	1
De Laere, B; Dirix, L; Grönberg, H; Lindberg, J; Rajan, P	1
Allan, AL; Annala, M; Basappa, NS; Beja, K; Chi, KN; Eigl, BJ; Ellard, SL; Finch, D; Gregg, RW; Hotte, SJ; Joshua, AM; Kollmannsberger, C; Macfarlane, RJ; North, S; Powers, J; Ruether, JD; Salim, M; Seymour, L; Tinker, A; Torri, V; Tu, D; Winquist, EW; Wyatt, AW	1
Abida, W; Armenia, J; Beltran, H; Benelli, M; Bianchini, D; Carreira, S; Chinnaiyan, AM; Cieslik, M; Coleman, I; Cyrta, J; De Sarkar, N; deBono, JS; Demichelis, F; Fedrizzi, T; Filipenko, J; Gopalan, A; Heath, EI; Heller, G; Kantoff, PW; Kunju, LP; Loda, M; Mateo, J; Miranda, S; Montgomery, RB; Mosquera, JM; Nava Rodrigues, D; Nelson, PS; Prandi, D; Pritchard, CC; Rescigno, P; Reuter, VE; Robinson, BD; Robinson, D; Rubin, MA; Sawyers, CL; Sboner, A; Scher, HI; Schultz, N; Taplin, ME; Tomlins, S; Van Allen, EM; Vinson, J; Wu, YM	1
Dubinsky, S; Emmenegger, U; McFarlane, TRJ; McLeod, AG; Thawer, A	1
Arasaratnam, M; Bhatnagar, A; Crumbaker, M; Gurney, H; McKay, MJ; Molloy, MP	1
Cattarino, S; Del Giudice, F; Frantellizzi, V; Gatto, A; Gentilucci, A; Maggi, M; Ricciuti, GP; Salciccia, S; Scarpa, S; Sciarra, A; Silvestri, I; Von Heland, M	1
Becker, DJ; Becker, KD; Iyengar, AD; Loeb, S; Makarov, D; Ng, J; Punekar, SR; Zaman, A	1
Hashimoto, J; Hashimoto, K; Hotta, H; Inoue, R; Kunishima, Y; Masumori, N; Muranaka, T; Shindo, T; Tabata, H; Takahashi, A; Tanaka, T; Yanase, M	1
Caram, MEV; Herrel, L; Hollenbeck, BK; Kaufman, SR; Modi, PK; Oerline, M; Ross, R; Shahinian, V; Skolarus, TA	1
Cotogno, P; Feibus, A; Ledet, E; Lewis, B; Sartor, O; Schiff, JP; Steinwald, P	1
Antonarakis, ES; Carducci, MA; Denmeade, SR; Eisenberger, MA; Fu, W; Isaacsson Velho, P; Lima, FAS; Markowski, MC; Marshall, CH; Mirkheshti, N; Paller, CJ; Qazi, F; Shaukat, F; Wang, H	1
Dorff, TB; Goldkorn, A; Groshen, S; Gross, ME; Kuhn, P; Pinski, JK; Quinn, DI; Sadeghi, S; Tsao-Wei, D	1
Beijnen, JH; Bergman, AM; Janssen, JM; Rosing, H; van Hoek, B; van Nuland, M	1
Altavilla, A; Burgio, SL; Conteduca, V; De Giorgi, U; De Lisi, D; Farolfi, A; Gurioli, G; Lolli, C; Menna, C; Ravaglia, G; Santini, D; Scarpi, E; Schepisi, G; Tonini, G	1
Chung, JS; Henderson, J; Hovelson, DH; Morgan, TM; Palapattu, GS; Qiao, Y; Reichert, Z; Singhal, U; Spratt, DE; Taichman, RS; Tomlins, SA; Wang, Y; Zaslavsky, AB	1
Armstrong, CM; Cai, D; Chen, J; Chen, N; Dai, J; Guo, W; Liu, J; Liu, Z; Ni, Y; Nie, L; Shen, P; Sun, G; Yin, X; Zeng, H; Zhang, H; Zhang, M; Zhang, X; Zhao, J; Zhao, P; Zhu, S; Zhu, X	1
Agarwal, N; Pal, SK; Swami, U	1
Banks, P; Bianchini, D; Caffo, O; Castro, E; Conteduca, V; De Bono, JS; De Giorgi, U; Dolling, D; Gil, T; Li, H; Lolli, C; Mehra, N; Morley, C; Olmos, D; Omlin, AG; Ong, M; Pezaro, CJ; Rediti, M; Rescigno, P; Romero-Laorden, N; Saez, MI; Sandhu, SK; Schmid, S; Sideris, S; Smeenk, S; Sternberg, CN; Zivi, A	1
Agarwal, N; Bellmunt, J; DiLorenzo, G; Sonpavde, G; Vogelzang, NJ; Zhang, TY	1
Attard, G; Lim, AC	1
Hotte, SJ; Loblaw, DA; Walker-Dilks, C; Winquist, E	1
Boegemann, M; Cronauer, MV; Hajili, T; Herrmann, E; Jentzmik, F; Krabbe, LM; Ohlmann, CH; Schnoeller, TJ; Schrader, AJ; Schrader, M; Stoeckle, M	1
de Wit, R; Fitzpatrick, JM	1
Gallego, IG; Garcia-Carbonero, R; Giménez, EV; Giuliani, R; Gravanis, I; Hemmings, RJ; Jiménez, JC; Lopez, AS; O'Connor, D; Pignatti, F; Salmonson, T	1
Attard, G; Bianchini, D; Chowdhury, S; de Bono, JS; Ferraldeschi, R; Lorente, D; Omlin, A; Pezaro, C; Rodriguez-Vida, A; Zivi, A	1
Fizazi, K; Loriot, Y	1
Pinto, Á	1
de Morrée, ES; de Wit, R; Mathijssen, RH; Moll, JM; Teubel, W; van Royen, ME; van Soest, RJ; van Weerden, WM; Wiemer, EA	1
Balani, G; Gipson, G; Srinivas, S; Tang, J; Wilson, L; Xiang, P; Yu, D; Zhong, L	1
Bouchaert, P; Branchereau, J; De La Taille, A; Lebdai, S; Robert, G	1
Basset, V; Crouzet, S; Flamand, V; Ploussard, G	1
Badrising, S; Bergman, AM; Coenen, JL; de Jong, IJ; Hamberg, P; Kerver, ED; Los, M; van den Berg, HP; van den Eertwegh, AJ; van der Noort, V; van Oort, IM; van Tinteren, H	1
Bianco, V; Fiaschi, AI; Francini, E; Francini, F; Laera, L; Paganini, G; Perrella, A; Petrioli, R; Roviello, G	1
Altavilla, A; Attard, G; Bianchini, D; de Bono, JS; Dearnaley, D; Ferraldeschi, R; Lorente, D; Omlin, AG; Parker, C; Pezaro, CJ	1
Böker, A; Geith, A; Gschwend, JE; Kuczyk, M; Merseburger, AS; Retz, M; Schmid, SC; Seitz, AK; Tauber, R; von Klot, C	1
Bahl, A	1
Antonarakis, ES; Bassi, S; Carducci, MA; Eisenberger, MA; Schweizer, MT; Wang, H; Zhou, XC	1
Brändle, M; Fornaro, J; Gillessen, S; Omlin, A; Rothermundt, C; Rupp, NJ; Schmid, S	1
Li, B; Liu, SX; Xia, J; Zhang, TS; Zhou, ZR	1
Chandler, DW; Haqq, CM; Kheoh, T; Molina, A; Peng, W; Ryan, CJ; Scher, HI; Welkowsky, E	1
Altavilla, A; Attard, G; Bianchini, D; de Bono, JS; Ferraldeschi, R; Grist, E; Lorente, D; Mateo, J; Ravi, P; Sideris, S; Smith, A; Wong, S; Zafeiriou, Z	1
Fizazi, K; Loriot, Y; Massard, C	1
Amadori, D; Bianchi, E; Burgio, SL; Carretta, E; Conteduca, V; De Giorgi, U; Fabbri, F; Kopf, B; Menna, C; Rossi, L	1
Al-Asaaed, S; Winquist, E	1
Lin, DW; Mostaghel, EA	1
Hoffman-Censits, J; Kelly, WK	1
Albers, P; Eichenauer, R; Geiges, G; Grimm, MO; König, F; Mickisch, G; Miller, K; Pfister, D; Schwentner, C; Suttmann, H; Zastrow, S	1
Al Nakouzi, N; Albigès, L; Beuzeboc, P; de La Motte Rouge, T; Fizazi, K; Gajda, D; Gleave, M; Gross-Goupil, M; Guillot, A; Le Moulec, S; Loriot, Y; Massard, C; Wang, C	1
Attard, G; de Bono, JS; Ferraldeschi, R; Luo, J; Welti, J	1
Blank, PR; Puri, D; Szucs, TD	1
Tombal, B	1
Labrie, F	1
Bianchi, E; Burgio, SL; Campadelli, E; Carretta, E; Carrozza, F; Conteduca, V; De Giorgi, U; Fabbri, P; Menna, C; Montanari, M; Rudnas, B	1
Bellmunt, J; de Bono, JS; Efstathiou, E; Kheoh, T; Li, J; Loriot, Y; Molina, A; Montgomery, B; Ryan, CJ; Scher, HI; Tran, N	1
Alimohamed, N; Atenafu, EG; Joshua, AM; Knox, JJ; Leibowitz-Amit, R; Seah, JA; Sridhar, SS; Tannock, IF; Templeton, AJ; Vera-Badillo, FE	1
Antonarakis, ES; Luo, J; Nakazawa, M	1
Antonarakis, ES; Luber, B; Nadal, R; Schweizer, MT; Suzman, DL	1
Pal, SK; Sartor, O	1
Balk, SP; Jiang, Z; Kantoff, PW; McKay, RR; Melnick, K; Montgomery, B; Smith, SE; Taplin, ME; Voznesensky, O; Werner, L; Wu, JS; Yuan, X; Zukotynski, KA	1
Byun, SS; Hong, SJ; Kheoh, T; Kim, CS; Kwak, C; Lee, HM; Ou, YC; Rhim, HY; Wan, Y; Wu, HC; Wu, TT; Yeh, H; Yu, MK	1
Boegemann, M; Brasso, K; de Bono, J; Lorente, D; Merseburger, AS; Retz, M; Schmid, SC; Schrader, AJ; Thomsen, FB; von Klot, CA	1
Duensing, S; Grüllich, C; Hadaschik, BA; Höfner, T; Hohenfellner, M; Jäger, D; Pahernik, S; Vallet, S	1
Akaza, H; Fukui, I; Iizuka, K; Matsubara, N; Niwakawa, M; Uemura, H; Yamaguchi, A	1
Mukai, H; Nishimura, Y; Oyama, R; Suzukawa, K	1
Begbie, S; Davis, ID; Gogna, K; Mainwaring, PN; Murphy, DG; Parnis, F; Steer, C; Woo, HH	1
Kikuchi, E; Kosaka, T; Miyajima, A; Miyazaki, Y; Oya, M; Yasumizu, Y	1
Gartrell, BA; Saad, F	1
Azad, AA; Chi, KN; Eigl, BJ; Heng, DY; Joshua, AM; Kollmannsberger, C; Leibowitz-Amit, R; Lester, R; Murray, RN; Wells, JC	1
Taplin, ME	1
Griffin, TW; Nandy, P; Poggesi, I; Ryan, CJ; Saad, F; Smith, MR; Stuyckens, K; Vermeulen, A; Xu, XS; Yu, MK	1
Dahut, WL; Madan, RA	1
Castellano, D; Daugaard, G; De Porre, P; Galli, L; Garrido, JM; Géczi, L; George, DJ; Goon, B; Hotte, SJ; Lee, E; Londhe, A; Mainwaring, PN; McGowan, T; Molina, A; Naini, V; Saad, F; Souza, C; Sternberg, CN; Tay, MH; Todd, MB	1
Attard, G; de Bono, JS; Grist, E	1
Baji, P; Berczi, C; Brodszky, V; Géczi, L; Gulácsi, L; Péntek, M; Rencz, F; Szûcs, M	1
Alcaraz, A; Caffo, O; da Silva, FC; Hammerer, P; Merseburger, AS; Roumeguère, T; Rozet, F	1
Alibhai, SM; Joshua, AM; Knox, JJ; Leibowitz-Amit, R; Sridhar, SS; Tannock, IF; Templeton, AJ	1
Li, L; Thompson, TC	1
Evans, CP; Isaacs, WB; Karantanos, T; Montironi, R; Thompson, TC; Tombal, B	1
Gong, CL; Hay, JW	1
Altavilla, A; Attard, G; de Bono, J; Dearnaley, D; Ferraldeschi, R; Gillessen, S; Lorente, D; Mateo, J; Omlin, A; Parker, C; Perez, R; Pezaro, C; Tunariu, N; Zafeirou, Z	1
Balk, SP; Bubley, GJ; Cai, C; Chen, EJ; Gao, S; Kantoff, PW; Lis, RL; Loda, M; Montgomery, RB; Nelson, PS; Schaefer, R; Sowalsky, AG; Taplin, ME; Troncoso, P; True, LD; Voznesensky, O; Ye, H	1
Ardiani, A; Donahue, RN; Gameiro, SR; Hodge, JW; Kwilas, AR	1
Adomat, H; Gleave, ME; Guns, ES; Kim, S; Mangalji, A; Moore, W; Pham, S; Toren, PJ; Zoubeidi, A	1
Auchus, RJ; Mundle, SD; Nguyen, S; Yu, MK	1
Aschelter, AM; Bassanelli, M; Giacinti, S; Marchetti, P; Milano, A; Roberto, M	1
Beer, TM; Graff, JN	2
Akaza, H; Imanaka, K; Nakatani, T; Nishiyama, T; Ozono, S; Satoh, T; Tanabe, K; Terai, A; Uemura, H; Yokomizo, A	1
Amadori, D; Bianchi, E; Burgio, SL; Caroli, P; Carretta, E; Conteduca, V; De Giorgi, U; Fabbri, F; Matteucci, F; Menna, C; Paganelli, G	1
Scagliotti, GV; Tucci, M; Vignani, F	1
Agarwal, N; Antonarakis, ES; Azad, A; Batten, JA; Cheng, HH; Chi, KN; Galsky, MD; Gulati, R; Heath, EI; Leiter, A; Montgomery, RB; Nadal, R; Pal, SK; Rehman, HT; Twardowski, P; Vaishampayan, UN; Yu, EY	1
Dahut, WL; Madan, R	1
Carles, J; de Bono, JS; De Porre, P; de Souza, P; Fizazi, K; Flaig, TW; Griffin, TW; Higano, CS; Kheoh, T; Li, J; Logothetis, CJ; Miller, K; Molina, A; Mulders, PF; Naini, V; Park, YC; Rathkopf, DE; Ryan, CJ; Saad, F; Shore, ND; Small, EJ; Smith, MR; Sternberg, CN; Taplin, ME; Yu, MK	1
Armstrong, AJ; Chin, B; Dhawan, MS; George, DJ; Harrison, MR; Healy, P; Oldan, J; Zhang, T	1
Anderson, SA; Azad, AA; Bazov, J; Bell, RH; Chi, KN; Collins, CC; Gleave, ME; Haegert, A; Le Bihan, S; McConeghy, B; Paris, P; Shukin, R; Small, EJ; Thomas, G; Volik, SV; Wang, Y; Wyatt, AW; Youngren, J	1
Attard, G; Bianchini, D; Crespo, M; de Bono, JS; Ferraldeschi, R; Figueiredo, I; Flohr, P; Lorente, D; Miranda, S; Nowakowska, K; Riisnaes, R; Rodrigues, DN; Sideris, S; Terstappen, LW; van Dalum, G; Zafeiriou, Z	1
Dan, TD; Den, RB; Dicker, AP; Eldredge-Hindy, HB; Gomella, LG; Hoffman-Censits, J; Hurwitz, MD; Kelly, WK; Lallas, CD; Lin, J; Trabulsi, EJ	1
Ndibe, C; Sonpavde, G; Wang, CG	1
Alexandre, J; Belleville, T; Blanchet, B; Goldwasser, F; Huillard, O; Noé, G; Thomas-Schoemann, A; Vidal, M	1
Abajo Del Álamo, C; Catalá Pindado, MÁ; Godoy Díez, M; Moreno Gómez, Á	1
Berlin, A; Fernández, MI	1
Amadori, D; Attard, G; Bianchi, E; Burgio, SL; Calistri, D; Carretta, E; Casadio, V; Conteduca, V; De Giorgi, U; Masini, C; Menna, C; Rossi, L; Salvi, S	1
Berruti, A; Bertaglia, V; Buttigliero, C; Fioramonti, M; Iuliani, M; Pantano, F; Ribelli, G; Santini, D; Scagliotti, GV; Tonini, G; Tucci, M; Vignani, F; Vincenzi, B; Zoccoli, A	1
Vignot, S	1
Caffo, O; Chiuri, VE; Conteduca, V; De Giorgi, U; Derosa, L; Fratino, L; Maines, F; Petracci, E; Santini, D; Santoni, M; Testoni, S; Veccia, A	1
Alyamani, M; Auchus, RJ; Bishop, AC; Bunch, D; Dreicer, R; Garcia, JA; Li, Z; Liu, J; Sharifi, N; Upadhyay, SK	1
Penning, TM	1
Bianco, V; Fiaschi, AI; Francini, E; Laera, L; Petrioli, R; Ponchietti, R; Roviello, G	1
Antonarakis, ES; Maughan, BL	2
Azoitei, A; Cronauer, MV; Damjanoski, I; Jentzmik, F; Zengerling, F	1
Antonarakis, ES; Carducci, MA; Chen, Y; Eisenberger, MA; Lu, C; Luo, J; Nakazawa, M; Paller, CJ	1
Rexer, H	2
Bambury, RM; Rathkopf, DE	1
He, L; Li, L; Long, Z	1
Antonarakis, ES; Carducci, MA; Chen, Y; Denmeade, SR; Eisenberger, MA; Lu, C; Luber, B; Luo, J; Nadal, R; Nakazawa, M; Paller, CJ; Wang, H	1
Crawford, ED; Higano, CS; Hussain, M; Petrylak, DP; Shore, ND	1
Bianco, V; Fiaschi, AI; Francini, E; Francini, F; Laera, L; Petrioli, R; Roviello, G	1
Bhargava, R; Hendricks, AR; Neyra, JA; Rocha, NA; Rodan, AR; Vaidya, OU	1
Benoist, GE; Gerritsen, WR; Kramers, C; Mulders, PF; Schers, HJ; van Erp, PH; Westdorp, H	1
Bergman, AM; Bos, MM; Chitu, D; de Morrée, ES; de Wit, R; Goey, SH; Hamberg, P; Mathijssen, RH; Nieuweboer, AJ; van der Meer, N; van Soest, RJ	1
Albiges, L; Antoun, S; Bayar, A; di Palma, M; Escudier, B; Fizazi, K; Ileana, E; Laplanche, A; Loriot, Y; Massard, C	1
Antonarakis, ES; Bassi, S; Maughan, BL; Nadal, R; Schweizer, MT; Suzman, DL; Xhou, XC	1
Bria, E; Caffo, O; Galligioni, E; Maines, F; Tortora, G; Trentin, C; Veccia, A	1
Bertaglia, V; Bironzo, P; Buttigliero, C; Di Maio, M; Scagliotti, GV; Tucci, M; Vignani, F	1
Assi, R; Mukherji, D; Shamseddine, A; Temraz, S	1
Audenet, F; Basset, V; Branchereau, J; de La Taille, A; Flamand, V; Lebdai, S; Lebret, T; Murez, T; Neuzillet, Y; Ploussard, G	1
Aarts, MJ; Badrising, SK; Bergman, AM; Coenen, JL; de Jong, IJ; Gelderblom, H; Haanen, JB; Hamberg, P; Kerver, ED; Los, M; van den Berg, HP; van den Eertwegh, AJ; van der Noort, V; van Oort, IM; van Voorthuizen, T; Vrijaldenhoven, S; Warmerdam, F	1
Barber, J; Button, MR; Davies, RS; Lester, JF; Palaniappan, N; Smith, C; Staffurth, J; Tanguay, J	1
Alesini, D; Basso, U; Caffo, O; Campadelli, E; Conteduca, V; D'Angelo, A; De Giorgi, U; Donini, M; Ermacora, P; Fratino, L; Gasparro, D; Giordano, M; Lo Re, G; Lolli, C; Maines, F; Massari, F; Messina, C; Procopio, G; Ratta, R; Veccia, A; Verderame, F; Zagonel, V	1
Bunz, T; Chamberlin, KW; Clement, JM; Holle, LM; Niemann, C; Patel, JM	1
Amadori, D; Attard, G; Bianchini, D; Carreira, S; Casadio, V; Casiraghi, N; Conteduca, V; de Bono, JS; De Giorgi, U; Demichelis, F; Ferraldeschi, R; Flohr, P; Gasi Tandefelt, D; Goodall, J; Gurioli, G; Jayaram, A; Rescigno, P; Romanel, A; Salvi, S; Tunariu, N; Wetterskog, D; Wingate, A; Zafeiriou, Z	1
Schweizer, MT; Yu, EY	1
Moore, A; Moore, DC	1
Savage, N	1
Alibhai, SM; Aziz, S; Breunis, H; Joshua, AM; Manokumar, T; Rizvi, SF; Tannock, IF	1
Antonarakis, ES; Denmeade, SR; Luber, B; Teply, BA	1
Bertaglia, V; Buttigliero, C; Di Maio, M; Scagliotti, GV; Tucci, M; Vignani, F	1
Balk, SP; Cai, C; Chen, S; Gao, S; Gerrin, S; Han, W; Mostaghel, EA; Nelson, PS; Patnaik, A; Sharma, A; Sowalsky, AG; Taplin, ME; Voznesensky, O; Wang, H; Ye, H; Yu, Z	1
Burgio, SL; Carretta, E; Casadio, V; Conteduca, V; Costantini, M; De Giorgi, U; Menna, C; Rossi, L; Salvi, S; Zoli, W	1
Brasso, K; Røder, MA; Thim, S; Thortzen, A	1
Boegemann, M; Eminaga, O; Herrmann, E; Hinkelammert, R; Krabbe, LM; Mikah, P; Papavassilis, P; Schrader, AJ; Semjonow, A	1
Gschwend, JE; Hatzichristodoulou, G; Heck, MM; Höppner, M; Kübler, H; Luppa, PB; Maurer, T; Nawroth, R; Retz, M; Schmid, SC; Seitz, AK; Tauber, R; Thaler, MA; Thalgott, M	1
Graham, L; Schweizer, MT	1
Armstrong, C; Gao, AC; Liu, C; Lou, W; Zhu, Y	1
Davies, RS; Lester, JF; Smith, C	1
Barsová, L; Bartoš, J; Chalupa, J; Dvořák, J; Forster, J; Hejzlarová, V; Holikova, M; Richter, I; Sochor, M; Stankuš, I	1
de Bono, JS; Figueiredo, I; Lorente, D; Plymate, SR; Rescigno, P; Riisnaes, R; Rodrigues, DN; Sharp, A; Sun, S; Welti, J; Zafeiriou, Z	1
Divine, GW; Hafron, JM; Hung, J; Hwang, C; Taylor, AR	1
Adamo, V; Barni, S; Boccardo, F; Bruno, M; Caffo, O; Caserta, C; Chiuri, VE; De Giorgi, U; De Vincenzo, F; De Vivo, R; Derosa, L; Dinota, A; Facchini, G; Fratino, L; Grassi, P; Messina, C; Mosca, A; Porcu, L; Procopio, G; Ricotta, R; Santini, D; Scavelli, C; Surace, G; Susi, M; Tartarone, A; Verzoni, E; Zaniboni, A	1
Abazeed, M; Alyamani, M; Auchus, RJ; Balk, SP; Li, J; Li, Z; Rogacki, K; Sharifi, N; Taplin, ME; Upadhyay, SK	1
Antoun, J; Bteich, F; Ghosn, M; Jalkh, A; Kourie, HR	1
Baeten, K; Bianchini, D; Crespo, M; Danila, DC; de Bono, JS; Figueiredo, I; Fleisher, M; Flohr, P; Kheoh, T; Lorente, D; Mateo, J; McCormack, R; Miranda, S; Molina, A; Olmos, D; Scher, HI; Seed, G; Terstappen, LW	1
Caffo, O; Sharifi, N	1
Uemura, H	1
Azuma, H; Inamoto, T	1
Azoitei, A; Cronauer, MV; Godau, B; Hoda, MR; Merseburger, AS; Schmid, E	1
Antonarakis, ES; Eshleman, JR; Frick, KD; Luo, J; Markowski, MC	1
Arslan, C	1
Azad, A; Black, PC; Chi, KN; Eigl, BJ; Gao, J; Gleave, ME; Joshua, AM; Stewart, C; Todenhöfer, T	1
Dhawan, M; Ryan, CJ	1
Bernemann, C; Boegemann, M; Luedeke, M; Schnoeller, TJ; Schrader, AJ; Steinestel, J; Steinestel, K	1
Antonarakis, ES; Luber, B; Maughan, BL; Nadal, R	1
Berger, I; Kramer, G; Madersbacher, S; Mohamad Al-Ali, B	1
Gschwend, J; Miller, K; Wolff, JM	1
Balk, SP; Bhasin, M; Bubley, GJ; Domachevsky, L; Kantoff, PW; Lis, R; Marck, BT; Matsumoto, AM; McKay, RR; Montgomery, B; Mostaghel, EA; Taplin, ME; Voznesensky, O; Werner, L; Zhang, Z; Zukotynski, KA	1
Biasco, E; Crucitta, S; Danesi, R; Del Re, M; Derosa, L; Falcone, A; Galli, L; Jenster, GW; Miccoli, M; Orlandini, C; Rofi, E; van Schaik, RH	1
Balea-Filgueiras, J; Martín-Herranz, I; Ramudo-Cela, L; Vizoso-Hermida, JR	1
Cookson, MS; Ritch, CR	1
Antonarakis, ES; Attard, G	1
Aitoku, Y; Basurto, E; Concialdi, K; DiBonaventura, M; Kimura, G; Ledesma, DA; Matsubara, N; McKinnon, I; Mohamed, AF; Narimatsu, A; Uemura, H; Wang, E; Yamaguchi, A	1
Srinivas, NR	1
De Porre, P; Xu, S	1
Bubley, GJ; Fiorillo, M; Heath, EI; McKay, RR; Montgomery, RB; Roberts, J; Taplin, ME; Werner, L	1
Aroasio, E; Berruti, A; Bertaglia, V; Buttigliero, C; DI Maio, M; Scagliotti, GV; Tucci, M; Vignani, F	1
Albiges, L; Attard, G; Bianchini, D; de Bono, J; Fizazi, K; Loriot, Y; Massard, C; Mateo, J; Mehra, N; Petrylak, DP; Pezaro, C; Ryan, CJ; Shen, L; Varga, A	1
Fenner, A	1
Chopra, A; Georgieva, M; Haaland, B; Lopes, G; Yeo, CM	1
Cristofanilli, M; Hoffman-Censits, JH; Kelly, WK; Kennedy, B; Kilpatrick, D; Leiby, B; Lewis, N; Lin, J; Mu, Z; Patel, SA; Sama, AR; Yang, H; Ye, Z	1
Aringer, M; Boegemann, M; Krabbe, LM; Rahbar, K; Schlack, K; Schrader, AJ; Semjonow, A; Steinestel, J; Thomes, S	1
Appleman, L; Beumer, JH; Holleran, JL; Kim, KP; Lewis, LD; Morris, MJ; Parise, RA; van Erp, N	1
Bezrukov, EA; Kondrashina, AV; Rapoport, LM	1
Concepcion, RS; Crawford, ED; Finkelstein, SE; Gomella, LG; Keane, TE; Koo, PJ; O'Sullivan, JM; Petrylak, DP; Saad, F; Shore, N; Sieber, P; Slovin, SF; Stone, NN; Tombal, B; Vogelzang, NJ; Yu, EY	1

Reviews

93 review(s) available for abiraterone and Prostatic Neoplasms, Castration-Resistant

Article	Year
Efficacy and safety of bipolar androgen therapy in mCRPC after progression on abiraterone or enzalutamide: A systematic review. Urologic oncology, 2022, Volume: 40, Issue:1 Topics: Androgens; Androstenes; Benzamides; Disease Progression; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Testosterone; Treatment Outcome	2022
Lower Fracture Rates in Patients Treated with Radium-223, Abiraterone or Enzalutamide, When Given Concurrently with Bone Health Agents: A Real-World Analysis. Clinical genitourinary cancer, 2022, Volume: 20, Issue:5 Topics: Abiraterone Acetate; Aged; Androgen Antagonists; Androgens; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Density; Denosumab; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Zoledronic Acid	2022
Increasing the efficacy of abiraterone - from pharmacokinetics, through therapeutic drug monitoring to overcoming food effects with innovative pharmaceutical products. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2022, Sep-01, Volume: 176 Topics: Abiraterone Acetate; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Drug Monitoring; Humans; Male; Pharmaceutical Preparations; Prostatic Neoplasms, Castration-Resistant	2022
Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review. Frontiers in endocrinology, 2022, Volume: 13 Topics: Androgens; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Quality of Life	2022
Androgen receptor-related micro RNAs in prostate cancer and their role in antiandrogen drug resistance. Journal of cellular physiology, 2020, Volume: 235, Issue:4 Topics: Androgen Antagonists; Androstenes; Benzamides; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen	2020
Efficacy and safety of abiraterone and enzalutamide for castration-resistant prostate cancer: A systematic review and meta-analysis of randomized controlled trials. Medicine, 2019, Volume: 98, Issue:44 Topics: Adult; Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Treatment Outcome	2019
M0CRPC overview of management options. World journal of urology, 2021, Volume: 39, Issue:2 Topics: Androstenes; Benzamides; Clinical Trials as Topic; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyrazoles; Thiohydantoins	2021
Corticosteroid switch after progression on abiraterone acetate plus prednisone. International journal of clinical oncology, 2020, Volume: 25, Issue:2 Topics: Abiraterone Acetate; Adrenal Cortex Hormones; Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Male; Middle Aged; Patient Selection; Prednisolone; Prednisone; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2020
Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review. Critical reviews in oncology/hematology, 2020, Volume: 146 Topics: Androstenes; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Docetaxel; Humans; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Radium; Treatment Outcome; Tumor Microenvironment	2020
Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis. Prostate cancer and prostatic diseases, 2020, Volume: 23, Issue:2 Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Blood Platelets; Humans; Lymphocytes; Male; Neutrophils; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant	2020
Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis. Prostate cancer and prostatic diseases, 2020, Volume: 23, Issue:4 Topics: Androgen Antagonists; Androstenes; Benzamides; Clinical Trials, Phase II as Topic; Disease Progression; Drug Administration Schedule; Humans; Kallikreins; Male; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome	2020
Systematic Review of Efficacy and Health Economic Implications of Real-world Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in? European urology focus, 2021, Volume: 7, Issue:4 Topics: Abiraterone Acetate; Androstenes; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2021
Metastatic castration-resistant prostate cancer: Academic insights and perspectives through bibliometric analysis. Medicine, 2020, Volume: 99, Issue:15 Topics: Androstenes; Benzamides; Bibliometrics; Bone Neoplasms; DNA Repair; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Publications; Receptors, Androgen; United Kingdom; United States; United States Food and Drug Administration	2020
Molecular underpinnings of systemic treatment resistance in metastatic castration-resistant prostate cancer Orvosi hetilap, 2020, 05-01, Volume: 161, Issue:20 Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Treatment Outcome	2020
Pharmacotherapeutic strategies for castrate-resistant prostate cancer. Expert opinion on pharmacotherapy, 2020, Volume: 21, Issue:12 Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Immunotherapy; Male; Nitriles; Phenylthiohydantoin; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids; Tissue Extracts	2020
Comparing the clinical efficacy and safety of abiraterone and enzalutamide in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021, Volume: 27, Issue:3 Topics: Aged; Androstenes; Benzamides; Cohort Studies; Humans; Male; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2021
Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses. Prostate cancer and prostatic diseases, 2021, Volume: 24, Issue:1 Topics: Androstenes; Benzamides; Cardiovascular System; Humans; Male; Network Meta-Analysis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant	2021
Comparison of effectiveness and safety outcomes of abiraterone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 2020, Volume: 23 Topics: Androstenes; Antineoplastic Agents; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Treatment Outcome	2020
Gonadotropin-Releasing Hormone Receptors in Prostate Cancer: Molecular Aspects and Biological Functions. International journal of molecular sciences, 2020, Dec-14, Volume: 21, Issue:24 Topics: Androstenes; Animals; Benzamides; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, LHRH; Signal Transduction	2020
Contemporary management of advanced prostate cancer: an evolving landscape. Clinical advances in hematology & oncology : H&O, 2021, Volume: 19, Issue:2 Topics: Adenocarcinoma; Androstenes; Benzamides; Clinical Trials as Topic; Combined Modality Therapy; Diagnostic Imaging; Disease Management; Docetaxel; Humans; Male; Multicenter Studies as Topic; Nitriles; Phenylthiohydantoin; Precision Medicine; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radiotherapy, Adjuvant; Radium; Taxoids; Therapies, Investigational	2021
Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone: a systematic review and meta-analysis. Prostate cancer and prostatic diseases, 2021, Volume: 24, Issue:4 Topics: Androstenes; Benzamides; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality of Life	2021
Steroid switch after progression on abiraterone plus prednisone in patients with metastatic castration-resistant prostate cancer: A systematic review. Urologic oncology, 2021, Volume: 39, Issue:11 Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Neoplasm Metastasis; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2021
Abiraterone-induced rhabdomyolysis resulting in acute kidney injury: A case report and review of the literature. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2018, Volume: 24, Issue:4 Topics: Acute Kidney Injury; Aged; Androstenes; Disease Progression; Fatal Outcome; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Rhabdomyolysis	2018
Efficacy and safety of post-docetaxel therapies in metastatic castration-resistant prostate cancer: a systematic review of the literature. Current medical research and opinion, 2017, Volume: 33, Issue:11 Topics: Androstenes; Benzamides; Compassionate Use Trials; Disease-Free Survival; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome	2017
The role of bone-targeted therapies for prostate cancer in 2017. Current opinion in supportive and palliative care, 2017, Volume: 11, Issue:3 Topics: Androstenes; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Male; Prospective Studies; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radium; Randomized Controlled Trials as Topic; Zoledronic Acid	2017
[Splice variant AR-V7 : Is it time for its routine use as a predictive marker in prostate cancer?] Der Urologe. Ausg. A, 2017, Volume: 56, Issue:9 Topics: Androgens; Androstenes; Benzamides; Biomarkers, Tumor; Genetic Markers; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; RNA, Messenger; Taxoids; Testosterone	2017
[Radium-223 dichloride in patients with castration-refractory prostate cancer]. Der Urologe. Ausg. A, 2017, Volume: 56, Issue:11 Topics: Androstenes; Benzamides; Bone Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Denosumab; Humans; Male; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Retreatment	2017
Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. European urology, 2018, Volume: 73, Issue:5 Topics: Aged; Androgen Antagonists; Androstenes; Benzamides; Biomarkers, Tumor; Congresses as Topic; Disease-Free Survival; Follow-Up Studies; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Risk Assessment; Survival Analysis; Treatment Outcome	2018
Current approaches to incorporation of radium-223 in clinical practice. Prostate cancer and prostatic diseases, 2018, Volume: 21, Issue:1 Topics: Androstenes; Benzamides; Bone Neoplasms; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium; Receptors, Androgen; Taxoids; Treatment Outcome	2018
New Opportunities for Targeting the Androgen Receptor in Prostate Cancer. Cold Spring Harbor perspectives in medicine, 2018, 12-03, Volume: 8, Issue:12 Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Resistance, Neoplasm; Gene Amplification; Humans; Male; Molecular Chaperones; Molecular Targeted Therapy; Mutation; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen	2018
Recent advances in the management of metastatic prostate cancer: optimizing use of existing therapies, while searching for novel interventions. Current opinion in oncology, 2018, Volume: 30, Issue:3 Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic	2018
Effectiveness and tolerability of targeted drugs for the treatment of metastatic castration-resistant prostate cancer: a network meta-analysis of randomized controlled trials. Journal of cancer research and clinical oncology, 2018, Volume: 144, Issue:9 Topics: Androstenes; Antineoplastic Agents; Disease-Free Survival; Humans; Male; Network Meta-Analysis; Prostatic Neoplasms, Castration-Resistant; Quinolones; Randomized Controlled Trials as Topic; Treatment Outcome	2018
Treatment of hormone-naïve metastatic prostate cancer. Current opinion in supportive and palliative care, 2018, Volume: 12, Issue:3 Topics: Androgen Antagonists; Androstenes; Clinical Trials, Phase III as Topic; Docetaxel; Drug Therapy, Combination; Humans; Male; Neoplasm Metastasis; Prospective Studies; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic	2018
[DNA damage repair: An emerging strategy in metastatic prostate cancer]. Bulletin du cancer, 2018, Volume: 105, Issue:10 Topics: Androstenes; Antineoplastic Agents; Benzamides; DNA Damage; DNA Repair; Docetaxel; Genomic Instability; Humans; Male; Nitriles; Phenylthiohydantoin; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids	2018
What kind of patients with castration-naïve prostate cancer can benefit from upfront docetaxel and abiraterone: A systematic review and a network meta-analysis. Urologic oncology, 2018, Volume: 36, Issue:12 Topics: Androstenes; Antineoplastic Agents; Docetaxel; Humans; Male; Network Meta-Analysis; Prostatic Neoplasms, Castration-Resistant	2018
[Abiraterone in castration resistant prostate cancer.] Archivos espanoles de urologia, 2018, Volume: 71, Issue:8 Topics: Androstenes; Humans; Male; Prostatic Neoplasms, Castration-Resistant	2018
Androgen deprivation therapy with chemotherapy or abiraterone for patients with metastatic hormone-naive prostate cancer: a systematic review and meta-analysis. Future oncology (London, England), 2019, Volume: 15, Issue:10 Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Drug Therapy, Combination; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2019
Germline DNA-repair Gene Mutations and Efficacy of Abiraterone or Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer. European urology focus, 2019, Volume: 5, Issue:5 Topics: Androstenes; Benzamides; DNA Repair; Germ Cells; Humans; Male; Mutation; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2019
Optimization of therapies for men with advanced prostate cancer: a review of recent developments with a look toward the future. Current opinion in oncology, 2019, Volume: 31, Issue:3 Topics: Androstenes; Docetaxel; Humans; Male; Medical Oncology; Precision Medicine; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radiotherapy; Randomized Controlled Trials as Topic	2019
Metastatic castration-sensitive prostate cancer: Abiraterone, docetaxel, or…. Cancer, 2019, 06-01, Volume: 125, Issue:11 Topics: Androstenes; Antineoplastic Agents; Docetaxel; Humans; Male; Prognosis; Prostatic Neoplasms, Castration-Resistant	2019
Management of anticoagulation in patients with metastatic castration-resistant prostate cancer receiving abiraterone + prednisone. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2019, Volume: 27, Issue:9 Topics: Androstenes; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Interactions; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Retrospective Studies; Thrombosis; Treatment Outcome	2019
Androgen receptor variant 7 (AR-V7) in sequencing therapeutic agents for castratrion resistant prostate cancer: A critical review. Medicine, 2019, Volume: 98, Issue:19 Topics: Androstenes; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Bridged-Ring Compounds; Drug Resistance, Neoplasm; Genetic Variation; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids	2019
Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review. Clinical oncology (Royal College of Radiologists (Great Britain)), 2013, Volume: 25, Issue:7 Topics: Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Taxoids; Tissue Extracts	2013
Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer. European urology, 2014, Volume: 65, Issue:6 Topics: Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Interactions; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Signal Transduction; Taxoids	2014
Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer. Cancer biology & therapy, 2014, Volume: 15, Issue:2 Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Humans; Male; Prostatic Neoplasms, Castration-Resistant	2014
[Corticotherapy in castration-resistant prostate cancer]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2013, Volume: 23 Suppl 1 Topics: Androstenes; Androstenols; Antineoplastic Agents; Apoptosis; Clinical Trials as Topic; Drug Therapy, Combination; Glucocorticoids; Humans; Inflammation; Male; Neovascularization, Pathologic; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Glucocorticoid; Survival Analysis; Treatment Outcome	2013
[Choice of new drugs in castration-resistant prostate cancer: predictive factors and effectiveness assessment]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2013, Volume: 23 Suppl 1 Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Docetaxel; Drug Resistance, Neoplasm; Evidence-Based Medicine; Humans; Male; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Risk Factors; Sensitivity and Specificity; Taxoids; Treatment Outcome	2013
Metastatic castration-resistant prostate cancer. Part 1: the challenges of the disease and its treatment. European journal of oncology nursing : the official journal of European Oncology Nursing Society, 2013, Volume: 17 Suppl 1 Topics: Alpha Particles; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Cancer Vaccines; Chlorides; Docetaxel; Humans; Male; Mitoxantrone; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Taxoids; Tissue Extracts	2013
Abiraterone for treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:3 Topics: Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Humans; Kallikreins; Male; Placebos; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant	2014
Secondary hormonal manipulation in castration resistant prostate cancer. The Canadian journal of urology, 2014, Volume: 21, Issue:2 Supp 1 Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Benzamides; Drug Therapy, Combination; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2014
Practical guide to the use of abiraterone in castration resistant prostate cancer. The Canadian journal of urology, 2014, Volume: 21, Issue:2 Supp 1 Topics: Androgens; Androstenes; Androstenols; Antineoplastic Agents; Disease Progression; Humans; Male; Practice Guidelines as Topic; Prostatic Neoplasms, Castration-Resistant; Testosterone; Treatment Outcome	2014
Practical guide to the use of enzalutamide. The Canadian journal of urology, 2014, Volume: 21, Issue:2 Supp 1 Topics: Androgen Receptor Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Drug Therapy, Combination; Humans; Male; Nitriles; Phenylthiohydantoin; Practice Guidelines as Topic; Prednisone; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Treatment Outcome	2014
[Metastatic castration-resistant prostate cancer: position paper for structured therapy monitoring]. Der Urologe. Ausg. A, 2014, Volume: 53, Issue:5 Topics: Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Taxoids	2014
Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene, 2015, Apr-02, Volume: 34, Issue:14 Topics: Androstenes; Antineoplastic Agents; Benzamides; DNA Damage; Drug Resistance, Neoplasm; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Response Elements; Signal Transduction	2015
Combined blockade of testicular and locally made androgens in prostate cancer: a highly significant medical progress based upon intracrinology. The Journal of steroid biochemistry and molecular biology, 2015, Volume: 145 Topics: Androgen Antagonists; Androgens; Androstenes; Androstenols; Animals; Antineoplastic Agents; Benzamides; Dehydroepiandrosterone; Endocrinology; Gonadotropin-Releasing Hormone; Humans; Male; Mutation; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Testosterone; Treatment Outcome	2015
Androgen receptor splice variants in the era of enzalutamide and abiraterone. Hormones & cancer, 2014, Volume: 5, Issue:5 Topics: Alternative Splicing; Androstenes; Animals; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen	2014
Multidisciplinary consensus: a practical guide for the integration of abiraterone into clinical practice. Asia-Pacific journal of clinical oncology, 2014, Volume: 10, Issue:3 Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Treatment Outcome	2014
Pathologic fracture in patients with metastatic prostate cancer. Current opinion in urology, 2014, Volume: 24, Issue:6 Topics: Androstenes; Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Pyridines; Radioisotopes; Radium; Zoledronic Acid	2014
Targeting extra-gonadal androgens in castration-resistant prostate cancer. The Journal of steroid biochemistry and molecular biology, 2015, Volume: 145 Topics: Androgen Receptor Antagonists; Androgens; Androstenes; Androstenols; Benzamides; Drug Resistance, Neoplasm; Humans; Male; Mutation; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Signal Transduction; Steroids	2015
[Clinical efficacy and safety of enzalutamide in metastatic castration-resistant prostate cancer: systematic review and meta-analysis]. Magyar onkologia, 2014, Volume: 58, Issue:3 Topics: Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Bone Neoplasms; Humans; Male; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome	2014
Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy? World journal of urology, 2015, Volume: 33, Issue:8 Topics: Androstenes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Practice Guidelines as Topic; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Taxoids; Tissue Extracts	2015
Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. European urology, 2015, Volume: 67, Issue:3 Topics: Androgen Antagonists; Androstenes; Animals; Antineoplastic Agents, Hormonal; Benzamides; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Signal Transduction; Thiohydantoins	2015
Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer. The oncologist, 2014, Volume: 19, Issue:12 Topics: Androstenes; Antineoplastic Agents, Hormonal; Disease Progression; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant	2014
Resistance to abiraterone in castration-resistant prostate cancer: a review of the literature. Anticancer research, 2014, Volume: 34, Issue:11 Topics: Androstenes; Androstenols; Animals; Drug Resistance, Neoplasm; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Review Literature as Topic	2014
Pharmacotherapeutic management of metastatic, castration-resistant prostate cancer in the elderly: focus on non-chemotherapy agents. Drugs & aging, 2014, Volume: 31, Issue:12 Topics: Aged; Androstenes; Benzamides; Health Services for the Aged; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Tissue Extracts	2014
Metastatic castration-resistant prostate cancer: time for innovation. Future oncology (London, England), 2015, Volume: 11, Issue:1 Topics: Androstenes; Antibodies, Monoclonal, Humanized; Benzamides; Clinical Trials, Phase III as Topic; Denosumab; Drug Resistance, Neoplasm; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Receptors, Androgen; Signal Transduction; Taxoids; Tissue Extracts	2015
Prostate cancer in 2014: The year chemotherapy finally gets some respect! Nature reviews. Urology, 2015, Volume: 12, Issue:2 Topics: Androstenes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatectomy; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids	2015
Corticosteroids in the management of prostate cancer: a critical review. Current treatment options in oncology, 2015, Volume: 16, Issue:2 Topics: Adrenal Cortex Hormones; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Mitoxantrone; Palliative Care; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome	2015
[Advances in the treatment of castration-resistant prostate cancer: emphasis in new hormonal therapies]. Revista medica de Chile, 2015, Volume: 143, Issue:2 Topics: Androstenes; Antineoplastic Agents, Hormonal; Benzamides; Biomarkers, Tumor; Disease Progression; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids	2015
Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC). The Journal of steroid biochemistry and molecular biology, 2015, Volume: 153 Topics: Androgen Receptor Antagonists; Androgens; Androstenes; Animals; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Male; Nitriles; Phenylthiohydantoin; Prostate; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen	2015
Androgen pathway resistance in prostate cancer and therapeutic implications. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:10 Topics: Androgens; Androstenes; Benzamides; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Point Mutation; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Protein Splicing; Receptors, Androgen; Signal Transduction	2015
Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer. Oncology (Williston Park, N.Y.), 2015, Volume: 29, Issue:6 Topics: Androgen Receptor Antagonists; Androstenes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Cost-Benefit Analysis; Denosumab; Diphosphonates; Enzyme Inhibitors; Fractures, Spontaneous; Humans; Imidazoles; Male; Nitriles; Pain; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Spinal Cord Compression; Zoledronic Acid	2015
Androgen receptor aberrations in the era of abiraterone and enzalutamide. World journal of urology, 2016, Volume: 34, Issue:3 Topics: Androstenes; Benzamides; Drug Resistance, Neoplasm; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Signal Transduction	2016
Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide. Urologic oncology, 2016, Volume: 34, Issue:8 Topics: Androgen Receptor Antagonists; Androstadienes; Androstenes; Benzamides; Benzimidazoles; Humans; Male; Naphthalenes; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyrazoles; Receptors, Androgen; Thiohydantoins; Triazoles	2016
Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies. The Journal of urology, 2015, Volume: 194, Issue:6 Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Disease Progression; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Survival Rate; Taxoids; Tissue Extracts	2015
[Hormone therapy in prostate cancer; a pharmacotherapeutic challenge]. Nederlands tijdschrift voor geneeskunde, 2015, Volume: 159 Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Benzamides; Disease Progression; Humans; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Testosterone; Treatment Outcome	2015
Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer. Critical reviews in oncology/hematology, 2015, Volume: 96, Issue:3 Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids	2015
Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. Cancer treatment reviews, 2015, Volume: 41, Issue:10 Topics: Androgens; Androstenes; Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Gene Amplification; Humans; Male; Mutation; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Receptors, Glucocorticoid; Up-Regulation	2015
New Compounds Targeting the Androgen Receptor for Treatment of Advanced Prostate Cancer. Current drug targets, 2016, Volume: 17, Issue:3 Topics: Androstenes; Benzamides; Drug Resistance, Neoplasm; Humans; Male; Molecular Targeted Therapy; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Signal Transduction; Treatment Outcome	2016
What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer? World journal of urology, 2016, Volume: 34, Issue:5 Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids	2016
Persistent androgen receptor addiction in castration-resistant prostate cancer. Journal of hematology & oncology, 2015, Nov-13, Volume: 8 Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Feedback, Physiological; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen	2015
Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer. Cancer treatment reviews, 2016, Volume: 44 Topics: Androstenes; Anilides; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma; Dasatinib; Denosumab; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Mitoxantrone; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyridines; Radioisotopes; Radium; Taxoids; Zoledronic Acid	2016
Targeting persistent androgen receptor signaling in castration-resistant prostate cancer. Medical oncology (Northwood, London, England), 2016, Volume: 33, Issue:5 Topics: Androgen Receptor Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Male; Molecular Targeted Therapy; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Signal Transduction	2016
Differential Side Effects Profile in mCRPC Patients Treated With Abiraterone or Enzalutamide: A Meta-Analysis of Randomized Controlled Trials. Clinical advances in hematology & oncology : H&O, 2016, Volume: 14, Issue:4 Suppl 5 Topics: Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cardiotoxicity; Clinical Trials, Phase III as Topic; Humans; Male; Nitriles; Odds Ratio; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic	2016
Prostate cancer: Interfering with abiraterone metabolism to optimize therapy. Nature reviews. Urology, 2016, Volume: 13, Issue:7 Topics: Androstenes; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Steroid 17-alpha-Hydroxylase	2016
C-terminally truncated constitutively active androgen receptor variants and their biologic and clinical significance in castration-resistant prostate cancer. The Journal of steroid biochemistry and molecular biology, 2017, Volume: 166 Topics: Alternative Splicing; Androgens; Androstenes; Androstenols; Animals; Benzamides; Biomarkers, Tumor; Codon, Terminator; Disease Progression; Epithelial-Mesenchymal Transition; Genetic Variation; Genome, Human; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Protein Domains; Signal Transduction; Thiohydantoins; Transcription Factors	2017
Utility of novel androgen receptor therapies in the real world: A nuanced approach. Urologic oncology, 2016, Volume: 34, Issue:8 Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen	2016
[Strategies for First-Line Treatment of mCRPC]. Aktuelle Urologie, 2016, Volume: 47, Issue:5 Topics: Androstenes; Benzamides; Drug Therapy, Combination; Humans; Male; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prednisolone; Prednisone; Prostatic Neoplasms, Castration-Resistant; Survival Rate	2016
Advances in the management of castration resistant prostate cancer. BMJ (Clinical research ed.), 2016, Oct-17, Volume: 355 Topics: Aged; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Management; Docetaxel; Humans; Immunotherapy; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome	2016
Prostate cancer: What is the optimal treatment sequence for mCRPC? Nature reviews. Urology, 2016, 10-31, Volume: 13, Issue:11 Topics: Androstenes; Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2016
Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide. Nature reviews. Urology, 2016, Volume: 13, Issue:12 Topics: Androstenes; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen	2016
Abiraterone or Enzalutamide in Advanced Castration-Resistant Prostate Cancer: An Indirect Comparison. The Prostate, 2017, Volume: 77, Issue:6 Topics: Androstenes; Benzamides; Clinical Trials, Phase III as Topic; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Survival Rate	2017
The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II). Urology, 2017, Volume: 104 Topics: Androgens; Androstenes; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Disease Progression; Humans; Immunotherapy; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Practice Guidelines as Topic; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome	2017

Trials

71 trial(s) available for abiraterone and Prostatic Neoplasms, Castration-Resistant

Article	Year
Comparison of out-of-pocket costs and adherence between the two arms of the prospective, randomized abiraterone food effect trial. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022, Volume: 30, Issue:3 Topics: Androstenes; Health Expenditures; Humans; Male; Prospective Studies; Prostatic Neoplasms, Castration-Resistant	2022
A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. Future oncology (London, England), 2022, Volume: 18, Issue:10 Topics: Adenocarcinoma; Androstenes; Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Benzamides; Humans; Immune Checkpoint Inhibitors; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyridines; Receptor Protein-Tyrosine Kinases	2022
Study protocol and preliminary results from a mono-centric cohort within a trial testing stereotactic body radiotherapy and abiraterone (ARTO-NCT03449719). La Radiologia medica, 2022, Volume: 127, Issue:8 Topics: Abiraterone Acetate; Androstenes; Chemoradiotherapy; Clinical Trial Protocols as Topic; Cohort Studies; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radiosurgery; Treatment Outcome	2022
Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial. The Lancet. Oncology, 2022, Volume: 23, Issue:10 Topics: Androgen Antagonists; Androgens; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Double-Blind Method; Humans; Male; Pain; Patient Reported Outcome Measures; Phthalazines; Piperazines; Prednisolone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Testosterone	2022
A Phase II Trial of Abiraterone With Dutasteride for Second-Generation Antiandrogen- and Chemotherapy-Naïve Patients With Castration-Resistant Prostate Cancer. Journal of clinical pharmacology, 2023, Volume: 63, Issue:4 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Abiraterone Acetate; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Dutasteride; Humans; Male; Membrane Proteins; Multienzyme Complexes; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2023
Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer. Clinical genitourinary cancer, 2023, Volume: 21, Issue:2 Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Exanthema; Humans; Hyperglycemia; Male; Prednisolone; Prednisone; Prostatic Neoplasms, Castration-Resistant	2023
Rucaparib or Physician's Choice in Metastatic Prostate Cancer. The New England journal of medicine, 2023, 02-23, Volume: 388, Issue:8 Topics: Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Genes, BRCA1; Genes, BRCA2; Humans; Indoles; Male; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant	2023
Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 06-20, Volume: 41, Issue:18 Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Nitriles; Prednisone; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2023
Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol. BMJ open, 2019, 09-11, Volume: 9, Issue:9 Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blood Glucose; Clinical Trials, Phase III as Topic; Denmark; Fatigue; Humans; Male; Neoplasm Invasiveness; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prednisolone; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome	2019
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. The New England journal of medicine, 2019, 12-26, Volume: 381, Issue:26 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Taxoids	2019
PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study. The Prostate, 2020, Volume: 80, Issue:1 Topics: Aged; Aged, 80 and over; Androstenes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Drug Resistance, Neoplasm; Humans; Immunotoxins; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Treatment Outcome	2020
Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy. PloS one, 2020, Volume: 15, Issue:3 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Androstenes; DNA Methylation; Dutasteride; Epigenesis, Genetic; Humans; Male; Membrane Proteins; Prognosis; Promoter Regions, Genetic; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2020
Olaparib for Metastatic Castration-Resistant Prostate Cancer. The New England journal of medicine, 2020, 05-28, Volume: 382, Issue:22 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Benzamides; Genes, BRCA1; Genes, BRCA2; Humans; Loss of Function Mutation; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant	2020
HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies. Annals of oncology : official journal of the European Society for Medical Oncology, 2020, Volume: 31, Issue:9 Topics: Abiraterone Acetate; Androgen Antagonists; Androstenes; Benzamides; Germ Cells; Humans; Male; Multienzyme Complexes; Nitriles; Phenylthiohydantoin; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2020
A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. European urology, 2021, Volume: 79, Issue:5 Topics: Androgens; Androstenes; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Testosterone	2021
A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer. Clinical genitourinary cancer, 2021, Volume: 19, Issue:1 Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Random Allocation; Sunitinib; Treatment Outcome; Tumor Microenvironment	2021
A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 10-15, Volume: 26, Issue:20 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Treatment Outcome	2020
Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. The Lancet. Oncology, 2020, Volume: 21, Issue:11 Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Benzamides; Disease-Free Survival; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Taxoids; Treatment Outcome	2020
Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer. Scientific reports, 2021, 03-18, Volume: 11, Issue:1 Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Maximum Tolerated Dose; Middle Aged; Niclosamide; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant	2021
Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE). Cancer chemotherapy and pharmacology, 2021, Volume: 88, Issue:1 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Humans; Indazoles; Male; Middle Aged; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Prednisone; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Thiohydantoins	2021
Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide. Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 07-01, Volume: 27, Issue:13 Topics: Aged; Aged, 80 and over; Androstenes; Antigens, Surface; Benzamides; Glutamate Carboxypeptidase II; Humans; Immunoconjugates; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Treatment Failure	2021
Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2021, Volume: 32, Issue:7 Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome	2021
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet (London, England), 2021, 07-10, Volume: 398, Issue:10295 Topics: Aged; Androstenes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Humans; Male; Piperazines; Prednisolone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Pyrimidines	2021
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study. European urology, 2021, Volume: 80, Issue:4 Topics: Abiraterone Acetate; Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome	2021
Loss of JCO precision oncology, 2021, Volume: 5 Topics: Aged; Androgen Antagonists; Androstenes; Anilides; Antineoplastic Agents, Hormonal; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Male; Nitriles; Oligopeptides; Prostatic Neoplasms, Castration-Resistant; Signal Transduction; Snail Family Transcription Factors; Tosyl Compounds	2021
Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 11-01, Volume: 27, Issue:21 Topics: Adrenal Cortex; Adult; Aged; Aged, 80 and over; Androgens; Androstenes; Antineoplastic Agents, Hormonal; Correlation of Data; Drug Combinations; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2021
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study. ESMO open, 2021, Volume: 6, Issue:5 Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Lymphocytes; Male; Neutrophils; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Taxoids	2021
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. Annals of oncology : official journal of the European Society for Medical Oncology, 2017, Jul-01, Volume: 28, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents, Hormonal; Benzamides; Biomarkers, Tumor; Circulating Tumor DNA; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Europe; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multiplex Polymerase Chain Reaction; Multivariate Analysis; Mutation; Nitriles; Odds Ratio; Patient Selection; Phenylthiohydantoin; Precision Medicine; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Risk Factors; Time Factors; Treatment Outcome	2017
Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance. Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, Aug-15, Volume: 23, Issue:16 Topics: Androstenes; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genetic Variation; Humans; Male; Neoplasm Metastasis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; RNA Interference	2017
High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer. Clinical genitourinary cancer, 2017, Volume: 15, Issue:6 Topics: Aged; Androstenes; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2017
Activity of cabazitaxel in patients with metastatic castration-resistant prostate cancer after treatment with single or dual regimens of novel androgen receptor-targeting agents. Medical oncology (Northwood, London, England), 2017, Aug-17, Volume: 34, Issue:9 Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Humans; Male; Molecular Targeted Therapy; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Treatment Outcome	2017
Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial. BMC cancer, 2017, Oct-10, Volume: 17, Issue:1 Topics: Adult; Aged; Androstenes; Benzamides; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids	2017
Platelets harbor prostate cancer biomarkers and the ability to predict therapeutic response to abiraterone in castration resistant patients. The Prostate, 2018, Volume: 78, Issue:1 Topics: Aged; Androstenes; Antineoplastic Agents; Biomarkers, Tumor; Blood Platelets; Disease-Free Survival; Docetaxel; Glutamate Carboxypeptidase II; Humans; Kallikreins; Male; Middle Aged; Neuropeptide Y; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome	2018
Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide. European journal of nuclear medicine and molecular imaging, 2018, Volume: 45, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Androstenes; Benzamides; Choline; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Positron Emission Tomography Computed Tomography; Prognosis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Reproducibility of Results; Retrospective Studies	2018
Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer. Nature communications, 2017, 11-28, Volume: 8, Issue:1 Topics: Androgens; Androstenes; Disease Progression; Humans; Male; Models, Theoretical; Neoplasm Metastasis; Pilot Projects; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Steroid 17-alpha-Hydroxylase; Testosterone; Time Factors; Treatment Failure; Treatment Outcome	2017
Population-based Analysis of Treatment Toxicity Among Men With Castration-resistant Prostate Cancer: A Phase IV Study. Urology, 2018, Volume: 113 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Canada; Cohort Studies; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Emergency Service, Hospital; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Multivariate Analysis; Nitriles; Ontario; Phenylthiohydantoin; Population Surveillance; Prognosis; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome	2018
Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 04-01, Volume: 36, Issue:10 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; DNA Repair; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Poly(ADP-ribose) Polymerase Inhibitors; Prednisone; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-ets; Receptors, Androgen	2018
A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer. The oncologist, 2018, Volume: 23, Issue:6 Topics: Aged; Androstenes; Benzamides; Humans; Hydrazines; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Triazoles	2018
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 05-10, Volume: 36, Issue:14 Topics: Aged; Aged, 80 and over; Androstenes; Biomarkers, Tumor; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Fasting; Food; Glucocorticoids; Humans; Male; Middle Aged; Prednisone; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Singapore; Testosterone; Treatment Outcome; United States	2018
Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts. Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 07-01, Volume: 29, Issue:7 Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Follow-Up Studies; Humans; Male; Neoplasm Metastasis; Neoplastic Cells, Circulating; Prednisone; Prognosis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Survival Rate	2018
Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol. BMJ open, 2018, 05-14, Volume: 8, Issue:5 Topics: Androgen Antagonists; Androstenes; Benzamides; Clinical Trials, Phase III as Topic; Disease Progression; Exercise Therapy; Humans; Male; Multicenter Studies as Topic; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Androgen; United States	2018
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. Oncology, 2018, Volume: 19, Issue:7 Topics: Age Factors; Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Phthalazines; Piperazines; Prognosis; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Risk Assessment; Survival Rate; Treatment Outcome	2018
Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 09-01, Volume: 36, Issue:25 Topics: Androstenes; Antineoplastic Agents; Benzamides; Double-Blind Method; Drug Resistance, Neoplasm; Humans; Hypertension; Liver; Male; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2018
Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss. Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 02-01, Volume: 25, Issue:3 Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplasm Metastasis; Piperazines; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrimidines; Treatment Outcome	2019
Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study). British journal of cancer, 2018, Volume: 119, Issue:9 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents, Hormonal; Dexamethasone; Disease Progression; Humans; Male; Middle Aged; Oncogene Proteins, Fusion; Pilot Projects; Prednisone; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; PTEN Phosphohydrolase; Receptors, Androgen; Survival Analysis; Treatment Outcome	2018
Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program. Future oncology (London, England), 2018, Volume: 14, Issue:26 Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Italy; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies	2018
Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 03-15, Volume: 25, Issue:6 Topics: Aged; Aged, 80 and over; Androgen Receptor Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Circulating Tumor DNA; Disease-Free Survival; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liquid Biopsy; Male; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Predictive Value of Tests; Prognosis; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; RNA-Seq; Tumor Suppressor Protein p53	2019
Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial. European urology, 2019, Volume: 75, Issue:6 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality of Life	2019
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program. BMC cancer, 2019, Jan-07, Volume: 19, Issue:1 Topics: Aged; Aged, 80 and over; Androstenes; Bone Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome	2019
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 05-01, Volume: 37, Issue:13 Topics: Aged; Aged, 80 and over; Androstenes; Benzamides; Humans; Male; Middle Aged; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Predictive Value of Tests; Progression-Free Survival; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; Reproducibility of Results; Treatment Outcome	2019
Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer. JAMA oncology, 2019, Jul-01, Volume: 5, Issue:7 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; Treatment Outcome; Tumor Suppressor Protein p53	2019
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205. Clinical genitourinary cancer, 2019, Volume: 17, Issue:3 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Canada; Disease Progression; Gonanes; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Prostatic Neoplasms, Castration-Resistant; PTEN Phosphohydrolase; Survival Analysis; Treatment Outcome	2019
Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC). Clinical genitourinary cancer, 2019, Volume: 17, Issue:4 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Humans; Male; Middle Aged; Neoplastic Cells, Circulating; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Treatment Outcome	2019
Androgen dynamics and serum PSA in patients treated with abiraterone acetate. Prostate cancer and prostatic diseases, 2014, Volume: 17, Issue:2 Topics: Abiraterone Acetate; Androgens; Androstenes; Double-Blind Method; Humans; Kallikreins; Male; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Testosterone; Treatment Outcome	2014
External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abiraterone. European urology, 2014, Volume: 66, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; ROC Curve; Survival Rate; Taxoids; Time Factors	2014
Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301. European urology, 2015, Volume: 67, Issue:5 Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Factors; Survival Analysis; Taxoids	2015
Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer. Prostate cancer and prostatic diseases, 2014, Volume: 17, Issue:4 Topics: Aged; Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Azasteroids; Biopsy; Bone Neoplasms; Drug Resistance, Neoplasm; Dutasteride; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Radiography, Interventional; Radionuclide Imaging; Radiopharmaceuticals; Surgery, Computer-Assisted; Technetium Tc 99m Medronate	2014
Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients. International journal of urology : official journal of the Japanese Urological Association, 2014, Volume: 21, Issue:12 Topics: Aged; Androgens; Androstenes; Antineoplastic Agents; Disease Progression; Docetaxel; Drug Therapy, Combination; Glucocorticoids; Humans; Incidence; Male; Orchiectomy; Prednisolone; Prostatic Neoplasms, Castration-Resistant; Republic of Korea; Survival Rate; Taiwan; Taxoids; Treatment Failure	2014
Phase-1 study of abiraterone acetate in chemotherapy-naïve Japanese patients with castration-resistant prostate cancer. Cancer science, 2014, Volume: 105, Issue:10 Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androstadienes; Androstenes; Androstenols; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Steroid 17-alpha-Hydroxylase	2014
Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer. Clinical pharmacokinetics, 2014, Volume: 53, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Biological Availability; Cross-Over Studies; Dietary Fats; Docetaxel; Double-Blind Method; Fasting; Food-Drug Interactions; Healthy Volunteers; Humans; Male; Middle Aged; Models, Biological; Prostatic Neoplasms, Castration-Resistant; Steroid 17-alpha-Hydroxylase; Taxoids; Young Adult	2014
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. The Lancet. Oncology, 2014, Volume: 15, Issue:11 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Androstenols; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prednisolone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Treatment Outcome	2014
[Recruiting participants - study of therapy of CRPC]. Aktuelle Urologie, 2014, Volume: 45, Issue:5 Topics: Adenocarcinoma; Androgen Antagonists; Androstenes; Biomarkers, Tumor; Disease Progression; Drug Therapy, Combination; Germany; Gonadotropin-Releasing Hormone; Humans; Male; Patient Selection; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant	2014
A phase 2 study of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer who had received docetaxel-based chemotherapy. Japanese journal of clinical oncology, 2014, Volume: 44, Issue:12 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids	2014
Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone. Oncotarget, 2014, Dec-15, Volume: 5, Issue:23 Topics: Aged; Androstenes; Antineoplastic Agents; Choline; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Image Interpretation, Computer-Assisted; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Tomography, X-Ray Computed	2014
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study The Lancet. Oncology, 2015, Volume: 16, Issue:2 Topics: Aged; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progression; Double-Blind Method; Follow-Up Studies; Humans; Male; Neoplasm Staging; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Survival Rate	2015
Hematologic Toxicity of Concurrent Administration of Radium-223 and Next-generation Antiandrogen Therapies. American journal of clinical oncology, 2017, Volume: 40, Issue:4 Topics: Aged; Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Blood Cells; Combined Modality Therapy; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Treatment Outcome	2017
The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer. European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:17 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Treatment Outcome	2015
High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting. European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:17 Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Double-Blind Method; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Outcome Assessment, Health Care; Phenylthiohydantoin; Prognosis; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Subcutaneous Fat	2015
A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, Feb-15, Volume: 23, Issue:4 Topics: Aged; Androgens; Androstenes; Disease Progression; Drug Resistance, Neoplasm; Dutasteride; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radiography; Receptors, Androgen	2017
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone. Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 01-01, Volume: 28, Issue:1 Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome	2017
A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone. The oncologist, 2016, Volume: 21, Issue:11 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Azepines; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Pyrimidines; Testosterone	2016

Other Studies

350 other study(ies) available for abiraterone and Prostatic Neoplasms, Castration-Resistant

Article	Year
Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer. European journal of medicinal chemistry, 2019, Jun-01, Volume: 171 Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Male; Models, Molecular; Molecular Structure; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Structure-Activity Relationship; Tumor Cells, Cultured	2019
Development of Novel AKR1C3 Inhibitors as New Potential Treatment for Castration-Resistant Prostate Cancer. Journal of medicinal chemistry, 2020, 09-24, Volume: 63, Issue:18 Topics: Aldo-Keto Reductase Family 1 Member C3; Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Drug Design; Enzyme Inhibitors; G1 Phase Cell Cycle Checkpoints; Humans; Male; Mice, Inbred BALB C; PC-3 Cells; Prostatic Neoplasms, Castration-Resistant; Xenograft Model Antitumor Assays	2020
Discovery and Structure-Based Optimization of Novel Atg4B Inhibitors for the Treatment of Castration-Resistant Prostate Cancer. Journal of medicinal chemistry, 2022, 03-24, Volume: 65, Issue:6 Topics: Apoptosis; Autophagy; Autophagy-Related Proteins; Cell Line, Tumor; Cysteine Endopeptidases; Humans; Male; Prostatic Neoplasms, Castration-Resistant	2022
Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer. Journal of medicinal chemistry, 2022, 09-22, Volume: 65, Issue:18 Topics: Androgen Receptor Antagonists; Cell Line, Tumor; Cell Proliferation; Hormones; Humans; Male; Nitriles; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen	2022
Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients. ESMO open, 2021, Volume: 6, Issue:5 Topics: Adult; Androgen Antagonists; Androstenes; Benzamides; Humans; Male; Myocardial Infarction; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Stroke	2021
Time on treatment with abiraterone and enzalutamide in the Patient-overview Prostate Cancer in The National Prostate Cancer Register of Sweden. Acta oncologica (Stockholm, Sweden), 2021, Volume: 60, Issue:12 Topics: Aged; Androstenes; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Sweden; Treatment Outcome	2021
Real-world outcomes of abiraterone and enzalutamide in first-line treatment of metastatic castration-resistant prostate cancer: which patients benefit most? European journal of hospital pharmacy : science and practice, 2023, Volume: 30, Issue:5 Topics: Alkaline Phosphatase; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies	2023
Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients. Prostate cancer and prostatic diseases, 2022, Volume: 25, Issue:1 Topics: Androstenes; Antineoplastic Agents; Benzamides; COVID-19; COVID-19 Vaccines; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; SARS-CoV-2; Treatment Outcome; Vaccination	2022
Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase. EBioMedicine, 2021, Volume: 72 Topics: Aged; Aged, 80 and over; Androstenes; Benzamides; Biomarkers, Tumor; Cell Line, Tumor; Ceramides; Circulating Tumor DNA; Drug Resistance, Neoplasm; Humans; Lysophospholipids; Male; Nitriles; Phenylthiohydantoin; Phosphotransferases (Alcohol Group Acceptor); Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Signal Transduction; Sphingosine	2021
Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer. Prostate cancer and prostatic diseases, 2022, Volume: 25, Issue:3 Topics: Adolescent; Adult; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2022
Comparison of clinical outcomes between androgen deprivation therapy with up-front abiraterone and bicalutamide for Japanese patients with LATITUDE high-risk prostate cancer in a real-world retrospective analysis. International journal of clinical oncology, 2022, Volume: 27, Issue:3 Topics: Abiraterone Acetate; Androgen Antagonists; Androgens; Androstenes; Anilides; Antineoplastic Combined Chemotherapy Protocols; Humans; Japan; Male; Neoplasm Recurrence, Local; Nitriles; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Tosyl Compounds	2022
Overall and progression-free survival of Afro-Caribbean men with metastatic castration-resistant prostate cancer (mCRPC). The Prostate, 2022, Volume: 82, Issue:2 Topics: Androstenes; Antineoplastic Agents; Benzamides; Black People; Docetaxel; Guadeloupe; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome	2022
Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone. JAMA network open, 2022, 01-04, Volume: 5, Issue:1 Topics: Aged; Androstenes; Antineoplastic Agents; Benzamides; Black or African American; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome; White People	2022
Potential and real drug interactions in patients treated with abiraterone or enzalutamide in clinical practice. Expert opinion on drug metabolism & toxicology, 2021, Volume: 17, Issue:12 Topics: Abiraterone Acetate; Androstenes; Benzamides; Cross-Sectional Studies; Drug Interactions; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2021
Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling. The Prostate, 2022, Volume: 82, Issue:5 Topics: Androgens; Androstenes; Animals; Cell Line, Tumor; Humans; Ligands; Male; Mice; Nitriles; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Receptors, Glucocorticoid	2022
Potential negative pharmacodynamic interaction of spironolactone and abiraterone in two prostate cancer patients. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2022, Volume: 28, Issue:5 Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Spironolactone; Treatment Outcome	2022
Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide. Minerva urology and nephrology, 2021, Volume: 73, Issue:6 Topics: Androstenes; Benzamides; Humans; Lymphocytes; Male; Neutrophils; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant	2021
Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy. World journal of urology, 2022, Volume: 40, Issue:5 Topics: Androgen Antagonists; Androgens; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Humans; Male; Propensity Score; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies	2022
Biomarkers for Predicting Abiraterone Treatment Outcome and Selecting Alternative Therapies in Castration-Resistant Prostate Cancer. Clinical pharmacology and therapeutics, 2022, Volume: 111, Issue:6 Topics: Androstenes; Biomarkers; Complementary Therapies; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2022
Risk of Metabolic and Cardiovascular Adverse Events With Abiraterone or Enzalutamide Among Men With Advanced Prostate Cancer. Journal of the National Cancer Institute, 2022, 08-08, Volume: 114, Issue:8 Topics: Aged; Androstenes; Benzamides; Humans; Male; Medicare; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome; United States	2022
Ascending Flaccid Paralysis Secondary to Hypokalemia in A Cancer Patient using Abiraterone - A Case Report. Current drug safety, 2023, Volume: 18, Issue:1 Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Humans; Hypokalemia; Male; Paralysis; Prednisone; Prostatic Neoplasms, Castration-Resistant	2023
Impact of Novel Hormonal Agents (Abiraterone, Enzalutamide) on the Development of Visceral and/or Brain Metastases in Patients With Bone-metastatic Castration-resistant Prostate Cancer. Clinical genitourinary cancer, 2022, Volume: 20, Issue:5 Topics: Abiraterone Acetate; Aged; Androstenes; Benzamides; Brain Neoplasms; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome	2022
Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment. Cell reports. Medicine, 2022, 05-17, Volume: 3, Issue:5 Topics: Androstenes; Benzamides; Drug Resistance, Neoplasm; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant	2022
Immediate Prostate-specific Antigen Decline After Enzalutamide Following Abiraterone Predicts Survival in Castration-resistant Disease. Anticancer research, 2022, Volume: 42, Issue:6 Topics: Androstenes; Benzamides; Docetaxel; Humans; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome	2022
Serum prolactin level as a predictive factor for abiraterone response in patients with metastatic castration-resistant prostate cancer. The Prostate, 2022, Volume: 82, Issue:13 Topics: Abiraterone Acetate; Androstenes; Humans; Male; Prolactin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome	2022
Skeletal-related events after abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer: A population-based study using the SEER-Medicare linked dataset. Urologic oncology, 2022, Volume: 40, Issue:8 Topics: Abiraterone Acetate; Aged; Androstenes; Benzamides; Denosumab; Humans; Male; Medicare; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome; United States	2022
A scoping review protocol to elucidate outcomes following abiraterone versus enzalutamide for prostate cancer. PloS one, 2022, Volume: 17, Issue:8 Topics: Abiraterone Acetate; Androstenes; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Review Literature as Topic; Treatment Outcome	2022
Changes in prostate-specific antigen kinetics during androgen-deprivation therapy as a predictor of response to abiraterone in chemonaïve patients with metastatic castration-resistant prostate cancer. Investigative and clinical urology, 2022, Volume: 63, Issue:5 Topics: Abiraterone Acetate; Aged; Androgen Antagonists; Androgens; Androstenes; Humans; Kinetics; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome	2022
Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases. Prostate cancer and prostatic diseases, 2023, Volume: 26, Issue:4 Topics: Abiraterone Acetate; Cardiovascular Diseases; Diabetes Mellitus; Humans; Male; Nitriles; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome; Veterans	2023
Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone Treatment. Molecular cancer research : MCR, 2022, 12-02, Volume: 20, Issue:12 Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant	2022
Remission of progressive metastatic castration-resistant prostate cancer during abiraterone therapy following unilateral adrenalectomy for a functioning adrenal adenoma. BMJ case reports, 2022, Oct-05, Volume: 15, Issue:10 Topics: Abiraterone Acetate; Adrenalectomy; Aldosterone; Androgens; Androstenes; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Testosterone; Treatment Outcome	2022
Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer. Medical science monitor : international medical journal of experimental and clinical research, 2022, Oct-14, Volume: 28 Topics: Abiraterone Acetate; Androstenes; Dihydrotestosterone; Humans; Male; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Steroid 17-alpha-Hydroxylase; Testosterone; Treatment Outcome	2022
Long-term use and risk of major adverse cardiac events: Comparing enzalutamide and abiraterone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer. International journal of cancer, 2023, 03-15, Volume: 152, Issue:6 Topics: Cardiovascular Diseases; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome	2023
Stereotactic body radiotherapy in oligoprogressive metastatic castration-resistant prostate cancer during abiraterone or enzalutamide. Tumori, 2023, Volume: 109, Issue:4 Topics: Antineoplastic Agents; Humans; Male; Nitriles; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Radiosurgery; Receptors, Androgen; Retrospective Studies; Treatment Outcome	2023
Impact of trough abiraterone level on adverse events in patients with prostate cancer treated with abiraterone acetate. European journal of clinical pharmacology, 2023, Volume: 79, Issue:1 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Membrane Proteins; Prospective Studies; Prostatic Neoplasms, Castration-Resistant	2023
Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling. Cancer research, 2023, 01-18, Volume: 83, Issue:2 Topics: Androgens; Animals; Humans; Male; Mice; Mitosis; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen	2023
Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study. World journal of urology, 2023, Volume: 41, Issue:1 Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Hormones; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome	2023
Qi Ling decoction enhances abiraterone treatment via suppression of autophagy in castration resistant prostate cancer. Aging, 2022, 12-19, Volume: 14, Issue:24 Topics: Androstenes; Autophagy; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Qi	2022
Should one use the combination of abiraterone and poly(ADP-ribose) polymerase inhibitors as first-line therapy for all patients with metastatic castration-resistant prostate cancer? Future oncology (London, England), 2022, Volume: 18, Issue:39 Topics: Androstenes; DNA Repair; Humans; Male; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms, Castration-Resistant	2022
Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy. The Prostate, 2023, Volume: 83, Issue:6 Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Hormones; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome	2023
Plasma extracellular vesicle circRNA signature and resistance to abiraterone in metastatic castration-resistant prostate cancer. British journal of cancer, 2023, Volume: 128, Issue:7 Topics: Abiraterone Acetate; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; RNA, Circular; Treatment Outcome	2023
Circulating tumor cell quantification during abiraterone plus prednisone therapy may estimate survival in metastatic castration-resistant prostate cancer patients. International urology and nephrology, 2023, Volume: 55, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease-Free Survival; Humans; Male; Neoplastic Cells, Circulating; Prednisone; Prostatic Neoplasms, Castration-Resistant	2023
Abiraterone-Docetaxel scheduling for metastatic castration-resistant prostate cancer based on evolutionary dynamics. PloS one, 2023, Volume: 18, Issue:3 Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome	2023
[Drug approval: Olaparib in combination with abiraterone for metastatic castration-resistant prostate cancer]. Bulletin du cancer, 2023, Volume: 110, Issue:4 Topics: Abiraterone Acetate; Antineoplastic Agents; Drug Approval; Humans; Male; Prostatic Neoplasms, Castration-Resistant	2023
PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2023, 05-15, Volume: 29, Issue:10 Topics: Biomarkers, Tumor; Humans; Male; Neoplastic Cells, Circulating; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome	2023
Neuroendocrine differentiation predicts the therapeutic efficacy of abiraterone and docetaxel as first-line therapy in metastatic castration-resistant prostate cancer. Journal of cancer research and clinical oncology, 2023, Volume: 149, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Female; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome	2023
Prostate-speciﬁc antigen response after Abiraterone treatment in mCRPC: PSA as a predictor of overall survival. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica, 2023, 02-22, Volume: 95, Issue:1 Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androgen Antagonists; Cohort Studies; Disease-Free Survival; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome	2023
Combining Poly(ADP)-Ribose Polymerase Inhibitors With Abiraterone in Castration-Resistant Prostate Cancer: Is Biomarker Testing Necessary? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 06-20, Volume: 41, Issue:18 Topics: Biomarkers; Humans; Male; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms, Castration-Resistant; Ribose	2023
Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2023, 08-01, Volume: 29, Issue:15 Topics: Androgen Receptor Antagonists; Circulating Tumor DNA; Humans; Male; Nitriles; Prospective Studies; Prostatic Neoplasms, Castration-Resistant	2023
Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learning. Nature communications, 2023, 04-08, Volume: 14, Issue:1 Topics: Androstenes; Biomarkers, Tumor; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2023
Comparison of circulating tumor DNA between African American and Caucasian patients with metastatic castrate-resistant prostate cancer post-abiraterone and/or enzalutamide. The Prostate, 2023, Volume: 83, Issue:11 Topics: Antineoplastic Agents; Black or African American; Circulating Tumor DNA; Humans; Male; Mutation; Nitriles; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome; White	2023
Real-World Treatment Patterns Among French Patients With Metastatic Castration-Resistant Prostate Cancer Under Abiraterone or Enzalutamide. Clinical genitourinary cancer, 2023, Volume: 21, Issue:5 Topics: Abiraterone Acetate; Androgen Antagonists; Humans; Male; Nitriles; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome	2023
Inhibition of Wnt/β-catenin pathway overcomes therapeutic resistance to abiraterone in castration-resistant prostate cancer. Molecular carcinogenesis, 2023, Volume: 62, Issue:9 Topics: beta Catenin; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Recurrence, Local; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen	2023
Frailty and survival among veterans treated with abiraterone or enzalutamide for metastatic castration-resistant prostate cancer. Journal of geriatric oncology, 2023, Volume: 14, Issue:5 Topics: Aged; Dementia; Frailty; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome; Veterans	2023
Circulating Tumor DNA Biomarkers for Response Assessment in Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2023, 08-01, Volume: 29, Issue:15 Topics: Biomarkers, Tumor; Circulating Tumor DNA; Humans; Male; Prostatic Neoplasms, Castration-Resistant	2023
Validation of an LC-MS/MS method for simultaneous quantification of abiraterone, enzalutamide and darolutamide in human plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2023, Jun-01, Volume: 1225 Topics: Chromatography, Liquid; Humans; Male; Nitriles; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Tandem Mass Spectrometry	2023
Mental health care utilization among men with castration-resistant prostate cancer receiving abiraterone or enzalutamide. Cancer medicine, 2023, Volume: 12, Issue:15 Topics: Androstenes; Humans; Male; Nitriles; Patient Acceptance of Health Care; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2023
Clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with abiraterone with or without ongoing androgen deprivation therapy: A retrospective case-control study. The Prostate, 2023, Volume: 83, Issue:13 Topics: Androgen Antagonists; Androstenes; Case-Control Studies; Humans; Male; Neoplasm Metastasis; Progression-Free Survival; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome	2023
A prospective, multicenter study on the clinical effectiveness of abiraterone in metastatic castration-resistant prostate cancer in Korea: Pre- vs. post-chemotherapy. Investigative and clinical urology, 2023, Volume: 64, Issue:5 Topics: Drug-Related Side Effects and Adverse Reactions; Humans; Male; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Republic of Korea; Treatment Outcome	2023
Survivin-targeted nanomedicine for increased potency of abiraterone and enzalutamide against prostate cancer. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2023, Volume: 192 Topics: Gold; Humans; Male; Metal Nanoparticles; Nanomedicine; Prostatic Neoplasms, Castration-Resistant; Survivin	2023
A common germline variant in CYP11B1 is associated with adverse clinical outcome of treatment with abiraterone or enzalutamide. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Dec-31, Volume: 169 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Androgens; Germ Cells; Humans; Male; Membrane Proteins; Nitriles; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Steroid 11-beta-Hydroxylase; Treatment Outcome	2023
Defining End Points in Phase II Trials of Metastatic Castration-Resistant Prostate Cancer. Re: Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Clinical genitourinary cancer, 2019, Volume: 17, Issue:5 Topics: Abiraterone Acetate; Androstenes; Humans; Male; Metformin; Pilot Projects; Prostatic Neoplasms, Castration-Resistant	2019
Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving Theranostics, 2019, Volume: 9, Issue:17 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Taxoids	2019
Bioanalytical evaluation of dried plasma spots for monitoring of abiraterone and ∆(4)-abiraterone from cancer patients. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2019, Sep-15, Volume: 1126-1127 Topics: Androstenes; Chromatography, Liquid; Dried Blood Spot Testing; Drug Monitoring; Humans; Linear Models; Male; Prostatic Neoplasms, Castration-Resistant; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry	2019
Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients. Annals of nuclear medicine, 2019, Volume: 33, Issue:12 Topics: Aged; Androstenes; Antigens, Surface; Benzamides; Gene Expression Regulation, Neoplastic; Glutamate Carboxypeptidase II; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome	2019
Managing lines of therapy in castration-resistant prostate cancer: real-life snapshot from a multicenter cohort. World journal of urology, 2020, Volume: 38, Issue:7 Topics: Aged; Aged, 80 and over; Androstenes; Benzamides; Cohort Studies; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2020
Improved Androgen Receptor Splice Variant 7 Detection Using a Highly Sensitive Assay to Predict Resistance to Abiraterone or Enzalutamide in Metastatic Prostate Cancer Patients. European urology oncology, 2021, Volume: 4, Issue:4 Topics: Androstenes; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen	2021
Abiraterone experience in a patient with metastatic castration-resistant prostate cancer on hemodialysis. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2019, Volume: 25, Issue:8 Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Renal Dialysis	2019
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort. British journal of cancer, 2019, Volume: 121, Issue:12 Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome	2019
Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. CON: Novel oral agents provide an attractive alternative to chemotherapy in metastatic hormone-sensitive prostate cancer. Current opinion in urology, 2020, Volume: 30, Issue:4 Topics: Administration, Oral; Androstenes; Benzamides; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Thiohydantoins	2020
Radiotherapy in metastatic castration resistant prostate cancer patients with oligo-progression during abiraterone-enzalutamide treatment: a mono-institutional experience. Radiation oncology (London, England), 2019, Nov-14, Volume: 14, Issue:1 Topics: Aged; Aged, 80 and over; Androgen Receptor Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiosurgery; Radiotherapy, Conformal; Receptors, Androgen; Retrospective Studies; Treatment Outcome	2019
Re: Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer. European urology, 2020, Volume: 77, Issue:3 Topics: Androstenes; Benzamides; Humans; Male; Mutation; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant	2020
Prognostic impact of C-reactive protein-albumin ratio for the lethality in castration-resistant prostate cancer. Medical oncology (Northwood, London, England), 2019, Nov-21, Volume: 37, Issue:1 Topics: Aged; Albumins; Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; C-Reactive Protein; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Predictive Value of Tests; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome	2019
TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer. Clinical genitourinary cancer, 2020, Volume: 18, Issue:2 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Circulating Tumor DNA; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Gain of Function Mutation; Humans; Liquid Biopsy; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prognosis; Prostate; Prostatic Neoplasms, Castration-Resistant; Tumor Suppressor Protein p53	2020
Propensity score-matched comparison of docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant intraductal carcinoma of the prostate. BJU international, 2020, Volume: 125, Issue:5 Topics: Administration, Oral; Aged; Androstenes; Antineoplastic Agents; Benzamides; Biopsy; Docetaxel; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Male; Nitriles; Phenylthiohydantoin; Propensity Score; Prostate; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Treatment Outcome	2020
A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population. International journal of cancer, 2020, 08-15, Volume: 147, Issue:4 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Bone Neoplasms; Chemoradiotherapy; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Phenylthiohydantoin; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Radium; Registries; Taxoids	2020
Real World Experience With Pembrolizumab in Recurrent or Advanced Prostate Cancer. Clinical genitourinary cancer, 2020, Volume: 18, Issue:4 Topics: Aged; Aged, 80 and over; Androstenes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Combined Modality Therapy; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radiosurgery; Retrospective Studies; Tissue Extracts	2020
Circulating miR-141 and miR-375 are associated with treatment outcome in metastatic castration resistant prostate cancer. Scientific reports, 2020, 01-14, Volume: 10, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Case-Control Studies; Circulating MicroRNA; Docetaxel; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Middle Aged; Neoplasm Metastasis; Prognosis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Survival Rate	2020
Systemic treatment for metastatic castrate resistant prostate cancer: Does seqence matter? The Prostate, 2020, Volume: 80, Issue:5 Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Drug Administration Schedule; Humans; Kallikreins; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate	2020
Der Urologe. Ausg. A, 2020, Volume: 59, Issue:1 Topics: Androstenes; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Taxoids	2020
Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2020, Volume: 28, Issue:10 Topics: Aged; Aged, 80 and over; Androstenes; Benzamides; Cohort Studies; Humans; Male; Medication Adherence; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2020
Role of the neutrophil/lymphocyte ratio in patients with metastatic castration-resistant prostate cancer treated first-line with abiraterone. Actas urologicas espanolas, 2020, Volume: 44, Issue:3 Topics: Aged; Aged, 80 and over; Androstenes; Humans; Leukocyte Count; Lymphocytes; Male; Middle Aged; Neoplasm Metastasis; Neutrophils; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome	2020
Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States. Clinical genitourinary cancer, 2020, Volume: 18, Issue:4 Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Follow-Up Studies; Humans; Male; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids; Tissue Extracts	2020
Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone. Advances in therapy, 2020, Volume: 37, Issue:5 Topics: Abiraterone Acetate; Adult; Aged; Androstenes; Antineoplastic Agents, Hormonal; Benzamides; Cohort Studies; Drug Administration Schedule; Health Care Costs; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies	2020
Preliminary results of targeted prostate-specific membrane antigen imaging in evaluating the efficacy of a novel hormone agent in metastatic castration-resistant prostate cancer. Cancer medicine, 2020, Volume: 9, Issue:10 Topics: Aged; Aged, 80 and over; Androstenes; Antigens, Surface; Antineoplastic Agents, Hormonal; Bone Neoplasms; Glutamate Carboxypeptidase II; Humans; Lymphatic Metastasis; Male; Middle Aged; Organotechnetium Compounds; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Retrospective Studies; Single Photon Emission Computed Tomography Computed Tomography; Treatment Outcome	2020
Combination of statin/vitamin D and metastatic castration-resistant prostate cancer (CRPC): a post hoc analysis of two randomized clinical trials. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020, Volume: 22, Issue:11 Topics: Androstenes; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Neoplasm Metastasis; Prednisone; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Vitamin D	2020
Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer. BJU international, 2021, Volume: 127, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Androstenes; Antineoplastic Agents; Benzamides; Chromogranin A; Docetaxel; Humans; Male; Middle Aged; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Phosphopyruvate Hydratase; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Proton Pump Inhibitors; Survival Rate	2021
Use of record linkage to evaluate treatment outcomes and trial eligibility in a real-world metastatic prostate cancer population in Scotland. Pharmacoepidemiology and drug safety, 2020, Volume: 29, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Benzamides; Clinical Decision-Making; Clinical Trials as Topic; Electronic Health Records; Eligibility Determination; Humans; Male; Medical Record Linkage; Middle Aged; Neoplasm Metastasis; Nitriles; Patient Selection; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Scotland; State Medicine; Time Factors; Treatment Outcome	2020
Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype. Annals of oncology : official journal of the European Society for Medical Oncology, 2020, Volume: 31, Issue:9 Topics: Abiraterone Acetate; Androgen Antagonists; Androstenes; Benzamides; Genotype; Germ Cells; Humans; Male; Multienzyme Complexes; Nitriles; Phenylthiohydantoin; Progesterone Reductase; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Steroid Isomerases; Treatment Outcome	2020
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer. Prostate cancer and prostatic diseases, 2020, Volume: 23, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Chemoradiotherapy; Clinical Trials, Phase III as Topic; Denosumab; Humans; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Treatment Outcome; Zoledronic Acid	2020
Blood platelet volume predicts treatment-specific outcomes of metastatic castration-resistant prostate cancer. International journal of clinical oncology, 2020, Volume: 25, Issue:9 Topics: Aged; Androstenes; Benzamides; Biomarkers, Tumor; Docetaxel; Erythrocytes; Humans; Male; Mean Platelet Volume; Nitriles; Phenylthiohydantoin; Platelet Count; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Treatment Outcome	2020
Homozygous HSD3B1(1245C) inheritance and poor outcomes in metastatic castration-resistant prostate cancer with abiraterone or enzalutamide: what does it mean? Annals of oncology : official journal of the European Society for Medical Oncology, 2020, Volume: 31, Issue:9 Topics: Androstenes; Benzamides; Germ Cells; Humans; Male; Multienzyme Complexes; Nitriles; Phenylthiohydantoin; Prospective Studies; Prostatic Neoplasms, Castration-Resistant	2020
Identifying Prostate Surface Antigen Patterns of Change in Patients with Metastatic Hormone Sensitive Prostate Cancer Treated with Abiraterone and Prednisone. Targeted oncology, 2020, Volume: 15, Issue:4 Topics: Aged; Androstenes; Antigens, Surface; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Treatment Outcome	2020
Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer. British journal of cancer, 2020, Volume: 123, Issue:6 Topics: Aged; Aged, 80 and over; Androstenes; DNA, Neoplasm; Humans; Male; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant	2020
Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer. Cancer treatment and research communications, 2020, Volume: 24 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Circulating Tumor DNA; Disease-Free Survival; Drug Resistance, Neoplasm; Follow-Up Studies; Gene Amplification; Humans; Kallikreins; Male; Middle Aged; Mutation; Neoplasm Grading; Nitriles; Phenylthiohydantoin; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies	2020
AR-V7 as a Biomarker for Resistance to Treatment with Abiraterone/Enzalutamide in Three Latin American Countries: A Hypothetical Cost-Saving Analysis. The oncologist, 2020, Volume: 25, Issue:12 Topics: Androstenes; Benzamides; Biomarkers; Colombia; Drug Resistance, Neoplasm; Humans; Latin America; Male; Mexico; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen	2020
Adding carboplatin to chemotherapy regimens for metastatic castrate-resistant prostate cancer in postsecond generation hormone therapy setting: Impact on treatment response and survival outcomes. The Prostate, 2020, Volume: 80, Issue:14 Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carboplatin; Disease Progression; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids; Treatment Failure	2020
Challenges of Treating a Patient With Advanced Prostate Cancer During the COVID-19 Pandemic. Oncology (Williston Park, N.Y.), 2020, 08-12, Volume: 34, Issue:8 Topics: Aged; Androgen Antagonists; Androstenes; Anticoagulants; Antineoplastic Agents; Betacoronavirus; Bone Density Conservation Agents; Bone Neoplasms; Cancer Pain; Coronavirus Infections; COVID-19; Disease Progression; Docetaxel; Drug Combinations; Eligibility Determination; Heparin, Low-Molecular-Weight; Humans; Intensive Care Units; Lopinavir; Male; Oxygen Inhalation Therapy; Palliative Care; Pandemics; Pneumonia, Viral; Prostatic Neoplasms, Castration-Resistant; Renal Insufficiency; Respiratory Insufficiency; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; SARS-CoV-2; Severity of Illness Index; Zoledronic Acid	2020
YB-1 variant and androgen receptor axis-targeted agents in metastatic castration-resistant prostate cancer patients. Pharmacogenomics, 2020, Volume: 21, Issue:13 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Cohort Studies; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Genotype; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Y-Box-Binding Protein 1	2020
Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy. Molecular pharmaceutics, 2020, 09-08, Volume: 17, Issue:9 Topics: Androgen Antagonists; Androstenes; Animals; Antibodies, Monoclonal; Antigens, Surface; Benzamides; Cell Line, Tumor; Centrosome; Glutamate Carboxypeptidase II; Humans; Immunoconjugates; Male; Mice; Mice, Nude; Nitriles; PC-3 Cells; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Tubulin Modulators; Xenograft Model Antitumor Assays	2020
PROACTA: a survey on the actual attitude of the Italian radiation oncologists in the management and prescription of hormonal therapy in prostate cancer patients. La Radiologia medica, 2021, Volume: 126, Issue:3 Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Attitude of Health Personnel; Benzamides; Combined Modality Therapy; Gonadotropin-Releasing Hormone; Health Care Surveys; Humans; Italy; Male; Nitriles; Phenylthiohydantoin; Prostatectomy; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radiation Oncologists; Risk Factors; Salvage Therapy	2021
The clinical benefit of sequential therapy with androgen receptor axis-targeted agents alone in patients with castration-resistant prostate cancer: A propensity score-matched comparison study. The Prostate, 2020, Volume: 80, Issue:15 Topics: Aged; Aged, 80 and over; Androgen Receptor Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Benzamides; Disease Progression; Drug Therapy, Combination; Humans; Male; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Propensity Score; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Treatment Outcome	2020
Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 11-15, Volume: 26, Issue:22 Topics: Androgen Antagonists; Androgens; Androstenes; Benzamides; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; RNA-Seq; Steryl-Sulfatase	2020
Impact of antiandrogen withdrawal syndrome in castration-resistant prostate cancer patients treated with abiraterone or enzalutamide. International journal of urology : official journal of the Japanese Urological Association, 2020, Volume: 27, Issue:12 Topics: Androgen Antagonists; Androstenes; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2020
Overall Survival Among Chemotherapy-Naive Patients With Castration-Resistant Prostate Cancer Under Abiraterone Versus Enzalutamide: A Direct Comparison Based on a 2014-2018 French Population Study (the SPEAR Cohort). American journal of epidemiology, 2021, 02-01, Volume: 190, Issue:3 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Comorbidity; Humans; Male; Nitriles; Phenylthiohydantoin; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Survival Analysis	2021
Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamide. Prostate cancer and prostatic diseases, 2021, Volume: 24, Issue:2 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Benzamides; Biomarkers, Tumor; Bone Neoplasms; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Prednisone; Prognosis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Transcriptome	2021
The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy. Urologic oncology, 2021, Volume: 39, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Male; Matrix Metalloproteinase 7; Middle Aged; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate	2021
Androgen receptor signaling-targeted therapy and taxane chemotherapy induce visceral metastasis in castration-resistant prostate cancer. The Prostate, 2021, Volume: 81, Issue:1 Topics: Aged; Aged, 80 and over; Androstenes; Benzamides; Docetaxel; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Risk Factors; Signal Transduction; Taxoids	2021
Prognostic significance of complete blood count parameters in castration-resistant prostate cancer patients treated with androgen receptor pathway inhibitors. Urologic oncology, 2021, Volume: 39, Issue:6 Topics: Aged; Aged, 80 and over; Androgen Receptor Antagonists; Androstenes; Benzamides; Blood Cell Count; Humans; Male; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate	2021
Influence of abiraterone and enzalutamide on body composition in patients with metastatic castration resistant prostate cancer. Cancer treatment and research communications, 2020, Volume: 25 Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Body Composition; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant	2020
Observational study on time on treatment with abiraterone and enzalutamide. PloS one, 2020, Volume: 15, Issue:12 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Benzamides; Chemotherapy, Adjuvant; Drug Prescriptions; Humans; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Registries; Sweden; Time Factors; Treatment Outcome	2020
Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience. Radiation oncology (London, England), 2021, Jan-06, Volume: 16, Issue:1 Topics: Aged; Aged, 80 and over; Androstenes; Combined Modality Therapy; Cytoreduction Surgical Procedures; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant	2021
Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance. BMC cancer, 2021, Jan-07, Volume: 21, Issue:1 Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Docetaxel; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Male; Prognosis; Prostatic Neoplasms, Castration-Resistant; Quality-Adjusted Life Years; Survival Rate; Taxoids	2021
Ferroptosis Inducers Are a Novel Therapeutic Approach for Advanced Prostate Cancer. Cancer research, 2021, 03-15, Volume: 81, Issue:6 Topics: Amino Acid Transport System y+; Androgen Antagonists; Androstenes; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carbolines; Cell Line, Tumor; Drug Resistance, Neoplasm; Ferroptosis; Fusion Regulatory Protein 1, Heavy Chain; Humans; Male; Mice; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Phospholipid Hydroperoxide Glutathione Peroxidase; Piperazines; Prostate; Prostatic Neoplasms, Castration-Resistant; Xenograft Model Antitumor Assays	2021
Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide. Prostate cancer and prostatic diseases, 2021, Volume: 24, Issue:2 Topics: Aged; Aged, 80 and over; Alternative Splicing; Androstenes; Benzamides; Biomarkers, Tumor; Cell-Free Nucleic Acids; Drug Resistance, Neoplasm; Exosomes; Follow-Up Studies; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Survival Rate	2021
Prognostic impact of prior local therapy in castration-resistant prostate cancer. Japanese journal of clinical oncology, 2021, Jul-01, Volume: 51, Issue:7 Topics: Aged; Androstenes; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Survival Analysis	2021
SEOM clinical guidelines for the treatment of advanced prostate cancer (2020). Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2021, Volume: 23, Issue:5 Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Docetaxel; Genes, BRCA1; Genes, BRCA2; Genetic Testing; Humans; Male; Medical Oncology; Nitriles; Orchiectomy; Phenylthiohydantoin; Phthalazines; Piperazines; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radiotherapy; Randomized Controlled Trials as Topic; Societies, Medical; Spain; Thiohydantoins	2021
Efficacy and tolerability of current treatments for hormone-refractory prostate cancer patients with visceral metastases. Future oncology (London, England), 2021, Volume: 17, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Androstenes; Benzamides; Docetaxel; Drug Administration Schedule; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies	2021
The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment failure with abiraterone for castration-resistant prostate cancer. The pharmacogenomics journal, 2021, Volume: 21, Issue:4 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Aged; Aged, 80 and over; Alleles; Androstenes; Genetic Association Studies; Genotype; Humans; Male; Membrane Proteins; Middle Aged; Multienzyme Complexes; Polymorphism, Genetic; Progesterone Reductase; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Steroid Isomerases; Treatment Failure	2021
Safety of concomitant therapy with radium-223 and abiraterone or enzalutamide in a real-world population. The Prostate, 2021, Volume: 81, Issue:7 Topics: Aged; Androstenes; Benzamides; Bone Neoplasms; Combined Modality Therapy; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium; Survival Rate; Veterans	2021
Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease. Japanese journal of clinical oncology, 2021, Aug-01, Volume: 51, Issue:8 Topics: Aged; Androstenes; Benzamides; Disease-Free Survival; Humans; Male; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome	2021
The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population. Prostate cancer and prostatic diseases, 2021, Volume: 24, Issue:3 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemoradiotherapy; Docetaxel; Follow-Up Studies; Humans; Male; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Survival Rate; Taxoids	2021
Treatment and Patient Selection for Patients with Metastatic Castration-resistant Prostate After Progression on Docetaxel and Abiraterone/Enzalutamide: When to Play Your CARD and When to Do Your PARP. European urology, 2021, Volume: 80, Issue:2 Topics: Androstenes; Benzamides; Docetaxel; Humans; Male; Nitriles; Orchiectomy; Patient Selection; Pharmaceutical Preparations; Phenylthiohydantoin; Poly(ADP-ribose) Polymerase Inhibitors; Prostate; Prostatic Neoplasms, Castration-Resistant	2021
Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide. Minerva urology and nephrology, 2021, Volume: 73, Issue:6 Topics: Androstenes; Benzamides; Humans; Lymphocytes; Male; Neutrophils; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies	2021
Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 07-15, Volume: 27, Issue:14 Topics: Adult; Aged; Aged, 80 and over; Androstenes; Benzamides; Chromosomal Instability; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Neurosecretory Systems; Nitriles; Phenotype; Phenylthiohydantoin; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2021
Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer. European journal of cancer (Oxford, England : 1990), 2021, Volume: 150 Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Benzamides; Biomarkers, Tumor; Cell Count; Clinical Decision-Making; Humans; Keratins; Leukocyte Common Antigens; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Predictive Value of Tests; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Reproducibility of Results	2021
Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment. The Prostate, 2021, Volume: 81, Issue:9 Topics: Androstenes; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prognosis; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiosurgery; Treatment Outcome	2021
Outcomes of treatment choices in poor prognosis prostate cancer: not against all odds. Annals of oncology : official journal of the European Society for Medical Oncology, 2021, Volume: 32, Issue:7 Topics: Androstenes; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome	2021
Aktuelle Urologie, 2021, Volume: 52, Issue:3 Topics: Androstenes; Hormones; Humans; Male; Prostatic Neoplasms, Castration-Resistant	2021
Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition. Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 08-15, Volume: 27, Issue:16 Topics: Androgen Receptor Antagonists; Androstenes; Benzamides; Circulating Tumor DNA; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant	2021
Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score-weighted comparative cohort study. European journal of cancer (Oxford, England : 1990), 2021, Volume: 152 Topics: Age Factors; Aged, 80 and over; Androstenes; Benzamides; Dose-Response Relationship, Drug; Humans; Kallikreins; Male; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Propensity Score; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Time Factors	2021
Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer. JAMA network open, 2021, 07-01, Volume: 4, Issue:7 Topics: Aged; Aged, 80 and over; Androstenes; Benzamides; Cognition; Drug Therapy; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium	2021
Hospitalization for adverse events under abiraterone or enzalutamide exposure in real-world setting: A French population-based study on prostate cancer patients. British journal of clinical pharmacology, 2022, Volume: 88, Issue:1 Topics: Acute Kidney Injury; Androstenes; Atrial Fibrillation; Benzamides; Brain Ischemia; Hospitalization; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Stroke; Treatment Outcome	2022
Exosomal TUBB3 mRNA expression of metastatic castration-resistant prostate cancer patients: Association with patient outcome under abiraterone. Cancer medicine, 2021, Volume: 10, Issue:18 Topics: Aged; Androstenes; Biomarkers, Tumor; Drug Resistance, Neoplasm; Exosomes; Gene Expression Regulation, Neoplastic; Humans; Kallikreins; Male; Progression-Free Survival; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Risk Assessment; RNA, Messenger; Tubulin	2021
Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer - an Australian multi-centre observational study. European journal of cancer (Oxford, England : 1990), 2021, Volume: 157 Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Australia; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Docetaxel; Humans; Incidence; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid	2021
Prognostic Score and Benefit from Abiraterone in First-line Metastatic, Castration-resistant Prostate Cancer. European urology, 2021, Volume: 80, Issue:5 Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Male; Middle Aged; Prognosis; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2021
Beyond Frontline Therapy with Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Real-World US Study. Clinical genitourinary cancer, 2021, Volume: 19, Issue:6 Topics: Abiraterone Acetate; Adult; Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome	2021
KAT2A-mediated AR translocation into nucleus promotes abiraterone-resistance in castration-resistant prostate cancer. Cell death & disease, 2021, 08-12, Volume: 12, Issue:8 Topics: Acetylation; Androstenes; Animals; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histone Acetyltransferases; Humans; Lysine; Male; Mice, Nude; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Protein Transport; Receptors, Androgen; RNA, Messenger; Up-Regulation	2021
The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer. The Prostate, 2021, Volume: 81, Issue:15 Topics: Aged; Androstenes; Antineoplastic Agents; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Progression-Free Survival; Prostate; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Treatment Outcome	2021
The effect of chemotherapy on the exposure-response relation of abiraterone in metastatic castration-resistant prostate cancer. British journal of clinical pharmacology, 2022, Volume: 88, Issue:3 Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome	2022
Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations. Current medical research and opinion, 2017, Volume: 33, Issue:6 Topics: Aged; Androstenes; Benzamides; Docetaxel; Drug Costs; Health Care Costs; Humans; Male; Medicare; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radium; Taxoids; United States	2017
Potential drug-drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in France. Cancer chemotherapy and pharmacology, 2017, Volume: 79, Issue:5 Topics: Aged; Aged, 80 and over; Androstenes; Comorbidity; Cross-Sectional Studies; Disease-Free Survival; Drug Interactions; Electronic Health Records; Enzyme Inhibitors; France; Humans; Male; Neoplasm Metastasis; Pain; Pharmacists; Polypharmacy; Prevalence; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies	2017
Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Jul-01, Volume: 35, Issue:19 Topics: Aged; Androstenes; Antineoplastic Agents; Benzamides; Cohort Studies; Disease-Free Survival; Humans; Kallikreins; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; RNA, Messenger; Treatment Outcome	2017
First-line management of metastatic castrate-resistant prostate cancer patients: Audit of real-life practices. Bulletin du cancer, 2017, Volume: 104, Issue:6 Topics: Age Factors; Aged; Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Bone and Bones; Docetaxel; Humans; Male; Medical Audit; Medical Oncology; Neoplasm Grading; Nitriles; Phenylthiohydantoin; Practice Patterns, Physicians'; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiation Oncology; Radionuclide Imaging; Regression Analysis; Surveys and Questionnaires; Taxoids; Tumor Burden; Urology	2017
Association Between Androgen Receptor Splice Variants and Prostate Cancer Resistance to Abiraterone and Enzalutamide. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, 07-01, Volume: 35, Issue:19 Topics: Androstenes; Benzamides; Humans; Male; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; RNA, Messenger	2017
Identification of risk factors predicting febrile neutropenia in patients with metastatic germ cell tumors receiving cisplatin-based combination chemotherapy. International journal of urology : official journal of the Japanese Urological Association, 2017, Volume: 24, Issue:6 Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Baltimore; Benzamides; Cisplatin; Febrile Neutropenia; Humans; Ifosfamide; Male; Neoplasms, Germ Cell and Embryonal; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Factors	2017
Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone. The Prostate, 2017, Volume: 77, Issue:9 Topics: Aged; Androstenes; Antineoplastic Agents; Disease-Free Survival; Drug Monitoring; Humans; Italy; Male; Medication Therapy Management; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Time	2017
Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naïve castration-resistant prostate cancer: The Kyoto-Baltimore collaboration. International journal of urology : official journal of the Japanese Urological Association, 2017, Volume: 24, Issue:6 Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Baltimore; Benzamides; Disease Progression; Drug Administration Schedule; Humans; International Cooperation; Japan; Kallikreins; Male; Neoplasm Grading; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Analysis; Time Factors	2017
Editorial Comment to Identification of risk factors predicting febrile neutropenia in patients with metastatic germ cell tumors receiving cisplatin-based combination chemotherapy. International journal of urology : official journal of the Japanese Urological Association, 2017, Volume: 24, Issue:6 Topics: Androstenes; Baltimore; Benzamides; Cisplatin; Drug Therapy, Combination; Febrile Neutropenia; Humans; Male; Neoplasms, Germ Cell and Embryonal; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Risk Factors	2017
Editorial Comment to Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naïve castration-resistant prostate cancer: The Kyoto-Baltimore collaboration. International journal of urology : official journal of the Japanese Urological Association, 2017, Volume: 24, Issue:6 Topics: Androstenes; Baltimore; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant	2017
Lactate dehydrogenase predicts combined progression-free survival after sequential therapy with abiraterone and enzalutamide for patients with castration-resistant prostate cancer. The Prostate, 2017, Volume: 77, Issue:10 Topics: Aged; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Disease-Free Survival; Drug Monitoring; Drug Resistance, Neoplasm; Humans; Japan; L-Lactate Dehydrogenase; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Predictive Value of Tests; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies	2017
Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D. Journal of oncology practice, 2017, Volume: 13, Issue:8 Topics: Aged; Androstenes; Antineoplastic Agents; Benzamides; Catchment Area, Health; Drug Prescriptions; Humans; Insurance Coverage; Male; Medical Oncology; Medicare Part D; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Practice Patterns, Physicians'; Prostatic Neoplasms, Castration-Resistant; United States; Urology	2017
Combining Abiraterone and Radiotherapy in Prostate Cancer Patients Who Progressed During Abiraterone Therapy. Anticancer research, 2017, Volume: 37, Issue:7 Topics: Aged; Aged, 80 and over; Androstenes; Combined Modality Therapy; Cytochrome P-450 Enzyme Inhibitors; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Survival Analysis	2017
Re: Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men with Metastatic Castration-resistant Prostate Cancer Treated with First- and Secon European urology, 2017, Volume: 72, Issue:6 Topics: Androstenes; Benzamides; Drug Resistance, Neoplasm; Humans; Male; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; RNA, Messenger	2017
Reply to Julie Steinestel, Christof Bernemann, Andres J. Schrader, and Jochen K. Lennerz's Letter to the Editor re: Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in C European urology, 2017, Volume: 72, Issue:6 Topics: Androstenes; Benzamides; Drug Resistance, Neoplasm; Humans; Male; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; RNA, Messenger	2017
Prognostic nutritional index predicts initial response to treatment and prognosis in metastatic castration-resistant prostate cancer patients treated with abiraterone. The Prostate, 2017, Volume: 77, Issue:12 Topics: Aged; Androstenes; Antineoplastic Agents; Cohort Studies; Follow-Up Studies; Humans; Male; Nutrition Assessment; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome	2017
Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey. European urology focus, 2018, Volume: 4, Issue:2 Topics: Androstenes; Biomarkers, Tumor; Clinical Decision-Making; Disease Progression; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplastic Cells, Circulating; Practice Patterns, Physicians'; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Surveys and Questionnaires; Taxoids; Treatment Outcome; Tubulin Modulators	2018
Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting. Medical oncology (Northwood, London, England), 2017, Aug-10, Volume: 34, Issue:9 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Longitudinal Studies; Male; Middle Aged; Molecular Targeted Therapy; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Taxoids; Treatment Outcome	2017
Commentary on: Abiraterone Plus Prednisolone in Metastatic, Castration-sensitive Prostate Cancer. Urology, 2017, Volume: 109 Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Castration; Disease-Free Survival; Humans; Male; Neoplasm Metastasis; Prednisolone; Prednisone; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids	2017
AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide. European urology, 2017, Volume: 72, Issue:5 Topics: Aged; Androstenes; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Kallikreins; Liquid Biopsy; Logistic Models; Male; Multivariate Analysis; Neoplastic Cells, Circulating; Nitriles; Odds Ratio; Phenylthiohydantoin; Polymerase Chain Reaction; Predictive Value of Tests; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; Reproducibility of Results; Retrospective Studies; Risk Factors; RNA, Messenger; Time Factors; Treatment Outcome	2017
Treatment with abiraterone in metastatic castration-resistant prostate cancer patients progressing after docetaxel: a retrospective study. Anti-cancer drugs, 2017, Volume: 28, Issue:9 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Kallikreins; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids	2017
Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer. Clinical genitourinary cancer, 2018, Volume: 16, Issue:2 Topics: Aged; Aged, 80 and over; Androstenes; Benzamides; Disease-Free Survival; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome	2018
AR-V7 predicting treatment response in metastasized prostate cancer: has it peaked? World journal of urology, 2018, Volume: 36, Issue:1 Topics: Androgen Receptor Antagonists; Androstadienes; Androstenes; Antineoplastic Agents; Benzamides; Benzimidazoles; Clinical Trials, Phase III as Topic; Humans; Male; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Receptors, Androgen; RNA Splice Sites; RNA, Messenger; Treatment Outcome	2018
Abiraterone or Docetaxel Plus Androgen Deprivation in Hormone-Sensitive Prostate Cancer: More Questions Than Answers. European urology, 2018, Volume: 73, Issue:6 Topics: Abiraterone Acetate; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids	2018
Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer. Scientific reports, 2017, Nov-14, Volume: 7, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Chlorine; Choline; Docetaxel; Gene Dosage; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Signal Transduction	2017
Prostate cancers that 'Wnt' respond to abiraterone. Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 02-01, Volume: 29, Issue:2 Topics: Abiraterone Acetate; Androstenes; Cell Cycle; Cell Proliferation; Genome-Wide Association Study; Humans; Male; Prednisone; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Wnt Signaling Pathway	2018
Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients. The Prostate, 2018, Volume: 78, Issue:4 Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Docetaxel; Humans; Male; Middle Aged; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Severity of Illness Index; Survival Analysis; Systemic Inflammatory Response Syndrome; Treatment Outcome	2018
p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer. Prostate cancer and prostatic diseases, 2018, Volume: 21, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Androstenes; Benzamides; Biomarkers, Tumor; Follow-Up Studies; Humans; Male; Middle Aged; Mutation; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; PTEN Phosphohydrolase; Retrospective Studies; Survival Rate; Tumor Suppressor Protein p53	2018
Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer. Nucleic acids research, 2018, 02-28, Volume: 46, Issue:4 Topics: Androstenes; Animals; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Chromatin; Disease Progression; Drug Resistance, Neoplasm; Epigenesis, Genetic; Genomics; Humans; Male; Mice, SCID; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; rap GTP-Binding Proteins; Receptors, Androgen; RNA Splicing	2018
Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration-resistant prostate cancer: A retrospective study. The Prostate, 2018, Volume: 78, Issue:4 Topics: Androstenes; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies	2018
Prognostic and Therapeutic Implications of Circulating Androgen Receptor Gene Copy Number in Prostate Cancer Patients Using Droplet Digital Polymerase Chain Reaction. Clinical genitourinary cancer, 2018, Volume: 16, Issue:3 Topics: Aged; Androstenes; Benzamides; Bridged-Ring Compounds; Disease Progression; Disease-Free Survival; DNA, Neoplasm; Gene Dosage; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Polymerase Chain Reaction; Prognosis; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Taxoids	2018
Nationwide population-based study on the use of novel antiandrogens in men with prostate cancer in Sweden. Scandinavian journal of urology, 2018, Volume: 52, Issue:2 Topics: Age Factors; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Cross-Sectional Studies; Drug Prescriptions; Educational Status; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Registries; Residence Characteristics; Sweden; Time Factors	2018
Taxane chemotherapy vs antiandrogen agents as first-line therapy for metastatic castration-resistant prostate cancer. BJU international, 2018, Volume: 121, Issue:6 Topics: Adult; Aged; Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Docetaxel; Drug Resistance, Neoplasm; Drug Substitution; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Propensity Score; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2018
Association among metabolic syndrome, inflammation, and survival in prostate cancer. Urologic oncology, 2018, Volume: 36, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Androstenes; Benzamides; Follow-Up Studies; Humans; Inflammation; Male; Metabolic Syndrome; Middle Aged; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Factors; Survival Rate	2018
Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer. The Prostate, 2018, Volume: 78, Issue:6 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Humans; Male; Middle Aged; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2018
Re: Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. European urology, 2018, Volume: 73, Issue:6 Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant	2018
Nuclear Receptor LRH-1 Functions to Promote Castration-Resistant Growth of Prostate Cancer via Its Promotion of Intratumoral Androgen Biosynthesis. Cancer research, 2018, 05-01, Volume: 78, Issue:9 Topics: Androgens; Androstenes; Animals; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Neoplasm Grading; Prostate; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Receptors, Cytoplasmic and Nuclear; Steroid 17-alpha-Hydroxylase; Xenograft Model Antitumor Assays	2018
Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. European urology, 2018, Volume: 74, Issue:2 Topics: Aged; Androgen Antagonists; Androstenes; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Benzamides; Biomarkers, Tumor; BRCA1 Protein; BRCA2 Protein; Clinical Decision-Making; DNA Mutational Analysis; DNA Repair Enzymes; Genetic Predisposition to Disease; Germ-Line Mutation; GPI-Linked Proteins; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Proteins; Nitriles; Phenotype; Phenylthiohydantoin; Precision Medicine; Progression-Free Survival; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Time Factors; Treatment Outcome	2018
Prostate cancer: AR-Vs not predictive in mCRPC. Nature reviews. Urology, 2018, Volume: 15, Issue:4 Topics: Androstenes; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant	2018
Abiraterone is effective and should be considered for the treatment of metastatic castrate-naïve prostate cancer. Expert opinion on pharmacotherapy, 2018, Volume: 19, Issue:5 Topics: Abiraterone Acetate; Androstenes; Anti-Inflammatory Agents; Docetaxel; Drug Therapy, Combination; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids	2018
Quantitation of the anticancer drug abiraterone and its metabolite Δ(4)-abiraterone in human plasma using high-resolution mass spectrometry. Journal of pharmaceutical and biomedical analysis, 2018, May-30, Volume: 154 Topics: Androgen Receptor Antagonists; Androstenes; Antineoplastic Agents; Biological Variation, Population; Chromatography, High Pressure Liquid; Humans; Male; Prodrugs; Prostatic Neoplasms, Castration-Resistant; Sensitivity and Specificity; Steroid 17-alpha-Hydroxylase; Tandem Mass Spectrometry	2018
Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide. International journal of cancer, 2018, 09-01, Volume: 143, Issue:5 Topics: Androgen Receptor Antagonists; Androstenes; Benzamides; Biomarkers, Tumor; Bone Neoplasms; DNA Copy Number Variations; DNA, Neoplasm; Drug Resistance, Neoplasm; Follow-Up Studies; Genomics; Humans; Longitudinal Studies; Male; Nitriles; Phenylthiohydantoin; Prognosis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen	2018
Low-Fat Abiraterone Food Effect Is of Little Consequence. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 05-10, Volume: 36, Issue:14 Topics: Abiraterone Acetate; Androstenes; Humans; Male; Prospective Studies; Prostatic Neoplasms, Castration-Resistant	2018
Plasma DNA and Metastatic Castration-Resistant Prostate Cancer: The Odyssey to a Clinical Biomarker Test. Cancer discovery, 2018, Volume: 8, Issue:4 Topics: Androstenes; Benzamides; Circulating Tumor DNA; DNA; Genomics; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant	2018
Indirect treatment comparison of cabazitaxel for patients with metastatic castrate-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen. PloS one, 2018, Volume: 13, Issue:4 Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Docetaxel; Humans; Male; Meta-Analysis as Topic; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Salvage Therapy; Survival Rate; Taxoids	2018
Response to flutamide, as second-line therapy after bicalutamide, predicts efficacy of abiraterone, not that of enzalutamide. BMC research notes, 2018, May-29, Volume: 11, Issue:1 Topics: Aged; Aged, 80 and over; Androstenes; Anilides; Antineoplastic Agents; Benzamides; Disease-Free Survival; Flutamide; Humans; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Tosyl Compounds	2018
Abiraterone plus olaparib in prostate cancer: a new form of synthetic lethality? The Lancet. Oncology, 2018, Volume: 19, Issue:7 Topics: Androstenes; Double-Blind Method; Humans; Male; Phthalazines; Piperazines; Prostatic Neoplasms, Castration-Resistant; Synthetic Lethal Mutations	2018
Real world evidence: Abiraterone use post-docetaxel in metastatic castrate-resistant prostate cancer. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2019, Volume: 25, Issue:6 Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate	2019
Abiraterone-Olaparib Combo Aids Men with mCRPC. Cancer discovery, 2018, Volume: 8, Issue:8 Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Humans; Male; Phthalazines; Piperazines; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2018
Radium-223 (Xofigo) with concurrent abiraterone or enzalutamide: predictive biomarkers of improved overall survival in a clinically advanced cohort. Current problems in cancer, 2019, Volume: 43, Issue:3 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Chemoradiotherapy; Follow-Up Studies; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Survival Rate	2019
Therapeutic Discovery for Castration Resistant Prostate Cancer: Patient-derived Xenograft Modelling Brings New Options to the Table. European urology, 2018, Volume: 74, Issue:5 Topics: Androstenes; Benzamides; Heterografts; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Ribosomes	2018
Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. European urology, 2018, Volume: 74, Issue:5 Topics: Androstenes; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azepines; Benzamides; Benzothiazoles; Drug Resistance, Neoplasm; Humans; Indoles; Male; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Naphthyridines; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-pim-1; Ribosomes; RNA Polymerase I; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays	2018
Improving outcome in patients with prostate and kidney cancer: heading in the right direction? Current opinion in supportive and palliative care, 2018, Volume: 12, Issue:3 Topics: Androstenes; Antineoplastic Agents; Clinical Decision-Making; Humans; Immunotherapy; Kidney Neoplasms; Male; Neoplasm Metastasis; Patient Participation; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Protein-Tyrosine Kinases	2018
Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer. BJU international, 2019, Volume: 123, Issue:2 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Asymptomatic Diseases; Dexamethasone; Disease Progression; Drug Substitution; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prognosis; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies	2019
Docetaxel-rechallenge in castration-resistant prostate cancer: defining clinical factors for successful treatment response and improvement in overall survival. International urology and nephrology, 2018, Volume: 50, Issue:10 Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease-Free Survival; Docetaxel; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Lymphatic Metastasis; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Orchiectomy; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Retreatment; Retrospective Studies; Survival Rate; Taxoids	2018
Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer. Cancer research, 2018, 10-15, Volume: 78, Issue:20 Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androstenes; Animals; Benzamides; Cell Line, Tumor; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; Humans; Male; Mice; Mice, SCID; Neoplasm Recurrence, Local; Neoplasm Transplantation; Nitriles; Oligonucleotides, Antisense; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Signal Transduction	2018
Cancer therapeutics-related cardiac dysfunction in a patient treated with abiraterone for castration-resistant prostate cancer. Journal of medical ultrasonics (2001), 2019, Volume: 46, Issue:2 Topics: Aged, 80 and over; Androstenes; Antineoplastic Agents; Disease Progression; Drug Substitution; Heart Failure; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2019
Low-Fat Abiraterone Food Effect Is of Great Consequence. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 10-20, Volume: 36, Issue:30 Topics: Abiraterone Acetate; Androstenes; Humans; Male; Prospective Studies; Prostatic Neoplasms, Castration-Resistant	2018
Reply to I.F. Tannock, P. Isaacsson Velho et al, M. Tiako Meyo et al, and F.J.S.H. Woei-A-Jin et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 10-20, Volume: 36, Issue:30 Topics: Androstenes; Humans; Male; Prospective Studies; Prostatic Neoplasms, Castration-Resistant	2018
Low-Dose Abiraterone With Food: Rebutting an Editorial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 10-20, Volume: 36, Issue:30 Topics: Abiraterone Acetate; Androstenes; Humans; Male; Prospective Studies; Prostatic Neoplasms, Castration-Resistant	2018
There Is Now Compelling Evidence to Further Evaluate Lower Doses of Abiraterone Acetate in Men With Metastatic Prostate Cancer: It Should Be Safer, May Be as Effective and Less Expensive. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 10-20, Volume: 36, Issue:30 Topics: Abiraterone Acetate; Androstenes; Humans; Male; Prospective Studies; Prostatic Neoplasms, Castration-Resistant	2018
Low-Dose Abiraterone Regimen: Drug Monitoring Might Be the Key. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 10-20, Volume: 36, Issue:30 Topics: Abiraterone Acetate; Androstenes; Drug Monitoring; Humans; Male; Prospective Studies; Prostatic Neoplasms, Castration-Resistant	2018
Dose Reduction May Jeopardize Efficacy of Abiraterone Acetate. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 10-20, Volume: 36, Issue:30 Topics: Abiraterone Acetate; Androstenes; Humans; Male; Prospective Studies; Prostatic Neoplasms, Castration-Resistant	2018
Reply to I.F. Tannock, P. Isaacsson Velho et al, R.Z. Szmulewitz et al, M. Tiako Meyo et al, and F.J.S.H. Woei-A-Jin et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 10-20, Volume: 36, Issue:30 Topics: Androstenes; Humans; Male; Prospective Studies; Prostatic Neoplasms, Castration-Resistant	2018
Is combining PARP and androgen receptor inhibition really a winning strategy in metastatic castration-resistant prostate cancer? The Lancet. Oncology, 2018, Volume: 19, Issue:9 Topics: Androstenes; Double-Blind Method; Humans; Male; Phthalazines; Piperazines; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen	2018
Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncolo Urologic oncology, 2018, Volume: 36, Issue:11 Topics: Aged; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome	2018
Precision Medicine Approaches When Prostate Cancer Akts Up. Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 02-01, Volume: 25, Issue:3 Topics: Androstenes; Humans; Male; Precision Medicine; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Receptors, Androgen	2019
Phosphorylation of androgen receptor serine 81 is associated with its reactivation in castration-resistant prostate cancer. Cancer letters, 2018, 12-01, Volume: 438 Topics: Androstenes; Animals; Benzamides; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Mice, Inbred ICR; Mice, SCID; Nitriles; Phenylthiohydantoin; Phosphorylation; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Serine; Xenograft Model Antitumor Assays	2018
Evaluation of Response to Enzalutamide Consecutively After Abiraterone Acetate/Prednisone Failure in Patients With Metastatic Castration-resistant Prostate Cancer. Clinical genitourinary cancer, 2018, Volume: 16, Issue:6 Topics: Abiraterone Acetate; Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisone; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Time Factors; Treatment Failure; Treatment Outcome	2018
Downregulation of Cancer research, 2018, 11-15, Volume: 78, Issue:22 Topics: Alternative Splicing; Androgen Antagonists; Androstenes; Animals; Benzamides; Cell Line, Tumor; Dipeptidyl Peptidase 4; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gene Expression Profiling; Humans; Male; Mice; Mice, SCID; Neoplasm Recurrence, Local; Neoplasm Transplantation; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; RNA, Small Interfering; Signal Transduction; Sitagliptin Phosphate	2018
Optimal control to develop therapeutic strategies for metastatic castrate resistant prostate cancer. Journal of theoretical biology, 2018, 12-14, Volume: 459 Topics: Androstenes; Disease Management; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance; Game Theory; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Quality of Life	2018
Expression of Androgen Receptor Variant 7 (AR-V7) in Circulated Tumor Cells and Correlation with Drug Resistance of Prostate Cancer Cells. Medical science monitor : international medical journal of experimental and clinical research, 2018, Oct-04, Volume: 24 Topics: Adult; Aged; Androstenes; Benzamides; Case-Control Studies; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Prognosis; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; RNA, Messenger	2018
Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC). British journal of cancer, 2018, Volume: 119, Issue:9 Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Glucocorticoids; Humans; Male; Pilot Projects; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant	2018
Re: Germline DNA-Repair Gene Mutations and Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer Receiving First-Line Abiraterone and Enzalutamide. The Journal of urology, 2018, Volume: 200, Issue:5 Topics: Androstenes; Benzamides; DNA; Germ Cells; Humans; Male; Mutation; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant	2018
Serum testosterone level as possible predictive marker in androgen receptor axis-targeting agents and taxane chemotherapies for castration-resistant prostate cancer. Urologic oncology, 2019, Volume: 37, Issue:3 Topics: Aged; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Neoplasm Grading; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Testosterone	2019
Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer. Nature communications, 2018, 11-16, Volume: 9, Issue:1 Topics: Androstenes; Angiogenesis Inhibitors; Animals; Benzamides; Cell Line, Tumor; HSP70 Heat-Shock Proteins; Humans; Male; Mice; Molecular Docking Simulation; Neoplasm Grading; Nitriles; Phenylthiohydantoin; Prostate; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Proteasome Endopeptidase Complex; Proteostasis; Receptors, Androgen; Ubiquitin; Ubiquitin-Protein Ligases; Ubiquitination	2018
Impact of timing of administration of bone supportive therapy on pain palliation from radium-223. Cancer treatment and research communications, 2019, Volume: 18 Topics: Androstenes; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Cancer Pain; Chemoradiotherapy; Follow-Up Studies; Humans; Male; Nitriles; Pain Management; Palliative Care; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Radium; Retrospective Studies; Time Factors	2019
Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 03-15, Volume: 25, Issue:6 Topics: Androstenes; Benzamides; Biomarkers, Tumor; Humans; Male; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Tumor Suppressor Protein p53	2019
Hard Problems Need "Soft" Science: Integrating Quality of Life into Treatment Decision Making. European urology, 2019, Volume: 75, Issue:6 Topics: Androstenes; Benzamides; Decision Making; Humans; Male; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality of Life	2019
Re: Olaparib Combined with Abiraterone in Patients with Metastatic Castration-Resistant Prostate Cancer: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial. The Journal of urology, 2019, Volume: 201, Issue:4 Topics: Androstenes; Double-Blind Method; Humans; Male; Phthalazines; Piperazines; Prostatic Neoplasms, Castration-Resistant	2019
Higher Risk of Fragility Fractures in Prostate Cancer Patients Treated with Combined Radium-223 and Abiraterone: Prednisone May Be the Culprit. European urology, 2019, Volume: 75, Issue:6 Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Fractures, Bone; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium; Treatment Outcome	2019
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer. European urology, 2019, Volume: 75, Issue:3 Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Humans; Kallikreins; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Spain; Time Factors	2019
Inhibition of Autophagy Improves the Efficacy of Abiraterone for the Treatment of Prostate Cancer. Cancer biotherapy & radiopharmaceuticals, 2019, Volume: 34, Issue:3 Topics: Adenine; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Male; Prostatic Neoplasms, Castration-Resistant	2019
Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer. Scientific reports, 2019, 03-11, Volume: 9, Issue:1 Topics: Aged; Aged, 80 and over; Androstenes; Animals; Antineoplastic Agents, Hormonal; Benzamides; Biomarkers, Tumor; Cell Line, Tumor; Cell-Free Nucleic Acids; Drug Resistance, Neoplasm; Gene Dosage; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Mutation; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Treatment Outcome	2019
Evaluation of the possible interference of abiraterone therapy on testosterone immunoassay. Clinical chemistry and laboratory medicine, 2019, Sep-25, Volume: 57, Issue:10 Topics: Abiraterone Acetate; Androstenes; Artifacts; Clinical Laboratory Techniques; Humans; Immunoassay; Male; Prostatic Neoplasms, Castration-Resistant; Testosterone	2019
Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy. Prostate cancer and prostatic diseases, 2019, Volume: 22, Issue:4 Topics: Adult; Aged; Androgen Antagonists; Androstenes; Dehydroepiandrosterone Sulfate; Disease Progression; Docetaxel; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Grading; Organic Anion Transporters; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Solute Carrier Organic Anion Transporter Family Member 1B3; Testosterone; Treatment Outcome	2019
Multidrug Cancer Therapy in Metastatic Castrate-Resistant Prostate Cancer: An Evolution-Based Strategy. Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 07-15, Volume: 25, Issue:14 Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Male; Models, Theoretical; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Simulation Training; Survival Rate; Treatment Outcome	2019
Impact of the introduction of novel hormonal agents on metastatic castration-resistant prostate cancer treatment choice. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2020, Volume: 26, Issue:2 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Clinical Decision-Making; Cohort Studies; Docetaxel; Humans; Male; Nitriles; Patient Selection; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome	2020
Pseudoprogression on PSMA PET imaging of a mCRPC patient under anti-PD1 treatment. European journal of nuclear medicine and molecular imaging, 2019, Volume: 46, Issue:7 Topics: Aged, 80 and over; Androstenes; Anilides; Antibodies, Monoclonal, Humanized; Antigens, Surface; Brachytherapy; Disease Progression; Gallium Radioisotopes; Gene Expression Regulation, Neoplastic; Glutamate Carboxypeptidase II; Goserelin; Humans; Ligands; Male; Nitriles; Positron-Emission Tomography; Programmed Cell Death 1 Receptor; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Salvage Therapy; Tosyl Compounds	2019
Early use of abiraterone and radium-223 in metastatic prostate cancer. The Lancet. Oncology, 2019, Volume: 20, Issue:5 Topics: Abiraterone Acetate; Androstenes; Double-Blind Method; Humans; Male; Prednisolone; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium	2019
Early use of abiraterone and radium-223 in metastatic prostate cancer. The Lancet. Oncology, 2019, Volume: 20, Issue:5 Topics: Abiraterone Acetate; Androstenes; Double-Blind Method; Humans; Male; Prednisolone; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium	2019
Genomic correlates of clinical outcome in advanced prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 06-04, Volume: 116, Issue:23 Topics: Aged; Androstenes; Benzamides; Biomarkers, Tumor; Drug Resistance, Neoplasm; Genomics; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Treatment Outcome	2019
Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer. Cancer chemotherapy and pharmacology, 2019, Volume: 84, Issue:1 Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Fasting; Humans; Longitudinal Studies; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prospective Studies; Prostatic Neoplasms, Castration-Resistant	2019
Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression. Anticancer research, 2019, Volume: 39, Issue:5 Topics: Aged; Androstenes; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Terminal Care; Treatment Outcome	2019
Serum testosterone level is a useful biomarker for determining the optimal treatment for castration-resistant prostate cancer. Urologic oncology, 2019, Volume: 37, Issue:7 Topics: Aged; Androgen Antagonists; Androstenes; Benzamides; Biomarkers, Tumor; Clinical Decision-Making; Disease Progression; Drug Resistance, Neoplasm; Feasibility Studies; Follow-Up Studies; Humans; Kallikreins; Male; Neoplasm Grading; Nitriles; Patient Selection; Phenylthiohydantoin; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Testosterone; Time Factors	2019
Adoption of Abiraterone and Enzalutamide by Urologists. Urology, 2019, Volume: 131 Topics: Androstenes; Benzamides; Drug Prescriptions; Humans; Male; Medicaid; Medicare; Nitriles; Phenylthiohydantoin; Practice Patterns, Physicians'; Prostatic Neoplasms, Castration-Resistant; United States; Urology	2019
Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer. BMC cancer, 2019, May-31, Volume: 19, Issue:1 Topics: Aged; Aged, 80 and over; Androstenes; Docetaxel; Humans; Leukocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Time Factors	2019
Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer. European urology, 2020, Volume: 77, Issue:1 Topics: Aged; Androstenes; Benzamides; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Mutation; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome; Wnt Signaling Pathway	2020
Efficacy, Tolerance, and Plasma Levels of Abiraterone and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer With a Hepatic Transplant. Clinical genitourinary cancer, 2019, Volume: 17, Issue:5 Topics: Abiraterone Acetate; Aged; Androstenes; Feasibility Studies; Humans; Liver Transplantation; Male; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2019
Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide. The Prostate, 2019, Volume: 79, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; DNA Copy Number Variations; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prognosis; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Survival Rate; Testosterone	2019
Circulating Tumor Cell-Based Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer. Neoplasia (New York, N.Y.), 2019, Volume: 21, Issue:8 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Computational Biology; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Prognosis; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2019
AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy. The Prostate, 2019, Volume: 79, Issue:13 Topics: Aged; Aldo-Keto Reductase Family 1 Member C3; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Image-Guided Biopsy; Immunohistochemistry; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies	2019
Characterizing the Wnt Pathway in Advanced Prostate Cancer: When, Why, and How. European urology, 2020, Volume: 77, Issue:1 Topics: Androstenes; Benzamides; Humans; Male; Mutation; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Wnt Signaling Pathway	2020
Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis. European urology oncology, 2020, Volume: 3, Issue:2 Topics: Androstenes; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome	2020
Management of castrate resistant prostate cancer-recent advances and optimal sequence of treatments. Current urology reports, 2013, Volume: 14, Issue:3 Topics: Androstenes; Androstenols; Anilides; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Humans; Imidazoles; Ipilimumab; Male; Naphthalenes; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyridines; Quinolines; Quinolones; Radioisotopes; Radium; Taxoids; Thionucleotides; Tissue Extracts	2013
Improved therapeutic targeting of the androgen receptor: rational drug design improves survival in castration-resistant prostate cancer. Current drug targets, 2013, Volume: 14, Issue:4 Topics: Androgen Antagonists; Androgens; Androstenes; Androstenols; Benzamides; Castration; Chromosome Aberrations; Drug Design; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; RNA, Messenger; Signal Transduction; Steroid 17-alpha-Hydroxylase	2013
Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. European urology, 2014, Volume: 65, Issue:1 Topics: Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Failure	2014
The European medicines agency review of abiraterone for the treatment of metastatic castration-resistant prostate cancer in adult men after docetaxel chemotherapy and in chemotherapy-naive disease: summary of the scientific assessment of the committee for The oncologist, 2013, Volume: 18, Issue:9 Topics: Adult; Androstenes; Androstenols; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Drug Approval; European Union; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome	2013
Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:1 Topics: Aged; Aged, 80 and over; Androstenes; Androstenols; Benzamides; Docetaxel; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome	2014
Towards random sequencing or precision medicine in castration-resistant prostate cancer? European urology, 2014, Volume: 65, Issue:1 Topics: Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids	2014
Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:18 Topics: Active Transport, Cell Nucleus; Androstenes; Androstenols; Benzamides; Blotting, Western; Cell Line, Tumor; Cell Nucleus; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Green Fluorescent Proteins; Humans; Male; Microscopy, Confocal; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Time-Lapse Imaging	2013
New therapeutic options in metastatic castration-resistant prostate cancer: Can cost-effectiveness analysis help in treatment decisions? Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2014, Volume: 20, Issue:6 Topics: Androstenes; Antineoplastic Agents; Benzamides; Cost-Benefit Analysis; Decision Trees; Drug Costs; Financing, Personal; Humans; Male; Models, Economic; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Quality-Adjusted Life Years; Survival Rate; Taxoids	2014
Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. Cancer, 2014, Apr-01, Volume: 120, Issue:7 Topics: Aged; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids; Treatment Outcome	2014
Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer. Anti-cancer drugs, 2014, Volume: 25, Issue:4 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Agents; Drug Therapy, Combination; Humans; Male; Mineralocorticoids; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Steroid 17-alpha-Hydroxylase	2014
Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. European urology, 2014, Volume: 66, Issue:3 Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retreatment; Retrospective Studies; Survival Rate; Taxoids; Treatment Failure	2014
Enzalutamide after docetaxel and abiraterone therapy in metastatic castration-resistant prostate cancer. Advances in therapy, 2014, Volume: 31, Issue:2 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Bone Neoplasms; Compassionate Use Trials; Disease-Free Survival; Docetaxel; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Failure	2014
The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. European urology, 2014, Volume: 66, Issue:4 Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cohort Studies; Disease Progression; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Assessment; Survival Rate; Taxoids; Treatment Outcome	2014
Abiraterone--what is wrong with the adrenal glands? Clinical genitourinary cancer, 2014, Volume: 12, Issue:4 Topics: Adrenal Gland Neoplasms; Androgen Antagonists; Androstenes; Humans; Male; Middle Aged; Prognosis; Prostatic Neoplasms, Castration-Resistant	2014
One size does not fit all: can we choose the best sequence of treatment in asymptomatic castration-resistant prostate cancer patients? European urology, 2014, Volume: 66, Issue:4 Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Humans; Lung Neoplasms; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids	2014
Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone. Endocrine-related cancer, 2014, Volume: 21, Issue:3 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androstenes; Androstenols; Biomarkers, Tumor; Bone Neoplasms; Chromogranin A; Enzyme-Linked Immunosorbent Assay; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate	2014
Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies. European urology, 2015, Volume: 68, Issue:2 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; France; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Signal Transduction; Taxoids; Time Factors; Treatment Outcome	2015
The use of the EVITA algorithm for clinical assessment of novel agents used in prostate cancer, metastatic melanoma, and systemic lupus erythematosus. European journal of clinical pharmacology, 2014, Volume: 70, Issue:8 Topics: Algorithms; Androstenes; Androstenols; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cancer Vaccines; Humans; Immunosuppressive Agents; Ipilimumab; Lupus Erythematosus, Systemic; Male; Melanoma; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Randomized Controlled Trials as Topic; Skin Neoplasms; Tissue Extracts	2014
Metastatic Castration-resistant Prostate Cancer: Piling Up the Benefits of Chemotherapy. European urology, 2015, Volume: 68, Issue:2 Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids	2015
PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer. Clinical genitourinary cancer, 2015, Volume: 13, Issue:1 Topics: Aged; Aged, 80 and over; Androstenes; Disease-Free Survival; Humans; Italy; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Analysis; Treatment Outcome	2015
Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole. European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:14 Topics: Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Ketoconazole; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome	2014
Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone. The Prostate, 2014, Volume: 74, Issue:13 Topics: Adenocarcinoma; Aged; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Bone Neoplasms; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome	2014
Prostate cancer: the best fit for enzalutamide in metastatic prostate cancer. Nature reviews. Clinical oncology, 2014, Volume: 11, Issue:9 Topics: Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Patient Selection; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids	2014
Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis. European urology, 2015, Volume: 68, Issue:2 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Compassionate Use Trials; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Drug Substitution; Europe; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Risk Factors; Taxoids; Time Factors; Treatment Outcome	2015
Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort. World journal of urology, 2015, Volume: 33, Issue:6 Topics: Aged; Androgen Antagonists; Androstenes; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Cohort Studies; Disease-Free Survival; Docetaxel; Flutamide; Humans; Leuprolide; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nitriles; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Tosyl Compounds; Treatment Outcome; Triptorelin Pamoate	2015
[Abiraterone acetate(ZYTIGA®)-development and literature review]. Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:7 Topics: Abiraterone Acetate; Androstadienes; Androstenes; Androstenols; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Steroid 17-alpha-Hydroxylase	2014
Limited in vitro efficacy of CYP17A1 inhibition on human castration resistant prostate cancer. Steroids, 2014, Volume: 92 Topics: Androstenes; Cell Line, Tumor; Enzyme Activation; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Real-Time Polymerase Chain Reaction; Steroid 17-alpha-Hydroxylase; Tandem Mass Spectrometry	2014
A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer. The Prostate, 2014, Volume: 74, Issue:15 Topics: Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Agents; Canada; Cytochrome P-450 Enzyme Inhibitors; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome	2014
Secondary hormone therapy for castration-resistant prostate cancer. Oncology (Williston Park, N.Y.), 2013, Volume: 27, Issue:5 Topics: Androgen Antagonists; Androstenes; Benzamides; Drug Resistance, Neoplasm; Humans; Male; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant	2013
Real-world experience with abiraterone. The Lancet. Oncology, 2014, Volume: 15, Issue:11 Topics: Androstenes; Androstenols; Humans; Male; Neoplasm Recurrence, Local; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant	2014
Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer. Journal of geriatric oncology, 2015, Volume: 6, Issue:1 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome	2015
New targets for resistant prostate cancer. Oncotarget, 2014, Oct-15, Volume: 5, Issue:19 Topics: Androgen Receptor Antagonists; Androstenes; Benzamides; beta Catenin; Humans; Male; Nitriles; Phenylthiohydantoin; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myb; Receptors, Androgen; Receptors, Glucocorticoid; Signal Transduction; Wnt Proteins	2014
Cost-effectiveness analysis of abiraterone and sipuleucel-T in asymptomatic metastatic castration-resistant prostate cancer. Journal of the National Comprehensive Cancer Network : JNCCN, 2014, Volume: 12, Issue:10 Topics: Androstenes; Asymptomatic Diseases; Bone Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Tissue Extracts	2014
Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. British journal of cancer, 2014, Dec-09, Volume: 111, Issue:12 Topics: Aged; Aged, 80 and over; Androstenes; Anti-Inflammatory Agents; Dexamethasone; Humans; Male; Middle Aged; Prednisone; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome	2014
Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Mar-15, Volume: 21, Issue:6 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; DNA Helicases; DNA-Binding Proteins; Drug Resistance, Neoplasm; Dutasteride; Humans; Ketoconazole; Leuprolide; Male; Middle Aged; Mutation; Progesterone; Prostatic Neoplasms, Castration-Resistant; PTEN Phosphohydrolase; Receptors, Androgen; Steroid 17-alpha-Hydroxylase	2015
Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway. Oncotarget, 2014, Oct-15, Volume: 5, Issue:19 Topics: Androgen Antagonists; Androstenes; Animals; Apoptosis; Benzamides; Cell Line, Tumor; Disease Progression; Humans; Immunomodulation; Immunotherapy; Male; Mice; Neuronal Apoptosis-Inhibitory Protein; Nitriles; Phenylthiohydantoin; Prostate; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; RNA Interference; RNA, Small Interfering; T-Lymphocytes	2014
Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer. Molecular cancer therapeutics, 2015, Volume: 14, Issue:1 Topics: Androstenes; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Naphthalenes; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Signal Transduction; Steroid 17-alpha-Hydroxylase; Triazoles; Xenograft Model Antitumor Assays	2015
Predicting treatment response in castration-resistant prostate cancer: could androgen receptor variant-7 hold the key? Expert review of anticancer therapy, 2015, Volume: 15, Issue:2 Topics: Alternative Splicing; Androstenes; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Treatment Outcome	2015
Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. Prostate cancer and prostatic diseases, 2015, Volume: 18, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome	2015
Abiraterone's efficacy confirmed; time to aim higher. The Lancet. Oncology, 2015, Volume: 16, Issue:2 Topics: Androstenes; Antineoplastic Agents, Hormonal; Bone Neoplasms; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant	2015
Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer. Clinical genitourinary cancer, 2015, Volume: 13, Issue:4 Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiography; Retrospective Studies; Taxoids; Treatment Outcome	2015
Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, May-15, Volume: 21, Issue:10 Topics: Aged; Aged, 80 and over; Androstenes; Biomarkers, Tumor; Disease-Free Survival; DNA Copy Number Variations; DNA Mutational Analysis; DNA, Neoplasm; Docetaxel; Drug Resistance, Neoplasm; High-Throughput Nucleotide Sequencing; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation, Missense; Neoplasm Metastasis; Neoplastic Cells, Circulating; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids	2015
Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents. British journal of cancer, 2015, Mar-31, Volume: 112, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Androstenes; Benzamides; Cell Line, Tumor; Disease Progression; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen	2015
A HPLC-fluorescence method for the quantification of abiraterone in plasma from patients with metastatic castration-resistant prostate cancer. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2015, May-01, Volume: 989 Topics: Androstenes; Chromatography, High Pressure Liquid; Humans; Male; Prostatic Neoplasms, Castration-Resistant	2015
[Some questions about abiraterone, breakfast and public funding]. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, 2015, Mar-01, Volume: 39, Issue:2 Topics: Androgen Receptor Antagonists; Androstenes; Breakfast; Drug Costs; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant	2015
Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone. British journal of cancer, 2015, May-12, Volume: 112, Issue:10 Topics: Aged; Aged, 80 and over; Androstenes; Case-Control Studies; Disease-Free Survival; DNA; DNA Copy Number Variations; Humans; Kallikreins; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Steroid 17-alpha-Hydroxylase	2015
Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment. Oncotarget, 2015, May-20, Volume: 6, Issue:14 Topics: Alkaline Phosphatase; Androstenes; Antineoplastic Agents; Blotting, Western; Bone and Bones; Bone Remodeling; Cell Differentiation; Collagen Type I; Enzyme-Linked Immunosorbent Assay; Humans; Male; Osteoblasts; Osteoclasts; Peptides; Prostatic Neoplasms, Castration-Resistant; Real-Time Polymerase Chain Reaction; Transcriptome	2015
[Abiraterone: Overall survival benefit and subsidiary issues]. Bulletin du cancer, 2015, Volume: 102, Issue:6 Topics: Androstenes; Antineoplastic Agents, Hormonal; Humans; Male; Prostatic Neoplasms, Castration-Resistant	2015
Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone. The Prostate, 2015, Volume: 75, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Androstenes; Disease Progression; Disease-Free Survival; Enzyme Inhibitors; Humans; Male; Metabolic Syndrome; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Factors; Steroid 17-alpha-Hydroxylase; Survival Rate; Treatment Outcome	2015
Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. Nature, 2015, Jul-16, Volume: 523, Issue:7560 Topics: 3-Hydroxysteroid Dehydrogenases; 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Androgen Receptor Antagonists; Androgens; Androstenes; Animals; Benzamides; Biosynthetic Pathways; Biotransformation; Cell Division; Chromatin; Dihydrotestosterone; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Survival Analysis; Xenograft Model Antitumor Assays	2015
Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate: a single-institution experience. Anti-cancer drugs, 2015, Volume: 26, Issue:8 Topics: Aged; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Endpoint Determination; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Failure	2015
Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:9 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Docetaxel; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Treatment Outcome	2015
[Non-interventional study of metastatic castration-resistant prostate cancer. Prospective, non-interventional trial on the influence of adherence to abiraterone treatment in patients with metastatic, castrate-resistant prostate cancer (IMPACT) - trial AP Der Urologe. Ausg. A, 2015, Volume: 54, Issue:7 Topics: Administration, Oral; Androstenes; Antineoplastic Agents; Carcinoma; Germany; Humans; Male; Medication Adherence; Prevalence; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Risk Factors; Treatment Outcome	2015
[A case of metastatic castration-resistant prostate cancer by abiraterone treatment]. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2015, Volume: 40, Issue:6 Topics: Androstenes; Bone Neoplasms; Disease Progression; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant	2015
Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA oncology, 2015, Volume: 1, Issue:5 Topics: Academic Medical Centers; Adenocarcinoma; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Baltimore; Benzamides; Biomarkers, Tumor; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Genetic Predisposition to Disease; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Middle Aged; Neoplastic Cells, Circulating; Nitriles; Patient Selection; Phenotype; Phenylthiohydantoin; Predictive Value of Tests; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; Risk Factors; RNA, Messenger; Taxoids; Time Factors; Treatment Outcome	2015
Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer: final analysis of overall survival. Anti-cancer drugs, 2015, Volume: 26, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Survival Analysis	2015
Rhabdomyolysis-induced acute kidney injury in a cancer patient exposed to denosumab and abiraterone: a case report. BMC nephrology, 2015, Jul-30, Volume: 16 Topics: Acute Kidney Injury; Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Denosumab; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Prostatic Neoplasms, Castration-Resistant; Rhabdomyolysis; Rosuvastatin Calcium	2015
Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer. The Prostate, 2015, Volume: 75, Issue:15 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome	2015
Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation. The Prostate, 2016, Volume: 76, Issue:1 Topics: Aged; Androstenes; Antineoplastic Agents; Benzamides; Disease-Free Survival; Docetaxel; Drug Monitoring; Drug Resistance, Neoplasm; Drug Substitution; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Netherlands; Nitriles; Phenylthiohydantoin; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome	2016
What Predicts Minimal Response to Abiraterone in Metastatic Castrate-resistant Prostate Cancer? Anticancer research, 2015, Volume: 35, Issue:10 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate	2015
Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients. Future oncology (London, England), 2015, Volume: 11, Issue:21 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Viscera	2015
Impact of a pharmacist-led oral chemotherapy-monitoring program in patients with metastatic castrate-resistant prostate cancer. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2016, Volume: 22, Issue:6 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Cohort Studies; Drug Monitoring; Humans; Male; Middle Aged; Nitriles; Pharmacists; Phenylthiohydantoin; Professional Role; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome	2016
Plasma AR and abiraterone-resistant prostate cancer. Science translational medicine, 2015, Nov-04, Volume: 7, Issue:312 Topics: Adult; Aged; Aged, 80 and over; Androstenes; DNA Copy Number Variations; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Point Mutation; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Young Adult	2015
Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer. Current treatment options in oncology, 2015, Volume: 16, Issue:12 Topics: Androstenes; Androstenols; Benzamides; Bridged-Ring Compounds; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; Taxoids	2015
Abiraterone-induced rhabdomyolysis: A case report. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2017, Volume: 23, Issue:2 Topics: Analgesics, Opioid; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Constipation; Creatine Kinase; Cytochrome P450 Family 17; Drug Therapy, Combination; Humans; Injections, Spinal; Male; Middle Aged; Morphine; Nausea; Pain Management; Prednisone; Prostatic Neoplasms, Castration-Resistant; Rhabdomyolysis; Vomiting	2017
Metastasis: Resistance fighters. Nature, 2015, Dec-17, Volume: 528, Issue:7582 Topics: Alternative Splicing; Androgen Antagonists; Androstenes; Benzamides; DNA Repair; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Thionucleotides	2015
Singapore Cancer Network (SCAN) Guidelines for the Management of Advanced Castrate-Resistant Prostate Cancer. Annals of the Academy of Medicine, Singapore, 2015, Volume: 44, Issue:10 Topics: Adenocarcinoma; Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Cancer Vaccines; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Ketoconazole; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Singapore; Taxoids; Tissue Extracts	2015
A prospective study examining elder-relevant outcomes in older adults with prostate cancer undergoing treatment with chemotherapy or abiraterone. Journal of geriatric oncology, 2016, Volume: 7, Issue:2 Topics: Activities of Daily Living; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Cytochrome P-450 Enzyme Inhibitors; Hand Strength; Humans; Male; Pilot Projects; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Surveys and Questionnaires	2016
The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer. Prostate cancer and prostatic diseases, 2016, Volume: 19, Issue:1 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Ketoconazole; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome	2016
ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, 07-15, Volume: 22, Issue:14 Topics: Androgens; Androstenes; Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Leuprolide; Male; Mice; Mice, SCID; Phosphatidylinositol 3-Kinases; Prostate; Prostatic Neoplasms, Castration-Resistant; Receptor, ErbB-2; Receptors, Androgen; Signal Transduction; Xenograft Model Antitumor Assays	2016
CYP17A1 polymorphisms and clinical outcome of castration-resistant prostate cancer patients treated with abiraterone. The International journal of biological markers, 2016, Jul-30, Volume: 31, Issue:3 Topics: Aged; Aged, 80 and over; Androstenes; Disease-Free Survival; Enzyme Inhibitors; Humans; Male; Middle Aged; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Factors; Steroid 17-alpha-Hydroxylase; Treatment Outcome	2016
A single-center experience with abiraterone as treatment for metastatic castration-resistant prostate cancer. Urologic oncology, 2016, Volume: 34, Issue:7 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Agents; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome	2016
Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer. BMC cancer, 2016, Mar-14, Volume: 16 Topics: Aged; Alkaline Phosphatase; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Disease-Free Survival; Humans; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2016
Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy. BJU international, 2017, Volume: 119, Issue:1 Topics: Aged; Aged, 80 and over; Androstenes; Chromogranin A; Disease-Free Survival; Humans; Male; Middle Aged; Neoplasm Metastasis; Phosphopyruvate Hydratase; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome	2017
Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer. Oncotarget, 2016, May-31, Volume: 7, Issue:22 Topics: Androgen Antagonists; Androstenes; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Genetic Variation; Humans; Male; Mice, SCID; Niclosamide; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; RNA Interference; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays	2016
Third-line Enzalutamide Following Docetaxel and Abiraterone in Metastatic Castrate-resistant Prostate Cancer. Anticancer research, 2016, Volume: 36, Issue:4 Topics: Aged; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome	2016
[Not Available]. Aktuelle Urologie, 2016, Volume: 47, Issue:2 Topics: Administration, Oral; Adult; Aged; Androstenes; Disease Progression; Drug Approval; Follow-Up Studies; Germany; Humans; Male; Medication Adherence; Middle Aged; Physician-Patient Relations; Prostatic Neoplasms, Castration-Resistant	2016
[Enzalutamide and Abiraterone in the Treatment of Metastatic Castration-resistant Prostate Cancer after Chemotherapy]. Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2016, Volume: 29, Issue:2 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies	2016
Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer. European urology, 2016, Volume: 70, Issue:4 Topics: Aged; Androstenes; Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Biopsy; Cell Line, Tumor; Cell Nucleus; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prognosis; Prostate; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; Retrospective Studies; Survival Rate; Time Factors	2016
The Effect of Time to Castration Resistance on Outcomes With Abiraterone and Enzalutamide in Metastatic Prostate Cancer. Clinical genitourinary cancer, 2016, Volume: 14, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Benzamides; Disease Progression; Disease-Free Survival; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Regression Analysis; Survival Analysis; Treatment Outcome	2016
Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study. Oncotarget, 2016, Jun-28, Volume: 7, Issue:26 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Biomarkers, Tumor; Docetaxel; Follow-Up Studies; Humans; Italy; Male; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids	2016
Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy. Nature, 2016, 05-26, Volume: 533, Issue:7604 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Abiraterone Acetate; Administration, Oral; Androgen Antagonists; Androgens; Androstenes; Animals; Cell Line, Tumor; Disease Progression; Dutasteride; Humans; Male; Mice; Oxidation-Reduction; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Xenograft Model Antitumor Assays	2016
Bilateral Choroidal Metastases from Prostate Cancer revealed in a patient under Abiraterone - Fourteen years after diagnosis. The Gulf journal of oncology, 2016, Volume: 1, Issue:21 Topics: Androstenes; Antineoplastic Agents; Disease Progression; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2016
Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer. European urology, 2016, Volume: 70, Issue:6 Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Clinical Trials as Topic; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Multivariate Analysis; Neoplasm Metastasis; Neoplastic Cells, Circulating; Prednisone; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant	2016
Could Steroidal Abiraterone Metabolites Possibly Explain Abiraterone Withdrawal Syndrome? European urology, 2016, Volume: 70, Issue:5 Topics: Abiraterone Acetate; Androstenes; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Substance Withdrawal Syndrome	2016
[Abiraterone (CYP17 inhibitor)]. Nihon rinsho. Japanese journal of clinical medicine, 2016, May-20, Volume: 74 Suppl 3 Topics: Androgens; Androstenes; Clinical Trials as Topic; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Steroid 17-alpha-Hydroxylase	2016
[Overview of the ongoing clinical trials for new treatments for castrate-resistant prostate cancer (CRPC)]. Nihon rinsho. Japanese journal of clinical medicine, 2016, May-20, Volume: 74 Suppl 3 Topics: Androstenes; Benzamides; Clinical Trials as Topic; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant	2016
Current understanding of resistance to abiraterone and enzalutamide in advanced prostate cancer. Clinical advances in hematology & oncology : H&O, 2016, Volume: 14, Issue:5 Topics: Androstenes; Antineoplastic Agents; Benzamides; Biomarkers; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Treatment Outcome	2016
Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide. The Prostate, 2016, Volume: 76, Issue:16 Topics: Androstenes; Benzamides; Biomarkers; Bridged-Ring Compounds; Cost Savings; Costs and Cost Analysis; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; Taxoids	2016
Do we need new trials for the abiraterone, enzalutamide and cabazitaxel in metastatic castrate-resistant prostate cancer for confirmation of treatment indications? World journal of urology, 2017, Volume: 35, Issue:3 Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids	2017
AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate. The Journal of urology, 2017, Volume: 197, Issue:1 Topics: Age Factors; Aged; Analysis of Variance; Androstenes; Biomarkers, Tumor; Case-Control Studies; Disease-Free Survival; Humans; Male; Middle Aged; Molecular Targeted Therapy; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Reproducibility of Results; Risk Assessment; RNA, Messenger; Survival Analysis; Treatment Outcome	2017
Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. European urology, 2017, Volume: 71, Issue:1 Topics: Androgen Receptor Antagonists; Androstenes; Benzamides; Drug Resistance, Neoplasm; Humans; Male; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; Retrospective Studies	2017
Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study. The Prostate, 2017, Volume: 77, Issue:1 Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Administration Schedule; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome	2017
Abiraterone for castration-resistant prostate cancer: adherence, survival and hospitalization : Analysis of a medical claims database. Wiener klinische Wochenschrift, 2017, Volume: 129, Issue:11-12 Topics: Administration, Oral; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Austria; Hospital Mortality; Hospitalization; Humans; Insurance Claim Review; Male; Medication Adherence; Middle Aged; Prevalence; Prostatic Neoplasms, Castration-Resistant; Risk Factors; Survival Rate; Treatment Outcome	2017
The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. European urology, 2017, Volume: 71, Issue:4 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents, Hormonal; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; RNA	2017
Re: Redirecting Abiraterone Metabolism to Fine-Tune Prostate Cancer Anti-Androgen Therapy. The Journal of urology, 2016, Volume: 196, Issue:5 Topics: Abiraterone Acetate; Androstenes; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen	2016
Study of cases of abiraterone discontinuation due to toxicity in pre-chemotherapy after 1 year's experience. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2017, Volume: 23, Issue:8 Topics: Abiraterone Acetate; Aged, 80 and over; Androstenes; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Safety-Based Drug Withdrawals; Taxoids; Time Factors; Treatment Outcome	2017
Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment. BMC urology, 2016, Nov-04, Volume: 16, Issue:1 Topics: Aged; Androstenes; Antineoplastic Agents; Docetaxel; Humans; Japan; Male; Patient Preference; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Taxoids	2016
Comment on: "Modeling the Relationship between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer". Clinical pharmacokinetics, 2017, Volume: 56, Issue:2 Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome	2017
Author's Reply to Srinivas: "Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer". Clinical pharmacokinetics, 2017, Volume: 56, Issue:2 Topics: Abiraterone Acetate; Androstenes; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant	2017
Efficacy of Therapies After Galeterone in Patients With Castration-resistant Prostate Cancer. Clinical genitourinary cancer, 2017, Volume: 15, Issue:4 Topics: Aged; Androstadienes; Androstenes; Benzamides; Benzimidazoles; Drug Therapy; Humans; Kallikreins; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Treatment Outcome	2017
An exploratory analysis of the association between levels of hormones implied in steroid biosynthesis and activity of abiraterone in patients with metastatic castration-resistant prostate cancer. Minerva urologica e nefrologica = The Italian journal of urology and nephrology, 2017, Volume: 69, Issue:4 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents, Hormonal; Hormones; Humans; Male; Middle Aged; Neoplasm Metastasis; Predictive Value of Tests; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Steroids; Treatment Outcome	2017
Prostate cancer: An abiraterone ultraresponsive phenotype. Nature reviews. Urology, 2017, Volume: 14, Issue:3 Topics: Androstenes; Heterografts; Humans; Male; Phenotype; Prostatic Neoplasms, Castration-Resistant	2017
The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone. International journal of molecular sciences, 2017, Feb-11, Volume: 18, Issue:2 Topics: Aged; Androstenes; Antineoplastic Agents; Humans; Kaplan-Meier Estimate; Leukocyte Count; Lymphocytes; Male; Middle Aged; Neoplasm Metastasis; Neutrophils; Prognosis; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2017
Simultaneous quantitation of abiraterone, enzalutamide, N-desmethyl enzalutamide, and bicalutamide in human plasma by LC-MS/MS. Journal of pharmaceutical and biomedical analysis, 2017, May-10, Volume: 138 Topics: Androstenes; Anilides; Benzamides; Chromatography, Liquid; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Spectrometry, Mass, Electrospray Ionization; Tosyl Compounds	2017
[Concomitant use of abiraterone acetate and triptorelin in patients with castration-resistant prostate cancer]. Urologiia (Moscow, Russia : 1999), 2016, Issue:1 Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Triptorelin Pamoate	2016